High-Value Investment Insights
Discover articles with exceptional investment signals and actionable insights from earnings calls
Exceptional Signals (19-20)
Articles with the strongest investment signals, representing significant opportunities or risks
Sea Limited (SE) Q4 2025: Shopee VIP Memberships Double, Powering 36% Revenue Acceleration
Sea Limited demonstrates a long reinvestment runway with high returns, significant developments (VIP memberships, loan book growth), improving unit economics, self-reinforcing business model, and deepening customer value. The business is exceptional in terms of future growth, disruptive, accelerating cash flow, and set for high revenue/EPS growth, making it a clear growth business.
Applied Optoelectronics (AAOI) Q4 2025: 800G Ramp to $25M+ Drives Capacity-Limited Surge
AAOI demonstrates a long reinvestment runway, disruptive model, accelerating growth, and improving unit economics. Backlog and customer demand are exceptional, with revenue and EPS growth forecasted well above 40%. The business is self-reinforcing via vertical integration and automation, with margin expansion and cash flow acceleration. The outlook is for a high-growth, industry-leading business.
TLN Q4 2025: Free Cash Flow Surges 2x as Data Center Demand and Contracted Cash Flows Accelerate
TLN demonstrates a long reinvestment runway, disruptive business model evolution, and accelerating growth driven by hyperscaler/data center demand. Cash flow, backlog, and contracted revenues are all inflecting. The business is transitioning from legacy merchant power to a high-growth, contracted model, with strong evidence of compounding economics and capital allocation discipline. The signal is exceptional and highly actionable for investors.
AEVA (AEVA) Q4 2025: Revenue Doubles as Top-Tier OEM and NVIDIA Awards Expand $80B Pipeline
AEVA demonstrates a long runway for high returns on capital, recent significant developments (OEM/NVIDIA wins, revenue doubling), improving unit economics, self-reinforcing business model, increasing customer value, exceptional forward guidance, disruptive model, accelerating cash flow, high growth, and a clear transition to a growth business. All criteria are strongly met with transcript evidence.
Lifestone Metals (LZM) Q1 2026: Nickel Prices Surge 37%, Unlocking Strategic Leverage for Kabanga
Lifestone Metals is at a major inflection: clear reinvestment runway, disruptive model with recycling, strong unit economics, compounding advantages, and accelerating growth. Recent nickel price surge and strategic partnerships signal exceptional future prospects and valuation upside.
TerraWulf (WULF) Q4 2025: $12.8B HPC Lease Pipeline Signals Power-Backed AI Platform Inflection
TerraWulf demonstrates a long reinvestment runway, a massive lease pipeline, improving unit economics, self-reinforcing power-backed business model, deepening customer value, and strong growth signals. The business is disruptive, transitioning to a cash flow machine with high growth rates and clear industry leadership potential.
Invent Electrics (NVT) Q1 2026: Infrastructure Surges to 55% of Sales, Data Center Orders Up 40%
Invent Electrics is demonstrating a major inflection with a long reinvestment runway, disruptive business model pivot, accelerating growth, and strong backlog visibility. Unit economics, customer value, and margin trajectory are all improving, with clear evidence of high ROIC opportunities and secular tailwinds. The business is now positioned as a high-growth, infrastructure-first platform with exceptional forward prospects.
Innodata (INOD) Q4 2025: 35% Growth Outlook Anchored by Data-Centric AI Innovation Pipeline
Innodata demonstrates a long reinvestment runway with high ROIC, significant recent growth, improving unit economics, a self-reinforcing business model, deepening customer value, exceptional guidance, a disruptive model, accelerating cash flow, high growth rates, and is positioned as a growth business. All signal criteria are met at the highest level.
Spire Global (SPIR) Q4 2025: RFGL Capacity to Expand 15x, Igniting Multi-Year Growth Runway
Spire exhibits a rare combination of a long reinvestment runway, disruptive business model, accelerating growth (50%+ guidance), improving unit economics, and clear self-reinforcing advantages (dual-continent manufacturing, fully deployed constellation). The business is transitioning into a high-growth phase with expanding margins and a robust, contracted pipeline. Signal is extremely high.
Sterling Infrastructure (STRL) Q4 2025: Backlog Surges 78% as Data Center Pipeline Expands
Sterling Infrastructure is showing a transformational growth inflection with a massive surge in backlog, accelerating margins, and a clear pivot to high-return, mission-critical projects. The business model is becoming more self-reinforcing, with high-value customers and strong cash flow. Guidance and backlog quality suggest exceptional future growth, making this highly actionable for investors.
Tempest (TEM) Q4 2025: Data Licensing Jumps 69% as AI-Driven Platform Pulls Ahead
Tempest demonstrates a long reinvestment runway, disruptive and self-reinforcing business model, rapidly improving unit economics, and accelerating growth in both revenue and backlog. The data licensing segment's 69% growth, high net revenue retention, and large TCV, along with AI-driven product innovation and platform leverage, signal exceptional future prospects and strong valuation upside.
LSCC Q1 2026: Compute and Communications Revenue Surges 86% as AMI Deal Doubles TAM
LSCC is exhibiting exceptional signal: long reinvestment runway, disruptive business model, accelerating growth (86% YoY in core segment), backlog visibility into 2027, margin expansion, and a doubling of TAM via AMI. The business is clearly transitioning to a higher-value platform model with compounding economics and high optionality.
CoreWeave (CRWV) Q4 2025: Revenue Backlog Soars $50B, Locking In Multi-Year AI Infrastructure Demand
CoreWeave demonstrates an extraordinary growth profile, with a massive and accelerating revenue backlog, improving unit economics, a disruptive business model, and multi-year visibility. The business is clearly in hypergrowth mode, with exceptional future prospects, high-margin optionality, and a self-reinforcing platform. All signal criteria are strongly met or exceeded.
Lucid (LCID) Q4 2025: Gravity Drives 72% Delivery Surge as Midsize Platform Nears Launch
Lucid demonstrates a long reinvestment runway, disruptive business model, and strong growth signals: 72% delivery surge, cost improvements, margin expansion, new platform launches, and a major autonomy partnership. The business is transitioning to high growth, with clear evidence of improving economics and compounding advantages.
Genius Sports (GENI) Q4 2025: Legend Deal Accelerates Path to $1.1B Revenue, 30% Margin
GENI demonstrates a long reinvestment runway, disruptive platform pivot, accelerating growth and margins, improving unit economics, and a business model with increasing customer value. The Legend acquisition is a major business evolution, and the company is transitioning to a high-growth, high-cash flow profile with expanding TAM. Signal is exceptional for investors.
B1 Medicines (ONC) Q4 2025: Brukinza Surges 49% as Global BTK Leadership Expands
B1 Medicines demonstrates a long reinvestment runway, exceptional growth, improving unit economics, and disruptive business model dynamics. Backlog and guidance revisions are strong, and the business is transitioning into a high-growth, cash-generative phase with expanding end markets and a diversified pipeline.
FTAI (FTAI) Q4 2025: SCI Fund Deploys $6B, Power Platform Ramps Toward 100-Unit Target
FTAI demonstrates a long reinvestment runway with high ROIC, significant recent developments, improving unit economics, and a self-reinforcing business model. Customer value is increasing, and the future outlook is exceptional with accelerated growth. The business model is disruptive, cash flow is accelerating, and revenue/EPS growth is projected well above 40%. The company is clearly in a strong growth phase.
Keysight (KEYS) Q1 2026: Orders Surge 30% as AI and Defense Tailwinds Broaden Demand
Keysight demonstrates a long reinvestment runway (AI, defense, recurring revenue), recent order growth above 30%, improving unit economics, self-reinforcing business model, and increasing customer value. The future outlook is exceptional with accelerating growth, and the business model is both disruptive and cash generative. The company is clearly in a growth phase, with strong revenue and EPS guidance.
Silvaco (SVCO) Q4 2025: IP Bookings Surge Nearly 5x, Unlocking Double-Digit Growth Path
Silvaco demonstrates a long reinvestment runway, a step-change in growth (IP bookings up 5x), and improving unit economics. The business model is becoming self-reinforcing with IP and AI-driven TCAD, customers are becoming more valuable, and future growth is exceptional per backlog and guidance. The business is clearly in a growth phase, with accelerating cash flow and disruptive potential.
Capricor Therapeutics (CAPR) Q4 2025: HOPE III Data Drives 91% Cardiomyopathy Progression Slowdown, Readying for Transformational Launch
Capricor is at a rare inflection: validated pivotal data, a first-in-class product with a long reinvestment runway, and a disruptive cell therapy model. The company is transitioning to commercial stage with clear operational and financial leverage, strong cash reserves, and a pipeline with expansion potential. The business is set up for high growth, exceptional backlog change, and is not a legacy or capped business. All signal questions are satisfied at the highest level.
SERV Robotics (SERV) Q4 2025: Fleet Expands 20X as Revenue Quality and Platform Scope Accelerate
SERV Robotics demonstrates an exceptional growth trajectory: a 20x fleet expansion, nearly 400% revenue growth, and a shift to high-quality, recurring revenues. The business model is disruptive, with clear self-reinforcing data flywheels, improving unit economics, and accelerating cash flow. The company is transitioning from proof-of-concept to a high-growth, compounding platform, with significant runway and optionality for further expansion.
Vicor (VICR) Q4 2025: Backlog Jumps 16% as Capacity Nears $1B Run Rate
Vicor demonstrates a long reinvestment runway, a disruptive and self-reinforcing business model, and is at a major inflection with backlog up 16% and fab utilization approaching 80%. Unit economics and margins are improving, IP licensing is accelerating, and the business is transitioning to high growth with potential for 40%+ annual revenue/EPS growth. All signal questions are supported by evidence from the article.
Target Hospitality (TH) Q4 2025: WHS Contracts Surge Past $495M, Driving 320% Data Center Community Expansion
The business is experiencing a transformative inflection, with a long reinvestment runway, disruptive model, accelerating backlog and revenue, improving margins, and clear evidence of secular tailwinds. All signal criteria are met at the highest level, with strong evidence from management commentary and financials.
ICHR Q1 2026: Q2 Revenue Guide Surges 17%, Margin Expansion Signals Structural Shift
Ichor demonstrates a long reinvestment runway, clear evidence of accelerating growth (guidance up 17% sequentially, over 30% in two quarters), improving unit economics, and deepening vertical integration. The business model is becoming more self-reinforcing, with proprietary content and customer stickiness rising. Guidance and backlog signal exceptional near-term growth, and the company is transitioning into a structurally higher-margin, higher-growth phase with strong cash flow potential. The business is clearly in a high-growth, non-legacy phase with multiple avenues for further upside.
WeRide (WRD) Q4 2025: Overseas Revenue Jumps 140% as Global Robotaxi Fleet Surges
WeRide demonstrates a long reinvestment runway, exceptional recent growth (over 100% in key metrics), improving unit economics, and a disruptive, asset-light business model. International expansion provides high-margin growth, and the business is transitioning into a high-growth, cash-generative phase with strong guidance and clear competitive advantages.
Legend Biotech (LEGN) Q4 2025: Carvicti Doses Scale to 10,000 as Early-Line Penetration Accelerates
Legend Biotech demonstrates a long reinvestment runway, exceptional recent growth, improving unit economics, a self-reinforcing business model, deepening customer value, and disruptive potential. The business is transitioning to profitability with accelerating cash flow and is positioned for continued high growth, making it highly relevant for investors seeking upside in the sector.
LifeMD (LFMD) Q4 2025: Weight Management Subscribers Double, Margin Expansion Accelerates Platform Leverage
LifeMD is demonstrating rapid growth, margin expansion, and platform leverage, with clear evidence of a long reinvestment runway and disruptive business model. Subscriber and revenue growth are accelerating, unit economics are improving, and the business is transitioning to a high-growth, cash-generative model. The company is building defensible moats through AI and insurance integration, and the outlook supports sustained high growth.
CIENA (CIEN) Q1 2026: Backlog Surges $2B as AI Data Center Demand Drives Multi-Year Visibility
CIENA demonstrates a long reinvestment runway, disruptive business model, and accelerating growth metrics (backlog up $2B, optical revenue +40% YoY). Unit economics and margins are improving, backlog/guidance point to exceptional future growth, and the business is positioned as a key enabler of the AI infrastructure wave. All signal criteria are strongly met.
Marvell (MRVL) Q4 2026: Data Center Revenue to Surge 40% as AI Demand Lifts FY27 Outlook by $1B
Marvell is demonstrating a long reinvestment runway, massive growth inflection (over 40% in key segments), improving unit economics, and a self-reinforcing business model. Customer value is deepening, guidance is being raised, and the business is both disruptive and high-growth, with accelerating cash flow and earnings power. The piece captures an exceptional, industry-leading growth story with material valuation upside.
Profound Medical (PROF) Q4 2025: 43% Revenue Jump as Tulsa Pipeline Hits 110 Systems
Profound Medical demonstrates a long reinvestment runway, disruptive model, and accelerating growth with strong recurring revenue signals and a large pipeline. Unit economics are improving, the business model is self-reinforcing, and customer value is deepening. Backlog and guidance are exceptional, and the business is transitioning to scale with high growth potential. The article provides clear evidence of all these factors.
Marti Technologies (MRT) Q4 2025: Gross Margin Soars to 61% as Multi-Service Platform Scales Nationwide
Marti Technologies demonstrates a long reinvestment runway, a disruptive platform model, accelerating growth (revenue doubling, margin swinging to 61%), and improving unit economics. There are multiple levers for further upside (take rate, city launches), and the company is transitioning to profitability with clear evidence of compounding network effects and customer value expansion. The outlook and business model are both exceptional and highly thesis-relevant for growth investors.
Liquidia (LQDA) Q4 2025: Eutrepia Captures 17% Market Share, Outpaces Inhaled Prostacyclin Growth
Liquidia is demonstrating exceptional growth, with a disruptive product gaining rapid market share, improving unit economics, strong cash flow, and clear evidence of a long reinvestment runway. Guidance and backlog suggest acceleration, and the business model shows compounding characteristics. The article captures all of these signals directly from the earnings call.
Broadcom (AVGO) Q1 2026: AI Semiconductor Revenue Surges 106%, Unlocking $100B+ 2027 Visibility
Broadcom demonstrates a long reinvestment runway, disruptive business model, and accelerating growth in both revenue and cash flow. Recent developments (106% AI revenue growth, $100B+ 2027 visibility) mark a structural business evolution. Unit economics and customer value are improving, with clear evidence of compounding advantages, robust backlog, and a transition to an AI-centric growth platform.
ANTA (NLFAR) Q4 2025: Loan Book Climbs 59% as Tokenized Gold and AI Lending Expand Platform Reach
ANTA demonstrates a long reinvestment runway, exceptional recent growth (110% revenue, 59% loan book), improving unit economics, a self-reinforcing model, deepening customer value, and a disruptive approach with tokenized gold and AI lending. Guidance and commentary suggest continued high growth and platform evolution, with the business positioned as a growth leader in a maturing market.
GeneDx (WGS) Q4 2025: Exome and Genome Revenue Jumps 54% as Sales Force Expansion Targets Untapped Markets
GeneDx demonstrates a long reinvestment runway, exceptional recent growth, improving unit economics, compounding data advantages, and a disruptive business model. The outlook is for continued high growth, margin expansion, and operational leverage, with clear signals of a business inflecting toward scale and profitability.
Credo (CRDO) Q3 2026: Revenue Triples as Zero-Flap Optics Ramp Pulls Forward
Credo is exhibiting hyper-growth with revenue tripling YoY, a clear long runway in AI infrastructure, expanding TAM, and accelerating product adoption. Unit economics and operating leverage are rapidly improving, customer value is deepening, and the business is transitioning to an optical/system-level model with high defensibility. Guidance and backlog both point to continued exceptional growth. This is a rare case of a business with visible, compounding drivers and a disruptive, self-reinforcing model.
Riot Platforms (RIOT) Q4 2025: Data Center Backlog Surges 302%, Anchoring Power-to-Lease Pivot
Riot is executing a rare pivot from legacy Bitcoin mining to a disruptive, high-growth data center model, validated by a 302% backlog surge and a marquee AMD lease. The business has a long reinvestment runway (1.7GW power), improving unit economics (vertical integration/capex savings), a self-reinforcing model (power, supply chain), and is transitioning to high-visibility, contracted cash flows. Growth rates and backlog expansion are exceptional, and the business is positioned as a sector leader with significant valuation upside.
Xeris (XERS) Q4 2025: Recorlev Patient Base Doubles, Unlocking 44% Revenue Surge
Xeris demonstrates a long reinvestment runway, exceptional recent growth, improving unit economics, and a self-reinforcing business model. Customer value is deepening, guidance is for continued high growth, and the business model is disruptive in rare disease/specialty pharma. Cash flow is accelerating, and the company is transitioning to a growth business with high annualized revenue and EPS growth. All criteria for high signal are met.
ASML (ASML) Q1 2026: Output Target Raised to 60 EUV Systems as AI Demand Outpaces Supply
ASML demonstrates a long reinvestment runway with high returns, exceptional backlog and growth acceleration, improving unit economics, self-reinforcing business model, increasing customer value, and disruptive technology. Revenue and EPS growth are high, and the business is squarely in growth mode with clear upside in the current industry cycle.
MP Materials (MP) Q4 2025: NDPR Oxide Output Doubles, Accelerating U.S. Magnetics Integration
MP Materials demonstrates a long reinvestment runway at high returns, with recent step-change growth in NDPR output and commercial magnetics ramp. Unit economics are improving, the business model is self-reinforcing, and customer value is rising. Guidance and backlog signal accelerating growth, and the business is clearly disruptive with a strong cash flow outlook. Revenue and EPS growth are poised to exceed 40%, and the company is positioned as a growth leader.
Natera (NTRA) Q4 2025: MRD Clinical Units Surge 56%, Expanding Oncology Moat
Natera demonstrates a long reinvestment runway, exceptional growth in MRD units, improving unit economics, and a self-reinforcing business model. Customer value is deepening, backlog and guidance point to accelerating growth, and the business model is highly disruptive with strong cash flow generation. The company is firmly in the high-growth category and is not a legacy or stalling business.
Solaris (SEI) Q4 2025: Power Solutions Reach 70% of Earnings, Backed by 500MW Hyperscaler Win
Solaris demonstrates an exceptional strategic pivot with a long reinvestment runway, major contract wins, improving unit economics, and a disruptive business model. Growth rates and backlog are accelerating, the business is structurally shifting to higher-value segments, and there is clear evidence of compounding advantages and future upside.
Accelerant (ARX) Q4 2025: Third-Party Premiums Hit 40%, Accelerating Platform Fee Shift
Accelerant is demonstrating a structural business model inflection with a long reinvestment runway, rapidly rising margins, and accelerating fee-based growth. The business is compounding network effects, improving unit economics, and showing disruptive potential in a traditionally staid industry. Guidance and backlog signal exceptional forward growth, with clear evidence of durable competitive advantages and cash generation. All signal criteria are met at the highest level.
Hut 8 (HUT) Q4 2025: Compute Revenue Doubles, Margin Expands to 61% as AI Pipeline Scales
Hut 8 is demonstrating a long reinvestment runway, disruptive business model, and accelerating growth in a high-value sector. The doubling of compute revenue, margin expansion, and multi-gigawatt pipeline indicate exceptional business evolution with strong unit economics, capital discipline, and future growth optionality. The business is in a clear growth phase with high investor relevance.
TSMC (TSM) Q1 2026: 74% Advanced Node Mix Drives $56B CapEx Ambition Amid Persistent AI Demand
TSMC demonstrates a long reinvestment runway at high ROIC, with massive CapEx and clear growth drivers. Recent developments show accelerating AI/HPC demand and significant backlog. Unit economics and margins are robust, and the business model is self-reinforcing. Customer value, cash flow, and growth outlook are all exceptional, with disruptive industry positioning and no signs of stalling. The company is executing at the heart of a secular megatrend.
Selcuity (CELC) Q4 2025: R&D Spend Climbs 40% as Getatilicib Nears $5B Market Opportunity
Selcuity is at a binary inflection with a potentially transformative drug, a large addressable market, and imminent regulatory and data catalysts. The business model is disruptive, with strong reinvestment opportunity, improving unit economics, and a clear path to rapid growth if successful. The article signals exceptional upside and risk, making it highly actionable for investors.
Genmab (GMAB) Q4 2025: Proprietary Medicine Sales Jump 54% as Pipeline Readouts Set Up 2027 Launch Wave
Genmab exhibits a long reinvestment runway, exceptional growth in proprietary medicines, improving unit economics, a self-reinforcing commercial model, and deepening customer value. The late-stage pipeline and guidance signal accelerating growth, with disruptive business models and increasing cash flow potential. The company is positioned as a high-growth, non-legacy biotech with clear valuation upside.
Cineverse (CNVS) Q3 2026: MatchPoint Drives 470% Workflow Surge as Giant, IndieQ Acquisitions Reshape Model
Cineverse demonstrates a long reinvestment runway, major business evolution via acquisitions, rapidly improving unit economics, compounding business model, deepening customer value, exceptional growth guidance, disruptive platform, accelerating cash flow, strong revenue/EPS growth, and is clearly a growth business.
Syndax (SNDX) Q1 2026: Revuforge Drives 224% Revenue Surge, Transplant Tailwind Set to Accelerate
Syndax demonstrates a long reinvestment runway with compounding revenue drivers, a disruptive business model in rare disease/oncology, accelerating growth (224% YoY), improving unit economics, high customer retention, and multiple near-term pipeline catalysts. The business is entering a compounding phase with strong signals for sustained high growth and valuation upside.
SES (SES) Q4 2025: ESS Revenue Jumps to 65% Mix as Drone, Materials Ramp Nears
SES is undergoing a major business model inflection with a clear long-term reinvestment runway. The ESS and drone segments are high-growth, disruptive, and show improving unit economics and margins. The company is transitioning to a recurring revenue model with strong cash discipline and proprietary AI platform, positioning it as a growth business with significant upside potential.
Riot Platforms (RIOT) Q1 2026: AMD Lease Doubles to 50MW, Unlocking $636M Revenue Visibility
Riot demonstrates a long reinvestment runway with high returns, a major inflection via the AMD lease, improving unit economics, and a self-reinforcing, vertically integrated model. Customer value is increasing, backlog and guidance are exceptional, and the business model is disruptive with accelerating cash flow. Growth rates are high, and the company is clearly transitioning to a growth platform, not a legacy business.
CourseUp Therapeutics (CORT) Q1 2026: Oncology Launch Captures 200+ Prescribers, Guidance Raised on Endocrine Surge
CourseUp demonstrates a long reinvestment runway, disruptive platform business model, and accelerating commercial and pipeline growth. There are clear signs of improving unit economics, deepening customer value, and multiple late-stage catalysts. The business is transitioning to multi-franchise scale with high growth, exceptional future prospects, and accelerating cash flow potential—all supported by evidence from the call.
SanDisk (SNDK) Q3 2026: $42B RPO Locks In Multi-Year Demand, Reshaping NAND Economics
SanDisk is undergoing a major business model transformation, locking in multi-year revenue at scale, showing accelerating growth and margin expansion. The recurring revenue base, high-value mix, and structural margin reset all point to a business with a long runway and substantial upside. The article provides clear evidence of a disruptive, high-growth, and cash-generative model with strong investor signal.
SoundHound (SOUN) Q4 2025: Agentic AI Drives 59% Revenue Surge and Expands Containment Rates Above 90%
SoundHound demonstrates a long reinvestment runway, disruptive business model, and exceptional growth signals: 59% revenue growth, margin expansion, improving unit economics, and high customer stickiness. Containment rates above 90% and broadening vertical reach support a compounding, high-ROIC business. The company is transitioning from R&D to scale, with visible operational leverage and a strong balance sheet, supporting a high signal score.
Zeta (ZETA) Q1 2026: Athena-Driven Pipeline Surges 40%, Reinforcing AI Platform Moat
Zeta demonstrates a long reinvestment runway, a disruptive business model, and clear evidence of accelerating growth (pipeline up 40%, ARPU up 21%, guidance raised to 37% revenue growth). Unit economics are improving, the data moat is deepening, and cash flow is accelerating. The business is not mature or capped and is positioned as a consolidator in a fast-evolving sector.
Circle (CRCL) Q4 2025: USDC On-Chain Volume Soars 247% as AI and Interoperability Drive Platform Expansion
Circle demonstrates a long reinvestment runway with high returns on capital, exceptional growth in on-chain volume and USDC circulation, improving unit economics, and strong self-reinforcing network effects. Customer value is deepening, future growth is exceptional, and the business model is both disruptive and cash-generative. Guidance and business evolution indicate sustained high growth, with Circle positioned as a leading growth platform in digital assets.
LLY Q1 2026: Dual Agonist Uptake Drives 53% OUS Market Share, Expanding Global Obesity Franchise
Lilly demonstrates a long reinvestment runway, exceptional recent growth, improving unit economics, and a self-reinforcing business model. Customer value is increasing, guidance is raised, and the business is disruptive with accelerating cash flow. The company is clearly a growth business with strong evidence of continued high revenue and EPS growth.
FTAI (FTAI) Q1 2026: Aerospace Products EBITDA Up 70% as Market Share Push Accelerates
FTAI demonstrates a long reinvestment runway, disruptive and self-reinforcing business model, accelerating growth, improving unit economics, and a decisive shift to recurring, fee-based earnings. The article evidences material inflection points (EBITDA up 70%, module production up 96%, SPV expansion, Mod 1 commercialization) and outlines a growth business with sustained optionality and upside.
Alphabet (GOOG) Q1 2026: Cloud Backlog Doubles to $462B, AI Drives Enterprise Surge
Alphabet is demonstrating exceptional growth and business evolution: Cloud backlog nearly doubled, revenue and margin growth are accelerating, and the business model is both disruptive and self-reinforcing. Unit economics are improving, customer value is deepening, and the company is clearly a growth business with a long reinvestment runway and high ROIC discipline. There are significant recent developments and strong forward guidance, supporting a top signal score.
YPF (YPF) Q4 2025: Shale Oil Output Surges 42%, Driving Record $5B EBITDA Amid Portfolio Shift
YPF is undergoing a significant business evolution, with a long reinvestment runway, exceptional recent growth in shale output, improving unit economics, self-reinforcing business model, and clear disruptive potential with the LNG project. All signal questions are strongly supported by the content.
TTMI Q1 2026: Data Center and Networking Sales Surge 61%, Accelerating CapEx to $320M
TTMI demonstrates a long reinvestment runway with high returns, exceptional recent growth (61% in key segments), improving unit economics, and a self-reinforcing, high-complexity business model. Customer value, backlog, and forward guidance all point to accelerating growth and cash flow. The business is clearly in a high-growth, disruptive phase with strong evidence of future upside.
META (META) Q1 2026: $107B Commitment Spike Signals Relentless AI Infrastructure Bet
META demonstrates a long reinvestment runway, massive uptick in commitments, improving unit economics, and a self-reinforcing business model. Customer value is increasing, guidance and backlog signal exceptional future growth, and the business model is highly disruptive. Accelerating cash flow, high growth rates, and clear transition to a growth business all support a top signal score.
KLA (KLAC) Q3 2026: Advanced Packaging Revenue Surges 57% as Demand Outpaces Industry Capacity
KLA demonstrates a long reinvestment runway, disruptive business model, and accelerating growth in advanced packaging (57% YoY). Unit economics are improving, recurring service revenue is compounding, and backlog visibility extends into 2027. The business is a clear growth leader in a sector with high barriers and secular tailwinds, with all key signal criteria strongly met.
Cipher Digital (CIFR) Q4 2025: $2B Bond Secures Hyperscale Pivot and $9.3B Lease Backlog
Cipher Digital is at a major business inflection: a full pivot to hyperscale data centers with a decade of contracted lease revenue, long reinvestment runway, and capital discipline. The business model is self-reinforcing, customer value is deepening, and the outlook is for high growth with accelerating cash flow. This is a clear growth business with exceptional signal for valuation upside.
Digital Realty (DLR) Q1 2026: Development Pipeline Surges 60% as AI Leasing Drives $1.8B Backlog
Digital Realty demonstrates a long reinvestment runway, exceptional growth in backlog (60% pipeline ramp, $1.8B backlog), improving unit economics, and a self-reinforcing business model. Customer value is rising, future growth is exceptional, and the model is disruptive in the context of digital infrastructure. Cash flow is accelerating, and the company is firmly in the high-growth category with secular tailwinds.
Palantir (PLTR) Q1 2026: U.S. Revenue Soars 104% as AIP Drives Institutional Adoption
Palantir is exhibiting a rare combination of hyper-growth, expanding margins, and deepening customer value, with a disruptive AI-native platform driving institutional adoption. The business model is self-reinforcing, unit economics are improving, and the runway for reinvestment is long given current capacity constraints. Backlog and guidance revisions signal exceptional future prospects, and the company is transitioning from pilot to core infrastructure status in critical sectors.
Merion Technologies (MIR) Q1 2026: Orders Surge 42% as Nuclear Tailwinds Expand $1.1B Backlog
Merion demonstrates a long reinvestment runway with clear avenues for high-return capital deployment, driven by a 42% order surge and record backlog. There is a recent, material business inflection. Unit economics and margins are set to improve with scale and integration, and the business model benefits from deepening network effects and recurring revenue. Customer value is increasing with higher order frequency and cross-sell. The outlook for exceptional growth is well-supported by backlog and guidance. The business is disruptive, cash flow is set to accelerate, and both revenue and EPS are positioned for >20% annual growth, making this a high-signal, thesis-relevant opportunity.
Carvana (CVNA) Q1 2026: Retail Units Up 40%, SG&A Per Unit Falls as Scale Drives Margin Leverage
Carvana demonstrates a long reinvestment runway, rapid growth, improving unit economics, and a self-reinforcing business model. Customer value is deepening, guidance is strong, and the business is both disruptive and transitioning into a cash-generative, high-growth phase. All major signal questions are met at the highest level, indicating substantial valuation upside and strategic interest for investors.
Lemonade (LMND) Q1 2026: Revenue Jumps 71% as Retention and Automation Drive Margin Expansion
Lemonade demonstrates long reinvestment runway, disruptive AI-first model, significant growth acceleration (71% revenue, 159% gross profit), improving unit economics and customer value, and is transitioning to EBITDA profitability. The business is not mature or capped, and all signal criteria for high-growth, high-potential, and disruptive businesses are clearly met and supported by management commentary and KPIs.
Seagate (STX) Q3 2026: Mosaic Drives Fuel 44% Revenue Surge as Cloud Demand Locks in Multi-Year Growth
Seagate demonstrates a long reinvestment runway with high ROIC, structural revenue/margin expansion, and a disruptive technology roadmap (HAMR). The business is in a high-growth phase with exceptional backlog and contract visibility, accelerating cash flow, and clear compounding advantages. All signal questions are fully satisfied with strong evidence from the earnings call.
Flowtech Industries (FTK) Q4 2025: Data Analytics Gross Profit Rises 1,433%, Reshaping Margin Structure
Flowtech demonstrates a rare, structural business model inflection with a massive, recurring, high-margin analytics segment now dominating gross profit. The business shows accelerating growth, high returns on capital, improving unit economics, and a disruptive, self-reinforcing model with strong customer stickiness. Backlog visibility, guidance, and segment performance all point to exceptional future growth and cash flow generation, making this a high-signal, thesis-relevant opportunity.
Bloom Energy (BE) Q1 2026: Oracle Project Drives 130% Revenue Surge, Capacity Expansion Accelerates
Bloom Energy is at a major inflection with a long runway, exceptional growth, improving unit economics, a self-reinforcing model, and accelerating cash flow. The business is disruptive and positioned for rapid, high-margin expansion, with all signals pointing to material valuation upside.
United Therapeutics (UTHR) Q4 2025: Tyvaso DPI Grows 24% as Pipeline Launches Set Up $4B Run Rate
United Therapeutics demonstrates a long reinvestment runway, with a disruptive model, accelerating growth, and pipeline launches that could materially shift revenue and market position. Unit economics, customer value, and business model self-reinforcement are all improving. The business is not mature or capped, and the evidence supports a high-growth, high-signal profile with multiple avenues for continued expansion.
ASE Technology (ASX) Q1 2026: ATM Segment Lifts to 91% of Operating Profit, LEAP Demand Drives CapEx Surge
ASE is showing a major business evolution with LEAP/ATM, clear reinvestment runway, margin expansion, and capital allocation to high-return opportunities. Growth rates, guidance, and business model disruption all support maximum signal. The business is not mature or capped, and the article demonstrates clear, actionable upside with high investor relevance.
CECO (CECO) Q4 2025: Backlog Surges 47% as Thermon Deal Sets Stage for $1.5B Industrial Platform
CECO displays a long reinvestment runway, a transformative acquisition, accelerating backlog, improving margins and cash flow, and clear signs of a disruptive, high-growth business model. Guidance and backlog signal exceptional forward growth. The article captures all these signals directly from the call.
Carvana (CVNA) Q4 2025: Retail Units Soar 43% as Operational Scale Drives Margin Leverage
Carvana demonstrates a long reinvestment runway, disruptive business model, and strong evidence of compounding scale benefits. The quarter shows exceptional growth, margin leverage, and improving unit economics. Customer value and automation are driving higher retention and NPS. Guidance and recent results point to accelerating growth and cash flow, and the business is clearly in a high-growth phase with significant market share opportunity.
Solaris (SEI) Q1 2026: Contracted Power Base Surges 40% as Behind-the-Meter Demand Accelerates
Solaris demonstrates a long reinvestment runway, disruptive business model, rapidly accelerating growth, improving unit economics, and deepening customer value. The company is transitioning into a high-growth, embedded partner with strong cash flow prospects and clear upside, offering exceptional signal for investors.
Zeta (ZETA) Q4 2025: Super-Scaled Customers Now 90% of Revenue, Accelerating Platform Flywheel
Zeta demonstrates a long reinvestment runway, accelerating growth, improving unit economics, and a self-reinforcing business model. Customer value is increasing, guidance is being raised, and the business is disruptive with high growth and cash flow acceleration. All signal criteria for an exceptional, high-upside business are met.
Corning (GLW) Q1 2026: Optical Sales Jump 36% as Hyperscaler Deals Extend Growth Horizon
Corning demonstrates a long reinvestment runway with high returns, exceptional recent growth (36% optical, 80% solar), improving unit economics, a self-reinforcing business model, and increasing customer value. Guidance and backlog are accelerating, the business model is disruptive, and cash flow is growing rapidly. The company is in clear growth mode with strong evidence of future upside.
IOVA Q4 2025: MTAGV Drives 30% Revenue Growth as Pipeline Expansion Accelerates
Iovance demonstrates a long reinvestment runway, exceptional recent growth, improving unit economics, and a disruptive, self-reinforcing business model. Customer value is increasing, cash flow is accelerating, and the company is transitioning to a diversified growth platform. The business is showing multiple signals of compounding value and is highly relevant for investors seeking upside.
BEAM (BEAM) Q4 2025: $500M Financing Extends Runway, Accelerates PKU and Sickle Cell Launch
BEAM demonstrates a long reinvestment runway, disruptive and scalable platform, rapidly expanding pipeline, improving unit economics, and strong financial flexibility. There are clear signs of business model compounding, regulatory tailwinds, and multiple high-growth opportunities. The business is positioned for exceptional future growth, with accelerating cash flow potential and a transition to a multi-asset, high-growth platform.
Sentient Technologies (SXT) Q1 2026: Natural Color Conversions Add $20M, Pushing Double-Digit Growth Path
SXT demonstrates a long reinvestment runway with high expected returns on capital, driven by the regulatory-driven natural color conversion. There is a significant business evolution with double-digit growth and a clear backlog ramp. Unit economics are improving, the business model is self-reinforcing (regulatory and competitive moats), and customers are becoming more valuable. Guidance and backlog suggest exceptional future growth. The business model is disruptive with a long runway, cash flow is accelerating, and revenue/EPS growth is likely to exceed 20%. SXT is a growth business at a major inflection.
MaxLinear (MXL) Q1 2026: Infrastructure Revenue Soars 136% as Data Center Ramps Drive Multi-Year Growth Recast
MaxLinear demonstrates a long reinvestment runway, a major inflection in growth, improving unit economics, and a self-reinforcing business model. Customer value is deepening, backlog and guidance revisions are exceptional, and the business is disruptive with broad TAM expansion. Cash flow is accelerating, and growth rates are well above 40%. The business has clearly transitioned to a high-growth phase with structural upside.
DigitalOcean (DOCN) Q4 2025: AI Customer ARR Surges 150%, Fueling 2026 Growth Acceleration
DigitalOcean demonstrates a long reinvestment runway (major capacity ramp), a step-function increase in AI customer ARR and backlog, improving and durable unit economics, and a self-reinforcing business model (agentic inference cloud). Customer value is deepening (zero churn in top cohort, expanding wallet share), and the business is transitioning into a high-growth, disruptive model with accelerating revenue and cash flow. The growth rates and backlog visibility are exceptional and clearly thesis-relevant.
LBRT Q1 2026: Convertible Debt Adds $1.3B Liquidity as Power Pipeline Surges Beyond Capacity
LBRT demonstrates a long reinvestment runway, secular and cyclical growth drivers, improving unit economics, and compounding business model advantages. The power pipeline and completions leverage signal outsized future growth and cash flow potential, with clear differentiation and industry read-through.
IonQ (IONQ) Q4 2025: RPO Surges to $370M as Full-Stack Quantum Platform Drives Fivefold Visibility
IonQ demonstrates exceptional growth and strategic positioning: fivefold RPO surge, 429% revenue growth, expanding commercial and international base, disruptive platform model, and accelerating cash flow potential. The business model is self-reinforcing, with deepening customer value, high R&D reinvestment, and a clear transition to a high-growth, sector-leading company. All signal criteria are fully met or exceeded.
Helix Energy (HLX) Q1 2026: Hornbeck Merger to Drive 106% EBITDA Growth, $75M Synergy Target
The merger is transformative, doubling EBITDA, unlocking significant synergies, and positioning the combined entity for high-return reinvestment across energy, defense, and renewables. The business model is self-reinforcing, with expanding backlog, improving unit economics, and clear disruption in the offshore services sector. Guidance and backlog signal strong future growth, and the article makes a compelling case for exceptional signal.
GE Vernova (GEV) Q1 2026: Backlog Surges $47B, Electrification and Gas Power Drive Multi-Year Upside
GE Vernova demonstrates all the hallmarks of a high-signal, high-upside business: long reinvestment runway, disruptive growth in electrification and gas power, accelerating backlog and cash flow, improving unit economics, and clear pricing power. The business model is self-reinforcing, customer value is deepening, and guidance revisions indicate exceptional growth. The company is not a legacy business but a clear growth leader in a secular cycle, with multi-year visibility and strategic optionality.
LAM Research (LRCX) Q3 2026: Gross Margin Hits 49.9% as AI-Driven Demand Accelerates Tool Outperformance
LAM Research demonstrates a long reinvestment runway, disruptive business model, and accelerating growth metrics (record margins, revenue, and services). The AI-driven demand shift, backlog visibility, and memory conversion acceleration provide exceptional forward guidance. Unit economics, customer value, and cash flow are all improving, and the business is in a clear growth phase with high optionality.
Docebo (DCBO) Q1 2026: Enterprise Expansions Drive 9-Point NRR Gap, Accelerating ARR Outlook
Docebo demonstrates a long reinvestment runway, significant recent growth, improving unit economics, a self-reinforcing business model, deepening customer value, and exceptional future guidance. The business is disruptive, accelerating cash flow, and positioned for high growth, with all evidence supported by the call.
Vicor (VICR) Q1 2026: Backlog Surges 70% as Capacity Expansion Unlocks $1.5B Runway
Vicor demonstrates a long reinvestment runway, a 70% backlog surge, improving unit economics, and a hybrid business model with strong IP leverage. Customer value is rising, future growth is exceptional, and the business model is disruptive with cash flow acceleration. Revenue and EPS are poised for >40% growth, and the company is firmly in growth mode.
Snowflake (SNOW) Q4 2026: $400M Mega-Deal and 42% RPO Surge Signal Durable AI-Fueled Expansion
Snowflake demonstrates a long reinvestment runway, exceptional growth signals (42% RPO surge, $400M mega-deal), improving unit economics, and a self-reinforcing business model. Customer value is deepening, and future guidance is robust. The business model is disruptive, cash flow is accelerating, and both revenue and EPS growth are well above 20%. This is a growth business with exceptional signal for valuation upside.
VECO (VECO) Q4 2025: Backlog Jumps 35% as AI Demand Drives Multi-Segment Order Acceleration
VECO demonstrates a long reinvestment runway, disruptive business model, and exceptional growth signals (notably a 35% backlog jump and multi-year order visibility). Unit economics are improving, customers are becoming more valuable, and the business is positioned for accelerating cash flow and EPS growth. The company's sector leadership, order momentum, and merger-driven scale provide strong evidence of outsized future potential.
Vertiv (VRT) Q1 2026: Americas Surge 44% as Capacity Investments Drive 30% Top-Line Growth
Vertiv demonstrates a rare combination of accelerating top-line growth, expanding margins, and a disruptive, self-reinforcing business model. The article details a long reinvestment runway, clear evidence of operational leverage, and substantial backlog visibility. Recent growth rates and guidance revisions are exceptional, and the company is positioned as a system-level winner in a structurally expanding market, providing strong valuation upside.
UXIN Q4 2025: Retail Volume Soars 124% as Superstore Rollout Accelerates Nationwide
UXIN is demonstrating a long reinvestment runway, with >100% growth, rapidly improving unit economics, and a disruptive, scalable superstore model. Backlog and guidance revisions are exceptional, and the business is transitioning into a high-growth, cash-generative platform with clear lateral opportunities and self-reinforcing advantages.
Cloudastructure (CSAI) Q4 2025: Total Contract Value Jumps 342% as Multi-Site Adoption Accelerates
Cloudastructure is showing exceptional growth, a long reinvestment runway, improving unit economics, and deepening customer value. The business model is disruptive and self-reinforcing, with accelerating recurring revenue and clear signals of becoming a high-growth, high-margin SaaS business. All signal questions are strongly supported by the transcript.
Duos Technologies (DUOT) Q4 2025: Data Center Revenue Surges 270% as Edge AI Demand Fuels $176M Contract Win
Duos is undergoing a major business model transformation with a long reinvestment runway, disruptive model, and high growth rates. The backlog, margin expansion, and recurring revenue model signal a potentially exceptional future. The article provides strong evidence of a growth business with significant optionality and high returns on capital.
TOYO (TOYO) FY25: Revenue Surges 142% on Ethiopia Ramp, U.S. Module Expansion Sets Stage for 2026
TOYO demonstrates a long reinvestment runway (U.S. expansion, Ethiopia as cost backbone), exceptional recent growth (142% revenue surge), improving unit economics (margin expansion), and a self-reinforcing model (traceability, policy compliance). Customer value is increasing, backlog/guidance is strong, and the business is disruptive in the U.S. solar context. Cash flow is accelerating, and the company is transitioning to a high-growth, industry-leading position.
CLSQ (LAES) Q4 2025: Quantum Pipeline Surges to $200M as Regulatory Urgency Drives Adoption
CLSQ demonstrates a long reinvestment runway, disruptive technology, and accelerating growth. The pipeline expansion, regulatory tailwinds, and certification milestones suggest a business on the cusp of rapid value creation. Unit economics, customer value, and cash flow are all improving, with a clear path to outsized growth and market leadership. The business model is self-reinforcing and highly relevant for investors seeking asymmetric upside.
MNSO Q4 2025: Overseas Revenue Climbs 31% as Multi-IP Strategy Accelerates Global Store Expansion
MNSO demonstrates a long reinvestment runway, disruptive business model, and accelerating growth in both revenue and profitability. The article describes exceptional recent developments (over 40% growth in key segments), improving unit economics and cash flow, and a self-reinforcing multi-IP strategy. The future outlook and guidance are strong, and the business is clearly in a high-growth phase with global optionality.
InVenture (INV) Q4 2025: G&A Down 61% as Platform Shifts to Self-Funding, $50M Bookings Signal Inflection
The business demonstrates a long reinvestment runway, a major inflection in bookings, improving unit economics, self-reinforcing platform effects, deepening customer value, and a disruptive model. Cash flow is accelerating, and growth rates are strong, with the company transitioning decisively into a growth phase.
Resolve AI (RZLV) Q4 2025: ARR Surges to $232M, Unlocking Agentic Commerce Scale
Resolve AI demonstrates a long reinvestment runway, major business evolution, improving unit economics, a self-reinforcing model, deepening customer value, and exceptional future growth based on guidance. The business is disruptive, with accelerating cash flow, and is transitioning to rapid growth with high revenue and EPS expansion potential. All signal criteria are met at the highest level.
Pony AI (PONY) Q4 2025: RoboTaxi Revenue Set to Triple as Fleet Targets 3,000+ Units
Pony AI demonstrates a long reinvestment runway, hyper-growth trajectory (tripling revenue, 3,000+ fleet target), and improving unit economics. The business model is disruptive, self-reinforcing, and leverages ecosystem partnerships for scale. Cash flow and margins are accelerating, with guidance pointing to exceptional growth. The company is clearly positioned as a high-growth, high-ROIC opportunity with major industry implications.
Veritone (VERI) Q4 2025: $12.9M Data Deal Unlocks 50M-Hour Content Pipeline, Pivots to AI Marketplace Scale
Veritone demonstrates a clear long-term reinvestment runway, a disruptive business model, and accelerating growth prospects. The $12.9M data deal, large content pipeline, and platform pivot signal a material business evolution with strong optionality, improving unit economics, and high future growth visibility. Risks are acknowledged, but the signal for investors is strong and actionable.
TE (TE) Q4 2025: $322M Capital Raise Unlocks G2 Solar Fab Buildout Amid U.S. Supply Chain Shift
T1 Energy demonstrates a long reinvestment runway with high ROIC potential, a major capital raise, and a pivotal new facility (G2 Austin) unlocking significant growth. Unit economics are improving, the business model is self-reinforcing due to regulatory and supply chain advantages, and customer value is deepening. Guidance and backlog signal exceptional future growth. The business is disruptive, cash flow is set to accelerate, and revenue/EPS growth is expected to be well above 40% annually. This is a growth business at a key inflection.
Revolution Medicines (RVMD) Q4 2025: R&D Spend Surges 57% as Eight Registrational Trials Drive Pipeline Expansion
RVMD demonstrates a long reinvestment runway, with major pipeline expansion and a disruptive approach to RAS-driven cancers. The business is transitioning from research to late-stage/commercial, with accelerating spend and multiple inflection points ahead. Unit economics and customer value are set to improve as clinical and commercial infrastructure scales. The business model is self-reinforcing, with high optionality, and the outlook for growth, cash flow, and value creation is exceptional based on pipeline and guidance.
PGEN Q4 2025: Pepsimios Launch Drives 149% Revenue Surge, RRP Market Adoption Accelerates
PGEN demonstrates a rare, high-signal commercial inflection: rapid revenue growth, improving unit economics, broadening market opportunity, and strong customer adoption. The business model is disruptive in rare disease, with a long reinvestment runway, accelerating cash flow, and clear growth trajectory. All signal criteria are decisively met.
Nvidia (NVDA) Q4 2026: Networking Revenue Jumps 3.5x, Cementing AI Factory Dominance
Nvidia shows a long reinvestment runway, exceptional recent growth (notably in networking), improving unit economics, and a self-reinforcing platform. Customer value is rising, backlog and guidance are robust, and the business is disruptive with cash flow acceleration. Revenue and EPS growth rates are well above 40%, and the company is firmly in the growth category.
KRMN Q4 2025: Backlog Surges 38% to $801M as Defense Demand Accelerates
KRMN demonstrates a long reinvestment runway with high ROIC, a massive surge in backlog (+38%), clear improvements in unit economics, and a self-reinforcing business model through vertical integration and M&A. Customer value is increasing, guidance is exceptional, and the business model is disruptive within defense manufacturing. Cash flow and growth metrics are accelerating, with guidance for over 50% YoY revenue growth, and the company is positioned as a growth business. All signal criteria are strongly met.
GDS (GDS) Q4 2025: AI-Driven Bookings Triple to 300MW, Unlocking 10%+ Yield on New Projects
GDS demonstrates a long reinvestment runway with high ROIC projects, a dramatic uptick in AI-driven bookings, improving unit economics, and a self-reinforcing business model. Customer value is increasing, backlog and guidance are exceptional, and the business is both disruptive and rapidly growing. Cash flow is accelerating, and growth rates are well above 40%. GDS is clearly a growth business with strong strategic optionality.
Kratos (KTOS) Q4 2025: Backlog Hits $1.57B as Hypersonics, Space, and Engine Ramp Drive Pipeline
Kratos displays a long reinvestment runway, disruptive business model, accelerating growth, improving unit economics, and strong backlog visibility. The business is transitioning into a high-growth phase with expanding margins and cash flow potential, supported by clear evidence from the earnings call.
HIT Q4 2025: Distribution Network Expands 34%, Unlocking Underpenetrated Self-Funded Health Market
HIT demonstrates a long reinvestment runway, disruptive business model, improving unit economics, and compounding self-reinforcing advantages. The company has posted very strong growth, with clear acceleration in revenue and backlog, and is transitioning into higher-value segments with expanding margins and cash flow. The business is early in market penetration, providing significant upside optionality.
EDAP (EDAP) Q4 2025: HIFU Revenue Climbs 34% as U.S. Adoption Accelerates Platform Shift
EDAP is demonstrating a long reinvestment runway, disruptive business model, rapidly accelerating growth in its HIFU business, improving unit economics, and clear recurring revenue expansion. The business is transitioning into a high-growth, higher-margin platform with significant optionality and strong guidance, supporting a maximum signal score.
So-Young (SY) Q4 2025: Aesthetic Center Revenue Surges 205%, Shifting Profit Engine and Expansion Playbook
So-Young demonstrates a long reinvestment runway with high returns, a disruptive and scalable business model, and clear evidence of accelerating growth, margin expansion, and improving unit economics. The article details exceptional backlog/revenue growth, customer value expansion, and a transition to a high-growth, cash-generative model. All signal criteria are fully satisfied.
HMR Q4 2025: Revenue Quadruples to $25M as Tanker Market Dislocation Drives Record Spot Rates
HMR demonstrates a long reinvestment runway with a scalable, asset-light model, a quadrupling of revenue, and strong operational leverage. There are clear disruptive elements, improving unit economics, accelerating cash flow, and the business is positioned for exceptional growth. All signal criteria are fully met based on the transcript.
Praxis (PRAX) Q4 2025: $1.5B Cash Fuels Dual NDA Launches and $20B CNS Ambition
Praxis demonstrates a long reinvestment runway, significant recent developments (dual NDAs, $1.5B cash), improving unit economics, and a self-reinforcing business model. Customer (prescriber/patient) value is increasing, and future growth is exceptional based on pipeline and guidance. The business model is disruptive with a long runway, cash flow is set to accelerate, and revenue/EPS growth is poised to exceed 40%. Praxis is clearly a growth business with substantial optionality.
Axon (AXON) Q4 2025: Bookings Surge 46% as AI-Driven Portfolio Broadens Revenue Base
Axon demonstrates a long reinvestment runway, disruptive business model, and accelerating growth with strong backlog and bookings. Unit economics, ARPU, and margins are improving; the business is not mature or capped. Guidance and backlog support exceptional future growth, and the business model is self-reinforcing and cash-generative.
Prenetics (PRE) Q4 2025: IM8 Revenue Run Rate Hits $120M, Driving 480% Growth and Strategic Reset
Prenetics demonstrates a long reinvestment runway, explosive growth, improving unit economics, and a disruptive, asset-light, recurring revenue model. The business is transitioning into a high-growth phase, with accelerating cash flow, strong guidance, and clear optionality for further upside. The model is self-reinforcing, with increasing customer value and exceptional future prospects.
PAYS Q4 2025: Patient Affordability Revenue Jumps 168%, Unlocking Operating Leverage Inflection
PAYS demonstrates a long reinvestment runway, with its patient affordability platform scaling rapidly and driving high returns. The business experienced a transformative uptick in growth (168% YoY in the segment), with improving margins and operating leverage. The model is self-reinforcing through technology and transparency, customers are becoming more valuable, and future guidance signals exceptional growth. The business model is disruptive in a large, underpenetrated market, with accelerating cash flow and strong revenue/EPS growth. The company is clearly in a growth phase, not legacy or stalling.
Carls Med (CARL) Q4 2025: 61% Revenue Growth as Personalized Spine Surgery Scales, Lead Times Cut to 6 Days
Carls Med demonstrates a long reinvestment runway (digital-first, scalable, high-ROIC niche), a 61% revenue growth inflection, improving margins and unit economics, and a disruptive, self-reinforcing business model. Customer value is deepening (surgeon onboarding, utilization), and growth is exceptional (guiding for 44% annual). Cash flow and EBITDA are poised to inflect. The business is a clear growth story, not a legacy or transitional case.
Blaze (BZAI) Q4 2025: Revenue Multiplies 20x as Asia-Pacific Drives $23.8M Quarter
Blaze demonstrates a long runway with high reinvestment opportunities, a dramatic revenue inflection, improving unit economics, and a shift to a platform model with recurring revenue. The business is disruptive, rapidly growing, and positioned for margin expansion, all evidenced by call commentary and financial data.
XPEV Q4 2025: Overseas Revenue Jumps to 15% as Physical AI Drives Margin Upside
XPeng demonstrates a long reinvestment runway with high ROIC potential, major growth inflections (overseas revenue, margin, first net profit), and improving unit economics. The business model is evolving to be self-reinforcing with clear network effects and platform leverage. Customer value is deepening, guidance is strong, and the company is transitioning from EV manufacturing to a disruptive global AI/robotics platform. The signal for investors is exceptionally high.
iQIYI (IQ) Q4 2025: Overseas Membership Revenue Soars 40%, Unlocking Second Growth Engine
iQIYI is showing a long reinvestment runway with high returns (AI, international, experiential), recent 40%+ growth in overseas revenue, improving unit economics, self-reinforcing business model (IP, AI, network effects), increasing ARPU/retention, exceptional future outlook, disruptive model, accelerating cash flow, and clear transition to a high-growth business. All signal criteria are met at the highest level.
Lemonade (LMND) Q4 2025: Gross Profit Surges 73% as AI-Driven Flywheel Accelerates
Lemonade demonstrates a long reinvestment runway, disruptive AI-driven business model, accelerating growth (both revenue and profitability), improving unit economics, and clear evidence of compounding structural advantages. Backlog/guidance is exceptional, and the business is in a high-growth phase with strong cash flow improvement. All signal criteria are met at the highest level.
Hesai Group (HSAI) Q4 2025: LiDAR Shipments Set to Double, Backlog Tops 6 Million Units
Hesai demonstrates a long reinvestment runway, disruptive business model, and accelerating growth (shipments, backlog, new product launches). Backlog and guidance revisions are exceptional, and the company's business model is self-reinforcing (platform, partnerships, cost advantages). Unit economics are improving, and the company is transitioning into a high-growth, cash-generative phase, with new verticals (physical AI) opening further upside.
Onto Innovation (ONTO) Q4 2025: Backlog Doubles, Advanced Packaging Set for 30%+ Growth Surge
ONTO demonstrates a long reinvestment runway, disruptive business model, and exceptional recent growth (backlog doubling, advanced packaging up 30%+). Unit economics and margins are improving, with clear evidence of self-reinforcing business dynamics and customer value deepening. Guidance and backlog point to sustained, above-market growth, and the business is positioned as a growth leader in a structurally advantaged segment.
Toyo (TOYO) Q4 2025: Ethiopia Ramp Fuels 142% Revenue Surge, U.S. Module Capacity Set to Double
Toyo demonstrates a rare combination of explosive growth (142% revenue, capacity doubling), improving margins, strong reinvestment runway, and clear competitive moats (traceability, policy compliance, integration). The business model is self-reinforcing, cash flow is accelerating, and guidance implies sustained high growth. The article signals a genuine inflection and exceptional investor opportunity.
Eton Pharmaceuticals (ETON) Q4 2025: EBITDA Margin Jumps to 29% as Rare Disease Portfolio Expands
Eton demonstrates a rare disease platform with a long reinvestment runway, high returns, and disruptive business model. There is a significant uptick in growth (83% revenue leap), improving unit economics, and expanding margins. The business is clearly in a high-growth phase, with strong backlog and pipeline, increasing customer value, and accelerating cash flow potential. Guidance and performance suggest exceptional future prospects.
Alarm Technologies (ALAR) Q4 2025: AI Product Revenue Jumps to 30%, Reshaping Growth Mix
ALAR is undergoing a material business model shift with AI products now 30% of revenue (up from 4%), a huge increase in data volumes, and clear evidence of a long reinvestment runway. Margins are compressed short-term due to investment, but there are clear signals of future leverage. Growth is rapid (guidance at 46% YoY), and the business is transitioning into a platform with increasing customer stickiness, competitive moats, and disruptive potential.
SQM (SQM) Q4 2025: Lithium Volumes Surge 50% as Pricing Rebounds, Demand Outpaces Supply
SQM demonstrates a long reinvestment runway with clear high-ROIC expansion, a material inflection in lithium volumes and pricing, improving unit economics, and a self-reinforcing multi-segment model. Customers are becoming more valuable, guidance is accelerating, and the business is transitioning into a high-growth phase with global optionality. The outlook is exceptional, and the business model is both disruptive and cash-generative, supporting a high signal score.
Waterdrop (WDH) Q4 2025: Insurance Revenue Soars 125% as AI-Native Strategy Accelerates
Waterdrop demonstrates a long reinvestment runway, disruptive AI-native business model, accelerating growth, and improving unit economics. Recent results and guidance indicate exceptional growth and margin expansion, with strong evidence of compounding advantages and a transition to a high-growth, cash-generative platform.
Applied Digital (APLD) Q3 2026: $2.15B Debt Deal Unlocks Investment-Grade Credit, Accelerates Hyperscale Expansion
The business demonstrates a long reinvestment runway, recent transformative developments (investment-grade credit, major debt raise, and nearly 1GW under construction), strong improving unit economics, and a self-reinforcing business model. Customer value is deepening, future outlook is exceptional, and the business model is disruptive in the AI data center space. Cash flow and growth prospects are accelerating, and the business is clearly in a high-growth phase.
Intuitive Machines (LUNR) Q4 2025: Backlog Surges to $943M as Acquisitions Drive 5X Revenue Scale-Up
Intuitive Machines demonstrates a long reinvestment runway, massive backlog growth, improving unit economics, and a disruptive, recurring-revenue business model. The company's transition to infrastructure services and national security, along with accelerating revenue and margin guidance, indicate high signal and valuation upside potential.
Global-e (GLBE) Q4 2025: EBITDA Margin Expands 420bps as AI-Driven Leverage Accelerates
GLBE demonstrates a long reinvestment runway, accelerating growth, improving margins, and a disruptive, defensible business model with clear evidence of compounding advantages. The guidance and performance signal durable, high-growth economics and exceptional future prospects, making it highly relevant for investors seeking upside.
Madrigal Pharmaceuticals (MDGL) Q4 2025: U.S. MASH Diagnosed Population Expands 50%, Extending Market Runway
Madrigal is demonstrating category creation with a 50% market expansion, high persistence rates, and a deepening pipeline. The business model is self-reinforcing, with long patent runway, high growth, and strong reinvestment optionality. Revenue and EPS are likely to grow at a high double-digit rate. The company is transitioning into a durable, high-growth franchise, making the signal exceptional.
Micron (MU) Q2 2026: Gross Margin Surges to 75% as AI Supply Constraints Reshape Industry Economics
Micron is demonstrating a long reinvestment runway, exceptional growth, and business model evolution with high returns on capital. There are significant recent developments, rapidly improving unit economics, and deepening customer value. The business is disruptive, cash flow is accelerating, and the company is transitioning into a high-growth, high-margin phase with strong forward guidance and industry read-through.
Ondas (ONDS) Q4 2025: Acquisition-Driven 629% Revenue Surge Signals Multi-Domain Defense Platform Inflection
Ondas demonstrates a rare inflection: massive revenue growth, a transformative acquisition spree, and a robust capital base signal a long reinvestment runway and high optionality. Unit economics are improving, the business model is platform-based and self-reinforcing, and guidance points to exceptional future growth. This is a high-signal, high-upside business evolution.
InspireMD (NSPR) Q4 2025: U.S. Revenue Jumps 74% Sequentially as C-Guard Prime Gains Traction
InspireMD is at a clear inflection: U.S. launch is driving rapid growth and margin expansion, guidance calls for 45-65% YoY growth, and pipeline milestones offer further acceleration. Unit economics are improving, the business model is compounding, and the company is transitioning to a high-growth, high-margin profile with strong reinvestment potential. The risk/reward is thesis-driven and highly actionable.
Elbit Systems (ESLT) Q4 2025: Backlog Soars $5.5B as Europe Drives 27% of Sales
Elbit exhibits all the hallmarks of a high-signal, high-upside business: a long reinvestment runway, record backlog growth, clear operational leverage, improving unit economics, and a disruptive, technology-led model. The company is growing rapidly, with accelerating cash flow, margin expansion, and a business model that is self-reinforcing through vertical integration and technology differentiation. The future outlook is exceptional, with visible growth drivers and clear industry read-throughs.
Advanced Energy (AEIS) Q1 2026: Data Center Revenue Surges 102%, Capacity Expansion Accelerates
AEIS demonstrates a long reinvestment runway, disruptive growth in data center and semiconductor, expanding margins, and accelerating cash flow. Recent developments include a 102% YoY surge in data center revenue and raised guidance for both revenue and margins. The business model is self-reinforcing, with clear evidence of compounding advantages, and the company is transitioning into a high-growth, high-ROIC phase. All signal criteria are met at the highest level.
Energy Vault (NRGV) Q3 2025: Backlog Doubles to $920M as AssetVault Platform Drives Recurring EBITDA Shift
Energy Vault is showing a rare combination of inflection: doubling backlog, a new recurring revenue model, accelerating growth, and strong margin discipline. The business has a long reinvestment runway, disruptive model, and is transitioning to high-quality, recurring EBITDA. All signal questions are satisfied at the highest level.
BWXT (BWXT) Q1 2026: Backlog Surges 77% as U.S. Nuclear Capacity Expansion Accelerates
BWXT demonstrates an extraordinary signal profile: a long reinvestment runway, disruptive model, accelerating backlog (+77%), improving unit economics, and strong cash flow growth. The business is at a sector inflection with high growth visibility, diversified revenue streams, and clear competitive advantages. All key signal questions score at the highest level based on the provided evidence.
Travere Therapeutics (TVTX) Q4 2025: Filspari Sales Surge 144% as IGAN Adoption Broadens, FSGS Approval Path Remains in Focus
Travere Therapeutics demonstrates a long reinvestment runway and high returns, with a disruptive business model in rare disease therapeutics. The 144% sales growth, expanding market penetration, and strong pipeline momentum all point to a business at a significant inflection. Unit economics, customer value, and cash flow are all improving, with strong guidance and a pivotal regulatory catalyst ahead. This is a high-signal, high-upside situation for investors.
TVTX Q1 2026: Filspari Revenue Jumps 88% as FSGS Approval Unlocks $3B Peak Sales Path
TVTX demonstrates a rare disease platform with a long reinvestment runway, high returns, and disruptive business model. The FSGS approval is a significant business evolution, with rapid growth and expanding addressable market. Unit economics are improving, the business model is self-reinforcing, customers are becoming more valuable, and cash flow is accelerating. The company is positioned for sustained high growth, with all signal questions strongly supported by the call's facts and guidance.
Semtech (SMTC) Q4 2026: Data Center Revenue Surges 58% as AI Infrastructure Fuels Multi-Year Growth
Semtech demonstrates a long reinvestment runway, a disruptive and self-reinforcing business model, and exceptional growth in data center and IoT segments. Backlog and guidance signal accelerating growth, with clear evidence of improving unit economics, customer value, and cash flow generation. The business is transitioning to a high-growth, high-margin profile with strong secular tailwinds.
VEON (VEON) Q4 2025: Digital Revenue Jumps 84%, Reaching 20% of Group Sales
VEON is showing a major inflection with digital revenue growth of 84%, now over 20% of group sales, and high EBITDA margins. The multiplay model, asset-light execution, and disciplined capital returns provide strong signals of a compounding, high-ROIC, disruptive business with long runway, improving economics, accelerating cash flow, and clear growth trajectory. The article captures these signals thoroughly.
ASP Isotopes (ASPI) Q4 2025: Revenue Surges 480% as Critical Materials Platform Launches Multi-Segment Commercialization
ASPI demonstrates a long reinvestment runway, disruptive business model, rapidly improving unit economics, and clear evidence of growth inflection (480% revenue growth). The business is transitioning from development to growth, with accelerating cash flow and multiple high-value verticals. The only deduction is on question 6, as guidance is strong but not exceptional (>30% acceleration) across all segments.
Establishment Labs (ESTA) Q4 2025: Preserve Drives 2x ASP, U.S. Share Hits 20% in Historic Launch Year
ESTA demonstrates a long reinvestment runway with premium-priced innovation, disruptive market expansion, accelerating margins, and cash flow. There is clear evidence of rapid growth, improved unit economics, and a self-reinforcing business model. The only area scoring slightly lower is annualized top-line/earnings growth, which, while robust, does not consistently exceed the 40% threshold.
Vir Biotechnology (VIR) Q4 2025: $1.7B Astellas Deal Accelerates Dual-Masked T-Cell Engager Platform
Vir is at a strategic inflection with a validated, scalable platform, a transformative partnership, and strong early clinical signal. The business model is disruptive and self-reinforcing, runway is long, and capital efficiency is high. The only deduction is on near-term revenue/EPS growth, which is promising but not yet at 40%+ annualized given the development stage.
Frontline (FRO) Q4 2025: VLCC Rates Surge 44% as Tight Fleet Age Profile Drives Cash Flow Upside
Frontline demonstrates a long reinvestment runway, significant recent growth (VLCC rates, backlog), improving unit economics, and a business model that is self-reinforcing through scale and compliance. Customer value is deepening, and forward guidance is bullish. The model is not fully disruptive (semi-disruptive score), but cash flow is accelerating, and growth rates are exceptional. The business is clearly in a growth phase with strong thesis relevance.
Crystal Biotech (KRYS) Q1 2026: Ex-US Revenue Jumps 39% as Global Launch Diversifies Growth
Crystal Biotech demonstrates a long reinvestment runway, disruptive business model, and self-reinforcing platform advantages. There are clear signs of accelerating growth, margin expansion, and pipeline momentum. The only deduction is for revenue/EPS growth not explicitly over 40%, but all other signals point to a high-growth, catalyst-rich business with significant upside.
INSM Q4 2025: Brensupri Launch Drives $1B+ 2026 Guide, Unlocking Bronchiectasis Market Expansion
Insmed demonstrates a long reinvestment runway, disruptive business model, and exceptional launch metrics. Unit economics, customer value, and cash flow are all improving. The only minor deduction is for the future outlook, which, while strong, is not yet at the 'exceptional' >30% growth threshold for all segments. Overall, signal is extremely high for a specialty pharma business at this stage.
Viant Technologies (DSP) Q4 2025: CTV Share Hits 46% as AI Outcomes Drive Performance Inflection
Viant demonstrates a long reinvestment runway with high ROIC potential, a disruptive and self-reinforcing business model, and accelerating growth in key metrics (CTV, AI-driven products). The only deduction is for question 9, as forward guidance implies just under 40% growth, not exceeding it. Otherwise, the business is inflecting and positioned for outperformance.
NESR (NESR) Q4 2025: Jafura Ramp Drives 35% Sequential Revenue Surge, Unlocks Multi-Year Growth Runway
NESR demonstrates a long reinvestment runway, a step-change in growth from the Jafura ramp, improving unit economics, and a self-reinforcing business model with growing contract visibility. Customer value is increasing, and the outlook/guidance is exceptional. The business model is semi-disruptive (not fully disruptive), hence a 1 for that question. Cash flow is accelerating, and the company is positioned as a growth leader with double-digit revenue and EPS growth expected. The only deduction is for question 7, as the business is not fundamentally disruptive but rather an aggressive regional consolidator with technology adoption.
Infinity Natural Resources (INR) Q4 2025: Production Surges 46% as Acquisitions Expand 10-Year Inventory
INR demonstrates a long reinvestment runway, a step-change in scale, and a disruptive business model for the sector. Recent acquisitions and integration of midstream assets signal exceptional growth and margin trajectory, with a 70% production ramp and improving unit economics. The business is not entirely disruptive (hence a 1 for Q7), but otherwise, signal is very high with clear evidence of accelerating growth, margin leverage, and optionality.
Entergy (ETR) Q1 2026: $14B CapEx Surge Anchored by Meta ESA, Unlocks 8.5% Retail Sales Growth Path
Entergy demonstrates a long, high-return reinvestment runway, a transformative Meta agreement, and accelerating growth in both sales and CapEx. Unit economics are improving, customer value is deepening, and the business is transitioning into a new growth phase. The model is not fully disruptive (hence a 1 on Q7), but the rest of the signals are exceptionally strong, with above-peer growth and clear upside optionality.
CECO (CECO) Q1 2026: Backlog Surges 72% as Power and Industrial Orders Fuel Multi-Year Visibility
CECO demonstrates a long reinvestment runway, record backlog growth, and accelerating order momentum—clear signals of a business at an inflection point. Unit economics and margins are improving, the business is diversifying, and the Thermon acquisition sets up further scale and synergy. While the business model is not deeply disruptive (scoring 1 on that axis), every other signal point is strongly positive with clear evidence of exceptional growth, cash flow improvement, and strategic positioning.
Celestica (CLS) Q1 2026: CCS Revenue Surges 76% as Hyperscaler Demand Accelerates
Celestica demonstrates an exceptional growth runway with hyperscaler demand, clear margin and cash flow improvement, and accelerating guidance. The business is transitioning up the value chain, but remains somewhat exposed to customer concentration and is not fully a disruptive platform, warranting a slightly lower score on disruption. Otherwise, the signal is very high across all dimensions.
CareCloud (CCLD) Q4 2025: Free Cash Flow Jumps 55% as AI and M&A Drive Platform Expansion
CareCloud demonstrates a long reinvestment runway, disruptive AI-driven business model, improving unit economics, expanding customer value, and accelerating free cash flow. Guidance and backlog indicate strong future growth, though revenue/EPS growth is likely in the 20-40% range, not above 40%. The business is transitioning into a growth phase with clear optionality.
Ocular Therapeutix (OCUL) Q1 2026: SOL1 Superiority Data Drives NDA Momentum and 12-Month Disease Control Narrative
OCUL demonstrates a long reinvestment runway, disruptive business model, and exceptional recent clinical results that reset the competitive landscape. Unit economics, customer value, and business model self-reinforcement are all improving or strong. The only slight deduction is on cash flow, which is not yet accelerating given the business is still pre-commercial. All other indicators point to a high-signal, high-upside growth story.
Prague Holdings (PRG) Q1 2026: Four GMV Soars 134%, Platform Ecosystem Drives Margin Expansion
PRG demonstrates a disruptive, high-growth model with a long reinvestment runway, improving unit economics, and expanding digital/subscription channels. Four’s triple-digit growth, high margins, and ecosystem integration are clear signals of compounding value. The only deduction is for forward outlook/guidance, which, while positive, is not yet exceptional (>30% acceleration) for the consolidated business.
Five9 (FIVN) Q4 2025: Enterprise AI Revenue Surpasses $100M, Fueling Backlog and Margin Expansion
Five9 demonstrates a long reinvestment runway, clear business model transition, improving unit economics, and a self-reinforcing platform. AI revenue and bookings are growing rapidly, with a disruptive model and accelerating cash flow. The only deduction is on revenue/EPS growth, which is strong but not consistently above 40%.
BrainsWay (BWAY) Q4 2025: Backlog Surges 43% as Recurring Model Drives Revenue Visibility
BrainsWay demonstrates a long reinvestment runway with high returns, significant backlog growth, improving unit economics, and a self-reinforcing ecosystem model. Customer value is deepening, and the business is transitioning to a recurring revenue model with accelerating cash flow. Growth is strong, though not quite at the 40%+ threshold for all metrics, but the strategic positioning and financial trajectory are highly attractive for investors seeking upside.
CLEAR (YOU) Q4 2025: Bookings Surge 25%, Clear One Record Validates Enterprise Identity Flywheel
CLEAR demonstrates a long reinvestment runway with high returns, significant recent developments (notably in B2B/healthcare), improving unit economics, and a self-reinforcing business model. Customer value is deepening, and the business is both disruptive and cash-generative. Revenue and EPS growth is strong but not above 40%, hence a 1 on question 9. The company is clearly in a growth phase with expanding opportunities.
Block (SQ) Q4 2025: Workforce Cut of 4,000 Sets Stage for 54% Profit Surge in 2026
Block is demonstrating a rare, high-impact business evolution: a radical cost reset, accelerating profit and margin guidance, deepening ecosystem engagement, and a disruptive, AI-native operating model. The business model is self-reinforcing and the company is positioned for high returns on capital. The only minor deduction is on revenue/EPS growth, which, while strong, does not exceed the 40%+ threshold for full marks.
Monolithic Power Systems (MPWR) Q1 2026: Enterprise Data Floor Raised to 85% as Demand Visibility Extends
MPWR demonstrates a long reinvestment runway, disruptive business model, and clear compounding advantages. The enterprise data segment's 85% YoY growth floor and capacity expansion are exceptional signals. Unit economics and customer value are improving, and backlog/order visibility is strong. The only slight deduction is on cash flow acceleration, which is moderate rather than exceptional in the near term. Overall, the business is in a high-growth, high-visibility phase with clear valuation upside.
CareDx (CDNA) Q1 2026: Testing Services Revenue Jumps 48% as Portfolio Reshapes for $12B TAM
CareDx demonstrates a long reinvestment runway, a major portfolio shift, improving unit economics, and a self-reinforcing business model. Customer value is deepening, guidance is raised, and the business is transitioning to high-margin, high-growth diagnostics. The only slight deduction is for revenue/EPS growth, which is guided at 20% (not 40%+), but all other signals are strong for a business with significant upside and transformation.
DLocal (DLO) Q4 2025: TPV Climbs 70%, Broadening Merchant Base and Platform Leverage
DLocal exhibits a long reinvestment runway, disruptive business model, accelerating TPV and cash flow, and strong customer retention. The only deduction is for future guidance being strong but not yet at the 'exceptional' acceleration level for gross profit. The business is high-growth, self-reinforcing, and differentiated, providing substantial signal for investors.
Unity (UNIT) Q4 2025: Fiber IRR Hits 22% as Hyperscaler Deals Drive Record Bookings
Unity displays a long reinvestment runway with high IRRs, record bookings, and a disruptive pivot to fiber. Unit economics are improving, and the business model is self-reinforcing with deepening customer value. The future outlook is strong with contracted economics, though revenue growth guidance is below 40%, warranting a slightly lower score on question 9. Overall, the signal is high due to the scale of transformation and capital efficiency.
Strong Signals (16-18)
Articles with valuable investment signals that merit attention
ARGX Q4 2025: VivGuard Drives 90% Growth as Ocular MG Approval Targets 7,000-Patient Expansion
ARGX demonstrates a long reinvestment runway, disruptive business model, and clear operating leverage. Growth is strong but not consistently above 40%, and future guidance is positive but not exceptional. Unit economics, customer value, and cash flow are all improving. The business is solidly in the growth category with high signal for investors.
Webull (BULL) Q4 2025: Marketing Spend Drives $3.9B Net Deposits, AI and Global Expansion Reshape Growth Profile
Webull demonstrates a long reinvestment runway, disruptive business model, improving unit economics, and deepening customer value. Recent growth is strong though not consistently above 40%, and the future outlook is positive but not exceptional. The business is not yet a giant but is on a clear growth trajectory, with some risks around new segments and execution.
Cadeler (CDLR) Q4 2025: Backlog Climbs to €2.8B as T&I Transition Drives Margin Upside
Cadeler demonstrates a long reinvestment runway, high returns on capital, and a disruptive, self-reinforcing business model. Backlog growth and utilization are exceptional, with clear evidence of improving unit economics and customer value. While revenue and EPS growth are strong, they do not exceed the 40% threshold for a perfect score, and the outlook, while very positive, is not described as 'exceptional' for all metrics. Nevertheless, the business is clearly in growth mode with significant strategic upside.
Seadrill (SDRL) Q4 2025: Backlog Grows $500M as Deepwater Demand Tightens Into 2027
Seadrill demonstrates a long reinvestment runway, significant backlog growth, improving unit economics, and a self-reinforcing business model with rising customer value. The business is transitioning to strong cash flow with high backlog coverage and repricing embedded, though the model is not fully disruptive (score 1 for question 7), and revenue/EPS growth is strong but not consistently above 40% (score 1 for question 9). Overall, the signal is high and actionable for investors.
GCT Semiconductor (GCTS) Q4 2025: 76% Sequential Revenue Surge Signals Early 5G Ramp
GCT is at a pivotal inflection with early 5G commercialization, strong sequential revenue growth, and expanding customer/vertical opportunities via satellite and IoT partnerships. The business model is disruptive and self-reinforcing with high optionality, but cash flow is not yet accelerating and revenue/eps growth, while strong, is not yet at the highest tier. Execution risk and customer concentration remain, but the signal for a growth transition is high.
AAPG Q1 2025: Dual-Engine Commercialization Drives 90% Revenue Growth, Global Trial Enrollment Accelerates
AAPG demonstrates a long reinvestment runway, disruptive dual-product model, self-reinforcing commercial and clinical execution, and improving unit economics. Revenue growth is sharply accelerating, and the company is transitioning to a self-funding global growth phase. The only slight deduction is for growth not yet at 40%+ for future guidance and backlog, but the overall signal is very high for a globalizing biotech at this inflection.
TransMedics (TMDX) Q4 2025: OCS Liver Share Jumps to 36%, Expanding U.S. Transplant Market
TransMedics demonstrates a long reinvestment runway with high returns on capital, clear disruptive potential, improving unit economics, and deepening customer value. The business is accelerating market creation and penetration, with strong cash flow and operating leverage emerging. Growth is strong but not consistently over 40%, and guidance for 2026 is robust but not exceptional. The business model is highly self-reinforcing and positioned for continued expansion, justifying a high signal score.
Amprius Technologies (AMPX) Q4 2025: Gross Margin Jumps 45 Points as NDAA Compliance Drives Defense Demand
Amprius demonstrates long runway, disruptive model, improving unit economics, and a clear inflection in demand and margin. Some guidance is strong but not yet 'exceptional' or above 40% growth, capping a couple of categories, but overall the business is showing high signal for investors.
CoStar Group (CSGP) Q4 2025: Homes AI Drives 134% Traffic Surge as Residential Margins Set to Expand
CoStar demonstrates a long reinvestment runway, disruptive business model, accelerating engagement and cash flow, and deepening customer value. There are clear signs of margin expansion and a durable data moat. While growth is strong, full-year guidance is below the 20%+ threshold for question 9, and near-term guidance is good but not exceptional for question 6. The business is not a new discovery but offers substantial ongoing upside.
Allegiance (TMC) Q4 2025: Backlog Surges 49%, Extending Data Center Visibility to 2029
Allegiance demonstrates a long reinvestment runway, exceptional backlog and growth acceleration, improving unit economics, and a self-reinforcing business model with increasing customer value. Guidance and backlog conversion point to strong future growth, but while the business model is robust, it is not fully disruptive. Revenue growth is strong but not consistently above 40%. The company is a clear growth business but not an undiscovered or uniquely disruptive opportunity.
CI&T (CINT) Q4 2025: Top 10 Client Revenue Up 17%, Accelerating AI-Driven Expansion
CI&T demonstrates a long reinvestment runway, disruptive business model, improving unit economics, and high customer value expansion. The business is not yet showing exceptional (30%+) growth in guidance but is clearly in high-growth transition. The model is self-reinforcing and cash flow is accelerating, but the pace of transition and client adoption means near-term growth is strong but not explosive.
Chime (CHYM) Q4 2025: Chime Card Drives 30% Credit Mix Surge, Fueling Margin Expansion
Chime demonstrates a long reinvestment runway, disruptive business model, and improving unit economics with a clear shift to higher-margin credit. Proprietary tech stack, embedded AI, and enterprise expansion provide self-reinforcing advantages. However, guidance suggests high (but not hyper) growth, and while the outlook is strong, it's not at the most exceptional level for backlog/guidance acceleration. Still, the business is clearly in a high-growth, compounding phase with strong signals for investors.
NU (NU) Q4 2025: ARPAC Rises 27% as Credit Expansion and AI Drive Monetization
Nubank demonstrates a long reinvestment runway, compounding scale, improving unit economics, and a disruptive, self-reinforcing business model. The company is transitioning to a global platform with accelerating monetization and AI leverage. While not all growth metrics are over 40%, the business is clearly a compounding growth story with high signal for investors.
Perion (PERI) Q4 2025: CTV Revenue Surges 59% as AI-Driven Execution Model Accelerates Growth
Perion is undergoing a major inflection, with high reinvestment potential, disruptive AI-driven model, and accelerating margin and cash flow. CTV and other core segments are growing rapidly, with clear evidence of improving unit economics and customer value. The only deduction is for future guidance, which is strong but not at the exceptional (30%+ growth) level, and for revenue/EPS growth, which is above 20% but not consistently 40%+.
Camtek (CAMT) Q4 2025: Hawk and Eagle Gen 5 to Drive 50%+ Revenue Mix Shift in 2026
Camtek demonstrates a long reinvestment runway with high returns (AI/advanced packaging), significant recent growth, improving unit economics, and a self-reinforcing model. Customer value is deepening and the business is disruptive in its segment. Cash flow is strong and accelerating. Growth is robust but not consistently over 40% annually, and future guidance is for double-digit, not hypergrowth. The business is clearly in a growth phase, but not at the most extreme end of signal.
Century Aluminum (CENX) Q4 2025: Oklahoma Smelter to Double U.S. Output, $200M Data Center Stake Unlocks New Value
Century Aluminum demonstrates a long reinvestment runway, a transformative growth project (Oklahoma smelter), improving unit economics, and business model advantages (policy, technology, and supply discipline). The business is not fully disruptive but is semi-disruptive within its sector. Revenue and EPS growth potential is strong but not likely to consistently exceed 40% annually. Overall, the signal is high and actionable for investors.
Pulse Biosciences (PLSE) Q4 2025: 96% One-Year Success in AFib Study Sets Stage for 2026 Clinical Ramp
Pulse Biosciences demonstrates a disruptive, high-growth platform with a long reinvestment runway supported by strong clinical data, robust IP, and strategic positioning. While cash flow is not yet accelerating and near-term revenue growth is gated by regulatory milestones, the business model and clinical results indicate high future signal and upside.
Vicor (VICR) Q4 2025: Backlog Jumps 16%, Capacity Nears Full Utilization as Licensing Accelerates
Vicor demonstrates a long reinvestment runway, strong recent backlog growth, improving unit economics and margins, and a disruptive business model with IP leverage. The business is clearly transitioning to a higher growth phase, but guidance for 2026 is somewhat cautious and the business, while high quality, is not yet at the 40%+ revenue/EPS growth threshold for a perfect score. Risks around capacity expansion and licensing cadence temper the exceptionalism, but the overall signal is very strong.
Comfort Systems USA (FIX) Q4 2025: Backlog Doubles to $12B as Data Center Demand Drives Multi-Year Visibility
FIX demonstrates a long reinvestment runway with high ROIC, a near-doubling of backlog, and clear margin expansion. Unit economics are improving, and the business model is increasingly self-reinforcing, especially with modular and data center focus. Customers are becoming more valuable, and future growth visibility is exceptional. While the business model is not fully disruptive, it is semi-disruptive due to modular scale. Cash flow and profitability are accelerating, though growth rates are likely in the 20-40% range rather than above 40%. The company is a growth business, not legacy or merely transitioning.
Akamai (AKAM) Q4 2025: CIS Accelerates 45% as Inference Cloud Drives $200M AI Commitment
Akamai is undergoing a major business model shift with a long reinvestment runway and disruptive potential in edge AI and security. The CIS segment is growing 45%+ with a landmark $200M contract, and security is compounding. Unit economics and customer value are improving, and the business is positioned for high growth, but near-term revenue/EPS growth guidance is below 20%, and cash flow is not yet accelerating, holding back a perfect score.
CenterPoint Energy (CNP) Q4 2025: Houston Peak Load to Surge 50% Two Years Early, Unlocking $10B+ CapEx Upside
CenterPoint is showing clear evidence of a long reinvestment runway at high returns, with a major demand inflection (50% peak load increase two years early), improving unit economics, and a self-reinforcing model due to regulatory and scale advantages. Customer value is rising, and the business model is semi-disruptive within the utility sector. Cash flow is accelerating, but revenue/EPS growth is strong but not consistently above 40%. The business is firmly in growth mode, but as a regulated utility, the upside is somewhat capped compared to tech or platform businesses.
Tandem Diabetes Care (TNDM) Q4 2025: Pharmacy Channel to Reach 15% of U.S. Sales Amid PAYGO Model Shift
Tandem demonstrates a long reinvestment runway with disruptive model changes (PAYGO, direct international), improving unit economics, and self-reinforcing business model. Customer value is rising, and the company is transitioning to higher recurring margin revenue. The business is clearly growth-oriented, but near-term growth (revenue/EPS) is temporarily muted by the transition, so not all metrics score the maximum. Still, the business is positioned for strong future upside.
Abacus Global Management (ABL) Q4 2025: Recurring Revenue Mix Targets 70% as AUM Surges Past $3B
Abacus Global Management demonstrates a long reinvestment runway, clear business model evolution, improving unit economics, and a self-reinforcing platform. The recurring revenue shift and data monetization provide significant upside, though near-term growth rates are strong but not hyperbolic. The business is transitioning to a high-quality compounding model with strong signals for future value creation.
Xometry (XMTR) Q4 2025: Marketplace Revenue Jumps 33% as Enterprise Penetration Deepens
Xometry demonstrates a long reinvestment runway, clear business model advantages, and accelerating enterprise adoption. Margins and cash flow are improving, and the business is disruptive in a large, fragmented market. While growth is robust, full-year guidance suggests a moderation below the highest acceleration tier, which slightly tempers the signal score. Nonetheless, the company is positioned as a high-growth, high-quality compounder with increasing competitive advantages.
BZ Q4 2025: Adjusted Operating Margin Hits 43.3% as AI-Driven Closed-Loop Services Accelerate
BZ demonstrates a long reinvestment runway, disruptive business model evolution, improving unit economics, and deepening customer value. While growth is strong and AI monetization is inflecting, near-term guidance is for high single-digit growth, not 20%+, so some signal points are slightly capped.
MercadoLibre (MELI) Q4 2025: AI-Fueled Ad Revenue Soars 67% as Ecosystem Investments Deepen
MELI demonstrates a long reinvestment runway, disruptive business model, improving unit economics, and compounding network effects. There is significant ad and fintech growth, but not all segments are growing at 40%+, so some scores are slightly lower. The business remains highly investable and thesis-relevant, with clear evidence of continued growth and strategic execution, though not all growth rates are at the highest possible threshold.
Taysha (TSHA) Q4 2025: $20M R&D Surge Accelerates TASHA-102 Pivotal Pathway
Taysha is at a pivotal point with a long reinvestment runway, significant recent developments, improving unit economics, and a disruptive business model addressing a high-value rare disease. The business is not yet a cash flow machine and near-term growth will hinge on pivotal data and approval, thus slightly lower scores for cash flow and growth rate. Overall, the signal is very high for a late-stage biotech with clear catalysts and valuation upside.
Palo Alto Networks (PANW) Q2 2026: SASE ARR Surges 40% as Platformization Drives Enterprise Consolidation
PANW demonstrates a long reinvestment runway, disruptive platformization, and improving unit economics with high retention and cross-sell. SASE and NGS ARR growth are robust, and the business model is self-reinforcing with expanding customer value. While the future is bright, guidance and backlog growth are strong but not at the most exceptional (over 40%+) level for all segments, and some revenue growth is acquisition-driven. The business is clearly a growth leader in a consolidating, high-signal sector.
Skyward Group (SKWD) Q4 2025: Apollo Deal Lifts Book Value 9%, Diversifies Risk Profile
Skyward demonstrates a long reinvestment runway (portfolio shift, Apollo deal), clear business evolution (Apollo deal, AVIP partnership), improving unit economics, and a self-reinforcing model (data/tech leadership). Customer value is deepening via new specialty and embedded offerings. Guidance is strong but not exceptional/accelerating, justifying a 1 on Q6 and Q9. The model is disruptive with cash flow acceleration, and growth is robust but not hyper-growth. Overall, signal is very high for a specialty insurer, though not at the extreme end of growth.
Glaukos (GKOS) Q4 2025: iDose-TR Drives 53% U.S. Glaucoma Growth, Epioxa Launch Sets Up 2H Surge
Glaukos is showing a multi-year growth inflection driven by innovative products with strong adoption, expanding markets, and a disruptive business model. While cash flow is not yet accelerating, operational leverage is in sight and growth is robust, though not quite at the highest tier for all metrics.
EXLS Q4 2025: Data and AI-Led Revenue Climbs 21% as Segment Surpasses 57% of Mix
EXLS is demonstrating a long reinvestment runway with high returns, a disruptive shift to AI-led services, improving unit economics, and a self-reinforcing business model. While growth is strong and the business is not mature, forward guidance points to high single to low double-digit growth (not >20%), so some signal is capped. Still, the transformation and cash flow profile are highly investable for growth-focused investors.
Melrose Properties (MRP) Q4 2025: $2.4B Third-Party Investment Surpasses Stretch Target, Validates Land Banking Model
Melrose demonstrates a long reinvestment runway, disruptive model, and strong recurring economics. There is robust growth in third-party capital and builder demand, with clear compounding effects and improving unit economics. The only deduction is for guidance not indicating >30% growth, and revenue/eps growth likely below 40%.
Astrana Health (ASTH) Q4 2025: 43% Revenue Surge Extends Delegated Risk Outperformance
Astrana Health is exhibiting strong revenue and EBITDA growth, expanding margins, and clear evidence of a long runway for reinvestment at high returns. The business model is disruptive and self-reinforcing, with improving unit economics and customer value. While guidance is conservative and not projecting >40% forward growth, the underlying momentum, technology leverage, and expanding risk pool provide strong signals of continued compounding.
PAR Technology (PAR) Q4 2025: AI-Driven ARR Jumps $17M, Multi-Product Deals Near 90%
PAR demonstrates a long reinvestment runway, disruptive AI-native model, and improving unit economics, with strong cross-sell and platform adoption. There is clear evidence of compounding advantages and increasing customer value. While ARR growth is mid-teens and not above 20%, the business is transitioning to higher-margin, recurring revenue with accelerating enterprise momentum. The only deduction is for growth not being above 20% annually, and future guidance is strong but not exceptional (i.e., not >30% acceleration).
DELL Q4 2026: AI Backlog Hits $43B, Doubling Revenue Growth Trajectory for FY27
Dell demonstrates a long reinvestment runway with high returns through its AI infrastructure expansion and strong backlog. There is a significant business inflection with record AI server demand, backlog, and revenue growth. Unit economics are improving, but the self-reinforcing model is strong but not quite at the level of a pure network effect, hence a 1. Customer value is deepening with broadening enterprise adoption. The outlook and guidance are exceptional, with growth accelerating above 40%. The business is semi-disruptive—transforming IT infrastructure but not a new platform. Cash flow is accelerating, and revenue/EPS growth is well above 40%. Dell is a clear growth business. The only deductions are for the business model's incremental, rather than truly disruptive, nature and somewhat less pronounced network effects.
Zscaler (ZS) Q2 2026: Non-Seat Metered Solutions Exceed 25% of New ACV, Fueling Platform Expansion
Zscaler demonstrates a long reinvestment runway, significant recent developments (notably the shift to metered solutions and AI-driven growth), improving unit economics, and a self-reinforcing business model. Customer value is deepening, and the business is clearly positioned for growth, though forward guidance implies strong but not exceptional acceleration. The model is disruptive, cash flow is accelerating, and growth is robust, but not at the hypergrowth threshold for every metric.
Rocket Lab (RKLB) Q4 2025: Backlog Surges 69% as SDA Win Anchors Multi-Year Visibility
Rocket Lab exhibits a long reinvestment runway, disruptive model, and strong backlog growth, underpinned by government contracts and vertical integration. Margins and unit economics are improving, and the business is transitioning to growth, though free cash flow and cash generation remain in build mode. Guidance and backlog imply high growth, but not quite at the extreme acceleration threshold for a perfect signal score.
CAI (CARES Life Sciences) Q4 2025: Clinical Profiling Revenue Jumps 199%, Fueling Early Detection Ambitions
CARES demonstrates a long reinvestment runway, disruptive business model, improving unit economics, and compounding data advantages. Revenue growth is strong but moderates in the outlook (23-26% guided), so not all signal questions score a 2. The business is not yet showing 40%+ growth for future guidance, but the platform and execution levers are exceptional for the sector.
Syndax (SNDX) Q4 2025: Revuforge Net Revenue Climbs 38% on Expanded AML Penetration
Syndax demonstrates a long reinvestment runway with high returns on capital, significant recent growth and backlog expansion (Revuforge and Nictimbo), and improving unit economics as scale increases. The business model is self-reinforcing, with evidence of network effects and growing customer value. The future is strong, but not yet at the level of 'exceptional' acceleration. The business is disruptive with a credible path to cash flow acceleration. Revenue growth is strong but not consistently above 40% yet, so a 1 is assigned for that metric. Overall, the business is in high-growth mode with strong signals for further upside.
Enlight (LASR) Q4 2025: A&D Revenue Soars 87% as Focus Shifts to Defense Growth
Enlight demonstrates a long reinvestment runway, business model transition, and strong operating leverage, with defense growth and margin expansion. The backlog and capital raise support future growth, and the exit from legacy segments improves the business mix. However, future growth is not yet at the exceptional (30%+) acceleration level, and there is some execution risk, so not every signal question scores a maximum.
Venture Global (VG) Q4 2025: Contracted LNG Capacity Climbs to 69% as Expansion Accelerates
Venture Global demonstrates a long reinvestment runway, disruptive modular buildout, improving unit economics, and deepening customer value. There is strong evidence of growth, self-funding, and margin expansion, but the guidance for 2026 is not at the exceptional acceleration threshold for some metrics. The business is clearly a growth leader in its sector, with some risks from arbitration and market volatility tempering the signal slightly.
MasTec (MTZ) Q4 2025: Backlog Jumps 33% to $18B, Locking in Multi-Year Visibility
MasTec shows a long reinvestment runway, record backlog growth, and improving unit economics. The business model has elements of self-reinforcing scale, and customers are becoming more valuable with increasing backlog and contract depth. The outlook is exceptional on backlog and guidance, but the business model is only semi-disruptive (not pure tech or platform), and projected growth is strong but not consistently above 40%. The company is a clear growth business with accelerating cash flow.
PubMatic (PUBM) Q4 2025: Emerging Revenue Soars 75% as Agentic AI Adoption Accelerates
PubMatic demonstrates a long reinvestment runway, disruptive business model, and self-reinforcing dynamics with AI and platform scale. There are double-digit and accelerating growth signals, strong margin expansion, and clear evidence of increasing customer value. However, while growth is strong, it is not consistently above 40% for all lines, and guidance for Q1 is high single-digit, which slightly tempers the signal score. The business is a growth leader, but not at the highest hypergrowth threshold.
Guerrilla Technology (GRRR) Q4 2025: Operating Loss Narrows 80% as Edge AI Demand Drives $7B Pipeline
GRRR demonstrates a long reinvestment runway (data center buildout, recurring GPU-as-a-service), a massive pipeline inflection, improving unit economics, and a disruptive, self-reinforcing business model. Customers are becoming more valuable and the business is transitioning to high-margin, recurring revenue. While guidance growth is strong, the wide range and execution risks temper the score slightly. Overall, this is a high-signal, high-upside business with strong investor relevance.
Dave (DAVE) Q4 2025: ARPU Jumps 36% as Subscription and AI Underwriting Drive Durable Growth Algorithm
Dave demonstrates a long reinvestment runway, improving unit economics, a self-reinforcing AI/data moat, and accelerating cash flow. Revenue/earnings growth is robust but not consistently above 40%, and while guidance is strong, it does not suggest 'exceptional' acceleration. The business model is disruptive with capital-light scaling and deepening customer value, supporting a high but not perfect signal score.
Samsara (IOT) Q4 2026: Large Customer ARR Jumps 37% as Multi-Product Adoption Accelerates
Samsara demonstrates a long reinvestment runway, strong network effects, improving unit economics, and a disruptive, data-driven business model. Growth is robust and broad-based, with significant ARR and customer expansion. While forward guidance is strong, growth rates are slightly below the highest threshold for some metrics, and future acceleration is implied rather than fully proven. Overall, the signal is very high, with clear upside and compounding potential.
Sport Radar (SRAD) Q4 2025: IMG Synergy Drives 25% Revenue Uplift Target, Buyback Plan Expands to $1B
SRAD demonstrates a long reinvestment runway, disruptive business model, self-reinforcing content/data flywheel, improving unit economics, and strong cash flow. Growth is strong but not hyperbolic, and prediction market optionality is early-stage. The business is positioned for high growth and margin expansion, though some upside is still contingent on regulatory clarity and execution.
EVGO (EVGO) Q4 2025: Stall Deployment Up 50%, Operating Leverage Inflection in Sight
EVGO demonstrates a long reinvestment runway, clear network effects, improving unit economics, and disruptive business model features. Recent results show material growth and margin expansion, though forward guidance for 2026 is not exceptional enough for a top score on future acceleration. Revenue growth is strong but not over 40%. The business is firmly in the growth category, with compounding advantages.
CrowdStrike (CRWD) Q4 2026: Falcon Flex ARR Surges 120% as AI Security Drives Platform Expansion
CrowdStrike demonstrates a long reinvestment runway, disruptive and self-reinforcing business model, and improving unit economics. Growth rates are strong but just below the extreme threshold for some questions, and guidance is robust but not at an exceptional acceleration. The business is clearly a high-growth, thesis-relevant opportunity for investors, but as a well-followed leader, the signal is slightly tempered by its scale and visibility.
Ocugen (OCGN) Q4 2025: OCU410 Shows 46% Lesion Reduction, Accelerating Gene Therapy Pipeline Milestones
Ocugen demonstrates a long reinvestment runway with disruptive, gene-agnostic therapies and strong recent clinical data. Backlog (pipeline) and clinical milestones are accelerating, with improving unit economics as scale is reached. The business model is self-reinforcing, and customer value is expanding. While cash flow is not yet accelerating (pre-commercial), the business is positioned for high growth and is transitioning to a commercial stage with multiple catalysts.
Omada Health (OMDA) Q4 2025: Gross Margin Hits 73% as Multi-Condition Platform Drives Durable Scale
Omada Health demonstrates a long reinvestment runway, disruptive and self-reinforcing business model, improving unit economics, and strong customer value expansion. Growth is rapid but not at hypergrowth levels (annual guidance at 22%). Backlog/guidance revision is good but not exceptional. Cash flow and margin expansion are strong, and the business is transitioning into a high-growth, scalable platform with upside optionality from new product launches.
NYAX (NYAX) Q4 2025: Recurring Revenue Hits 72% of Sales as Platform Margins Reach 48%
NYAX demonstrates a long reinvestment runway, compounding business model, and clear margin/ARPU expansion, with high recurring revenue and a strong platform effect. While revenue growth is strong (22-25% organic), it falls short of the 40%+ threshold for the highest score in some categories. The business is clearly growth-oriented and disruptive, but some guidance and backlog measures are not at the most exceptional levels.
Voyager Technologies (VOYG) Q4 2025: Backlog Jumps 41% as Defense Demand Accelerates
Voyager shows a long reinvestment runway, disruptive model, and compounding advantages via vertical integration and innovation. Backlog growth and guidance are exceptional, with clear business evolution. Cash flow is not yet accelerating and near-term growth is below 40%, so those points are marked lower. Overall, the business is high-signal for investors seeking growth and inflection.
NIO (NIO) Q4 2025: Vehicle Margin Climbs to 18.1% as Premium SUV Mix Drives Profitability
NIO demonstrates a long reinvestment runway, disruptive business model, improving unit economics, and accelerating growth. The business is transitioning into a cash flow generator with strong premium mix and infrastructure moats. However, the outlook, while strong, is not yet exceptional (guidance is robust but not explosive), and some elements (chip monetization, global expansion) remain in early innings, warranting a slightly conservative signal score.
Village Farms (VFF) Q4 2025: International Export Sales Jump 384%, Fueling Margin Expansion
Village Farms demonstrates a long runway with high returns on capital, exceptional recent growth in international exports, and clear margin expansion. Unit economics and cash flow are improving, the business model is gaining self-reinforcing elements with EU GMP leadership, and customer value is increasing. While disruptive potential is present, it is not fully at the level of platform businesses, and revenue growth is strong but not consistently above 40%. The signal is high, but not at the absolute maximum due to these moderations.
AMTX Q4 2025: Biogas Net Income Hits $12M, MVR Upgrade to Unlock $32M Annual Cash Flow
Aemetis demonstrates a long reinvestment runway with high returns via asset buildout and environmental credits. There are significant recent developments (RNG profitability, MVR upgrade), improving unit economics, and a self-reinforcing business model. Customer value is increasing with higher credit capture. Backlog/guidance is strong but not yet exceptional. The model is disruptive and cash flow is set to accelerate, but near-term growth rates are likely under 40%, and execution risk remains.
CareCloud (CCLD) Q4 2025: Free Cash Flow Surges 55% as AI-Driven Acquisitions Expand Hospital Reach
CareCloud demonstrates a long reinvestment runway, disruptive AI-led business model, strong unit economics, and a clear path to margin expansion and cash flow growth. The company is transitioning into a high-growth phase with significant optionality, though not all future growth is guaranteed (hence a deduction on question 6 and 9, as guidance is strong but not yet 40%+). The business model is self-reinforcing and customer value is increasing, with significant cross-sell opportunities. The overall signal is very high, with only a minor deduction for guidance not being at the most exceptional level.
ServiceTitan (TTAN) Q4 2026: MAX Cohort Doubles Subscription Revenue, AI Orchestration Expands
ServiceTitan demonstrates a long reinvestment runway, high returns on capital, and a disruptive, self-reinforcing AI-driven business model. MAX adoption is doubling subscription revenue in early cohorts, and usage-based monetization is accelerating. However, while growth is strong, guidance remains measured and not all segments are accelerating above 40%. The business is clearly transitioning into a compounding growth phase with strong signals of durable competitive advantage.
Wheaton Precious Metals (WPM) Q4 2025: Antamina Stream Doubles to 18% Portfolio Share, Unlocking 50% Growth Path
Wheaton demonstrates a long reinvestment runway, record-breaking deal flow, improving unit economics, and a compounding business model. Customer value and cash flow are both improving. While the business is not disruptive in a tech sense, its streaming model is sector-leading. Guidance and backlog support strong growth, but not at hyper-growth levels (>40% annually), so some scores are conservatively marked down.
Kestra (KMTS) Q3 2026: Gross Margin Expands 900bps as Territory Buildout Drives 63% Growth
Kestra demonstrates a long reinvestment runway with high returns, significant recent growth (63% revenue, 900bps margin expansion), improving unit economics, and a self-reinforcing rental model. Customers are becoming more valuable, and the business is transitioning to a cash flow machine. While growth is robust, some signals (like future guidance acceleration) are not yet exceptional, and annualized growth is strong but not above 40%. The business is disruptive with clear opportunities, but still in early innings of market expansion.
YB (YB) Q4 2025: Insurance Distribution Surges 35% as AI-Driven Personalization Scales Platform Reach
Yuanbao demonstrates strong reinvestment runway, rapid growth, and improving unit economics, with a disruptive AI-driven business model and high cash flow potential. While growth is robust, guidance is less specific, and near-term growth rates are high but not at the extreme acceleration threshold. The business is clearly in a high-growth phase with significant optionality and competitive barriers.
UAMY Q4 2025: Revenue Surges 163% as Government Contracts and Vertical Integration Reshape Outlook
UAMY demonstrates a significant inflection with government contracts, vertical integration, and a long reinvestment runway. The business model is becoming self-reinforcing, customer value is deepening, and the company is positioned as a growth business. However, cash flow acceleration and near-term revenue/EPS growth are not yet at the highest levels, warranting a slightly lower score for those items. Overall, the signal for valuation upside and business model transformation is very strong.
CLLS Q4 2025: $53M Cash Burn Drives Focused Allogeneic CAR-T Execution and Pivotal Milestone Readouts
Selectus demonstrates a long reinvestment runway, disruptive and self-reinforcing business model, and strong pipeline optionality. There are recent significant developments (internal manufacturing, pivotal trial progress, high response rates) and clear growth potential. However, the business is still pre-commercial and cash flow is not yet accelerating, and while growth is strong, it is not yet at the highest tier (over 40% annualized). The business is solidly in the growth category, but some metrics are just shy of the top score due to pre-commercial status and pending inflection.
Intuitive Surgical (ISRG) Q1 2026: Da Vinci 5 Drives 23% Revenue Growth, Expanding Innovation-Led Margin Leverage
ISRG demonstrates a long reinvestment runway, disruptive model, and compounding advantages with clear international growth and innovation. There is strong evidence of margin and unit economic improvement, and premium innovation is driving revenue ahead of procedures. Guidance is raised, but not at a 30%+ acceleration, so growth is strong but not hyperbolic. Some regional headwinds temper the overall growth signal.
STMicroelectronics (STM) Q1 2026: AI and Data Center Revenue Set to Top $500M, Accelerating Transformation
STM demonstrates a long reinvestment runway, clear disruptive momentum in AI/data center, and improving unit economics. Recent events (NXP acquisition, AWS partnership) are highly material. While cash flow is not yet accelerating due to transformation costs, the business is transitioning to a growth trajectory with high visibility and exceptional future prospects. Revenue and EPS growth are strong but not yet above 40%, and cash flow acceleration is moderate rather than rapid.
ON Semiconductor (ON) Q1 2026: AI Data Center Revenue Doubles, Margin Expansion Signals Recovery
ON Semiconductor is showing clear signs of secular growth with strong reinvestment runway, significant recent growth in AI and energy storage, and improving unit economics. The business model is increasingly self-reinforcing with high-value content gains in automotive and AI. While not fully disruptive, the company is transitioning to a high-growth profile with accelerating cash flow and margin leverage. Some elements (like revenue/EPS growth rate) are strong but not at the highest threshold.
AMBER (AMBR) Q4 2025: Premium Revenue Surges 572% as AI-Driven Platform Model Scales
AMBER demonstrates a long reinvestment runway, clear disruptive model, and major margin/recurring revenue inflection. While growth is strong, full-year guidance is qualitative and near-term revenue growth is not over 40%, so some signal is tempered. However, the regulatory wins, AI-native platform, and premiumization strategy represent highly investable strategic shifts.
NXP Semiconductors (NXPI) Q1 2026: Data Center Revenue Set to Surpass $500M, Doubling Year-Over-Year
NXP is demonstrating a long reinvestment runway, clear margin expansion, and accelerating growth in new verticals—especially data center. The business model is self-reinforcing and customers are becoming more valuable. Guidance and backlog signal exceptional near-term growth. However, while disruptive in some verticals, the business is not fully disruptive across all areas, and revenue growth is strong but not consistently above 40%.
IONIS (IONS) Q1 2026: Olazarsen Peak Sales Raised 50% to $3B, Anchoring Commercial Expansion
IONIS demonstrates a long reinvestment runway, disruptive business model, and multiple growth drivers with clear optionality. The peak sales upgrade, commercial execution, and pipeline breadth provide strong signal. Some growth metrics (revenue/EPS) are not yet at hyper-growth levels, and cash flow is not yet accelerating, so the score is not a perfect 20.
Generac (GNRC) Q1 2026: Data Center Backlog Jumps $300M, Powering CNI Growth Visibility
Generac demonstrates a long reinvestment runway, exceptional backlog growth, improving unit economics, and a self-reinforcing business model, particularly in CNI/data centers. The business model is more evolutionary than disruptive, and while growth is strong, it is not consistently above 40%. Overall, the signal is high due to rare multi-year backlog visibility and margin expansion, but not at the highest disruptive or hypergrowth threshold.
Teradyne (TER) Q1 2026: AI Drives 87% Revenue Surge, Shifting Portfolio to Compute-Centric Growth
Teradyne demonstrates a long reinvestment runway, disruptive business model, improving unit economics, and strong growth in AI-driven segments. However, while growth is robust, near-term guidance and visibility are somewhat constrained by order lumpiness and customer concentration, so not all metrics are at the highest possible level.
AMBER International (NBR) Q1 2026: Premium Segment Soars 572% as AI Suite Launch Nears
AMBER demonstrates a long reinvestment runway, disruptive business model, improving unit economics, and self-reinforcing platform dynamics. The Premium segment’s 572% growth and margin expansion are highly material. While future growth is strong, explicit guidance for full-year acceleration is absent, so the score is slightly reduced. Nonetheless, the business is positioned as a growth leader with significant optionality.
Microsoft (MSFT) Q3 2026: AI ARR Doubles to $37B, Usage-Based Model Drives Platform Shift
Microsoft demonstrates a long runway with high ROIC, disruptive business model evolution, and strong compounding customer economics. There is clear evidence of improving unit economics, deepening customer engagement, and a major business model shift. However, while growth is strong, it is not above 40% annually at the consolidated level, and future guidance—though robust—is not at an exceptional acceleration threshold. The business is clearly a growth leader but not an under-the-radar or overlooked opportunity, slightly lowering the signal score.
Alamos Gold (AGI) Q1 2026: Island Gold Reserve Doubles, Unlocking $12B NPV Expansion
Alamos Gold demonstrates a long reinvestment runway with the Island Gold expansion, a significant recent reserve increase, and improving unit economics. The business model is increasingly self-reinforcing, with growing customer value and a strong growth outlook. While not fully disruptive, the company is transitioning to a more capital-efficient, high-return model with accelerating cash flow. Revenue growth is strong, though not consistently above 40%. The article signals a clear transition into a high-growth phase, making it highly actionable for investors.
Bandwidth (BAND) Q1 2026: Cloud Communications Revenue Jumps 13% as AI Drives Usage Model Shift
Bandwidth demonstrates a long reinvestment runway, improving unit economics, and a disruptive, self-reinforcing business model, with accelerating cash flow and growth. The only deduction is for growth rates and guidance, which, while strong, are not at the very top end (over 40%) for all metrics.
Antero Resources (AR) Q1 2026: HG Acquisition Accelerates $80M Synergy Run-Rate, Propelling Margin Expansion
Antero demonstrates a long reinvestment runway, rapid synergy realization, improving unit economics, and self-reinforcing export advantages. Customer value is rising via regional demand, and the outlook is exceptional with 20% production growth. The business model is not fully disruptive but has some lateral opportunity. Cash flow is accelerating, but revenue/EPS growth is just below the highest tier. This is a growth business with clear valuation upside.
Stagwell (STGW) Q1 2026: Net New Business Surges $80M, Setting Up Double-Digit Growth Path
Stagwell demonstrates a long reinvestment runway, disruptive business model, improving unit economics, and strong customer value growth. The recent surge in net new business and government contract wins indicate a significant business evolution. However, while growth is strong, full-year guidance implies high single- to low-double-digit growth, not 40%+, so some signal questions are scored conservatively. Still, the business is clearly transitioning to higher-margin, tech-driven growth with accelerating cash flow.
Alnylam (ALNY) Q1 2026: TTR Franchise Surges 153% YoY, Propelling $1B+ Quarterly Milestone
Alnylam demonstrates a long reinvestment runway, disruptive RNAi platform, and accelerating TTR franchise growth. There is clear evidence of improving unit economics, expanding customer value, and self-reinforcing business model. While the growth is strong, guidance does not indicate >40% revenue/EPS growth, and backlog/guidance revision is strong but not exceptional. The business is firmly in the growth category and shows robust cash flow scaling.
SILC Q1 2026: Design Wins Double Revenue Growth Pace, Securing 33% Inflection
SILC demonstrates a long reinvestment runway, major design win acceleration, and improving unit economics. The business model is compounding, customers are becoming more valuable, and guidance revisions are exceptional. AI/PQC initiatives add disruptive optionality. However, cash flow is improving but not yet fully accelerating, and revenue growth is strong but not consistently above 40%.
Western Digital (WDC) Q3 2026: Cloud Revenue Jumps 48% as AI Data Workloads Accelerate HDD Demand
Western Digital demonstrates a long reinvestment runway, strong recent growth (48% YoY in cloud), improving unit economics, and a self-reinforcing model via LTAs and technology leadership. Customer value is increasing, and cash flow is accelerating. While disruptive elements are present, the business model is not fully disruptive (score 1 for Q7). Revenue/EPS growth is strong but not consistently above 40% (score 1 for Q9). Overall, the business signals high strategic value and inflection.
ASUR Q1 2026: AI-Driven Margin Jumps 800bps as Assure Central Adoption Surges
ASUR demonstrates a long reinvestment runway with AI-driven margin expansion, a disruptive platform shift, and strong recurring revenue trends. There is clear unit economics improvement, self-reinforcing business model elements, and increasing customer value. While backlog and revenue growth are strong, the guidance is conservative, so not all metrics are at the highest possible growth acceleration, warranting slight deductions.
Duolingo (DUOL) Q1 2026: AI Content Output Surges 10x, Setting Up Durable User Growth
Duolingo demonstrates a long reinvestment runway, disruptive AI-driven business model, and improving unit economics. User and revenue growth are strong but not at the highest possible level (>40%), and future guidance is good but not exceptional. The business is clearly in growth mode with accelerating cash flow and increasing customer value, but the growth rates and outlook are just short of the most extreme signal.
Paymentus (PAY) Q1 2026: AI-Driven Bill Wallet Launches as Revenue Jumps 30%
Paymentus demonstrates a long reinvestment runway, disruptive platform launch, and improving economics. The guidance revision is positive but not exceptional (under 30% acceleration), and forward growth is strong but not hyper-growth. Otherwise, the business model, cash flow, and strategic positioning are highly attractive.
Grab (GRAB) Q1 2026: On-Demand GMV Jumps 24% as AI and EV Initiatives Deepen Competitive Moat
Grab demonstrates a long reinvestment runway with high returns, significant recent growth (24% GMV, 67% loan disbursal), improving unit economics, and a self-reinforcing business model. Customer value is deepening, and the business model is disruptive. Cash flow is accelerating, and the company is a clear growth business. However, revenue/EPS growth is strong but not above 40%, and guidance/growth outlook, while solid, is not at a truly exceptional acceleration level.
Twist Bioscience (TWST) Q2 2026: Therapeutics Revenue Surges 55% on AI-Driven Demand Expansion
Twist Bioscience demonstrates a long runway for reinvestment at high returns, disruptive business model, improving unit economics, and self-reinforcing platform dynamics. Recent growth is strong, but not at the highest acceleration tier. The business is not yet a cash flow machine, and while growth is robust, guidance and backlog do not indicate >40% acceleration. Nevertheless, the business is clearly in growth mode and is strategically positioned for continued upside.
Sky Bioscience (SKYE) Q4 2025: 22% Combo Weight Loss Drives Add-On Obesity Strategy
SKYE demonstrates a long reinvestment runway, disruptive business model, and strong early clinical results with meaningful optionality. However, the business is still in a clinical transition phase and not yet demonstrating accelerating cash flow or 40%+ growth, so scores are capped on those dimensions. The signal is high due to the clear inflection and platform potential, but some risks and execution hurdles remain.
Fulcrum Therapeutics (FULC) Q1 2026: $333M Cash Runway Extends to 2029 as Sickle Cell Data Drives Next-Phase Strategy
Fulcrum Therapeutics demonstrates a long reinvestment runway, disruptive business model, improving unit economics, and strong customer value trajectory. The clinical and financial data signal potential for high growth, though not yet at the 'exceptional' level for all metrics (e.g., growth is strong but not clearly >40% annually, cash flow is not yet accelerating at scale). The company's first-mover advantage and regulatory catalysts provide substantial upside, but some risks and uncertainties remain.
Silicon Motion (SIMO) Q1 2026: EMMC and UFS Revenue Surges 140% as NAND Scarcity Reshapes Market
SIMO demonstrates a long reinvestment runway, clear margin and revenue growth, and increasing relevance in AI/cloud infrastructure. While growth is strong, it is not at hypergrowth (40%+) levels, and some aspects (disruptiveness, future exceptional growth) are present but not at the highest possible tier.
Guardian Pharmacy Services (GRDN) Q4 2025: Adjusted EBITDA Margin Expands 200bps as Scale and Acquisitions Accelerate Profitability
Guardian demonstrates a long reinvestment runway, high returns on capital, and clear operating leverage. There are significant growth drivers (demographics, acquisitions), improving unit economics, and a self-reinforcing business model. While guidance is strong, growth is not exceptional enough for full marks in some areas, and the business model, though robust, is not highly disruptive.
OrthoPediatrics (KIDS) Q4 2025: Gross Margin Jumps to 73% as Product Super Cycle Accelerates
OrthoPediatrics demonstrates a long reinvestment runway with high returns, a clear business model inflection, and improving unit economics. The business model is increasingly self-reinforcing, customers are becoming more valuable, and the company is transitioning to a cash flow machine. While the growth outlook is strong, guidance is for low double digits, so not all signal questions reach the highest threshold. The business is innovative but not fully disruptive, and some future growth is implied rather than proven.
Bicara Therapeutics (BCAX) Q4 2025: 129 Global Sites and $414.8M Cash Position Fuel Fisera Launch Trajectory
Bicara exhibits a long reinvestment runway, disruptive business model, improving unit economics, and operational momentum. While not all growth metrics are at the highest threshold (e.g., guidance is strong but not >40% growth), the company is positioned for significant value creation if execution continues. The business is clearly in a late-stage acceleration phase with substantial upside optionality.
ATEC (ATEC) Q4 2025: EBITDA Margin Expands 400bps as Surgeon Adoption Drives Durable Growth
ATEC demonstrates a strong growth profile with expanding margins, improving unit economics, and a long runway for reinvestment. While the business model is innovative and disruptive within its niche, growth and guidance—though robust—do not quite reach the highest acceleration thresholds. The business is a structural share gainer, but not a newly discovered or under-followed name.
Codexis (CDXS) Q4 2025: EcoSynthesis Drives $38.9M Revenue Surge as RNA Platform Gains Traction
Codexis demonstrates a long reinvestment runway with disruptive platform potential and is transitioning into a high-growth RNA manufacturing market. The business model is self-reinforcing with emerging network effects, and customer value is deepening. While growth is strong, the near-term acceleration is not yet exceptional (less than 30%). Cash flow is improving but not yet accelerating. Revenue growth is in the 20-40% range, and the business is moving from transition to growth.
Teck Resources (TECK) Q4 2025: Copper EBITDA Margin Hits 50% as Anglo Merger Drives Scale
Teck is positioned for high returns on capital with a long copper runway, margin expansion, and major merger-driven scale. Recent developments (merger, margin surge, QB ramp) are significant. Unit economics and self-reinforcing model are evident, and customer value is increasing via byproduct leverage. However, while growth is strong, it is not at the hyper-growth level (over 40% YoY), and the business model, while transformative, is not fully disruptive. Cash flow is accelerating, and the business is clearly in a growth phase, but some risks remain around integration and capex peak.
Cadence (CDNS) Q1 2026: $8B Backlog Signals Agentic AI-Driven Demand Surge
Cadence demonstrates a long reinvestment runway, disruptive business model, and strong backlog-driven growth, with clear signs of compounding advantages. While growth is strong and the business is positioned for continued expansion, near-term margin dilution and guidance conservatism temper the signal score. The business is not a new discovery but remains highly investable for valuation upside.
Caterpillar (CAT) Q1 2026: Backlog Surges 79% as Data Center Demand Triggers Engine Capacity Expansion
Caterpillar demonstrates exceptional backlog growth, strong reinvestment at high returns, and a clear pivot to secular growth drivers. While not a disruptive business model, the company is executing on a large-scale capacity expansion with accelerating cash flow and high revenue/earnings growth. The signal is strong, though the business is well-known and not a new growth story, which slightly tempers the score.
SI-Bone (SIBN) Q4 2025: Physician Base Jumps 18% as ASC Penetration and Trauma Partnerships Expand
SI-Bone demonstrates a long reinvestment runway, high ROIC potential, and strong recent developments (physician base growth, ASC penetration, trauma partnerships). Unit economics and business model are self-reinforcing, with improving customer value. However, while guidance and backlog point to continued growth, the acceleration is not at an exceptional (30%+) level, and the business, while innovative, is not fully disruptive. Growth rates are strong but not hyper-growth, and the business is a clear growth story, not a legacy or stalling one.
Kodiak Gas Services (KGS) Q4 2025: Contracted Horsepower Backlog Extends Into 2028 as Lead Times Top 100 Weeks
Kodiak demonstrates a long runway for reinvestment with high returns, a fully contracted backlog, and improving unit economics. The DPS acquisition and AI-driven efficiency add optionality and margin expansion. The business model is self-reinforcing, and customer value is increasing. While growth is strong, the guidance suggests growth moderates below the 40% threshold, and the business—while very solid—is not disruptive to the extent of a tech platform. Some risk remains on integration and execution.
ASTS Q4 2025: $1.2B Backlog Anchors Commercial Ramp as Satellite Output Scales
ASTS demonstrates a long reinvestment runway, significant backlog growth, improving unit economics, a self-reinforcing business model, and deepening customer value. The business model is disruptive with strong government and commercial demand, but the business is not yet showing exceptional (30%+) growth in guidance, and cash flow acceleration is not yet clear. The company is in a growth phase but faces execution risks.
Intellia Therapeutics (NTLA) Q4 2025: Lombosi Phase 3 Enrollment Surpasses 80, Paving Path to First CRISPR Launch
Intellia demonstrates a long reinvestment runway, disruptive business model, and strong customer value expansion. While commercial inflection is imminent and growth potential is high, the business is not yet showing >40% revenue/earnings growth, and cash flow is not yet accelerating (but is projected). Regulatory risks temper the signal slightly, but the opportunity is substantial.
Constellation Energy (CEG) Q4 2025: 20% Base EPS CAGR Anchors Post-Calpine Growth Trajectory
Constellation Energy demonstrates a strong growth runway, high returns on capital, and improving unit economics, with clear self-reinforcing business model elements and growing customer value. While the business is not disruptive in the traditional tech sense, it is semi-disruptive within utilities, and cash flow is accelerating. Guidance and backlog are strong but not at hypergrowth levels, and while the business is a growth platform, some upside is left unmodeled, justifying a slightly conservative score.
ATI (ATI) Q1 2026: Backlog Surges 10% to $4.1B, Locking In Multi-Year Demand Visibility
ATI demonstrates a long runway in high-value segments with strong backlog and mix-driven margin expansion. There are clear improvements in unit economics, self-reinforcing business model elements, and accelerating cash flow. While growth rates are strong, not all segments are at hypergrowth levels (>40%), and some elements (like disruption) are moderate rather than extreme. Overall, signal is high but not at the absolute maximum.
Gogo (GOGO) Q1 2025: Service Revenue Jumps 143% as Galileo and 5G Position for Multi-Orbit Upside
Gogo exhibits a long reinvestment runway, disruptive business model, and improving unit economics. Service revenue and margins are surging, and government/defense tailwinds expand TAM. However, 2025 is a trough year for cash flow, and while growth is strong, guidance does not indicate >40% forward acceleration, capping some scores. Still, the business is clearly transitioning to a higher-growth, higher-margin model with substantial optionality.
Centuri (CTRI) Q4 2025: Backlog Jumps 59% as Bookings Hit $4.5B, Locking in Multi-Year Growth Visibility
Centuri demonstrates a long reinvestment runway, significant backlog growth (59%), improving unit economics, and a self-reinforcing model via MSAs and bid selectivity. Customer value is increasing, and guidance/backlog suggest robust growth, though not at hypergrowth levels. The business is not fully disruptive (traditional infrastructure services), and while cash flow is improving, it is not yet accelerating. Revenue and EPS growth are strong but not consistently above 40%. The business is clearly in a growth phase.
Li Auto (LI) Q4 2025: R&D Hits RMB 11.3B as AI and Direct Sales Strategy Reshape Core Model
Li Auto demonstrates a long reinvestment runway with high R&D and AI spend, proprietary chips, and a disruptive direct sales model. There is a significant uptick in BEV orders and operational reset, but growth guidance is around 20%, not >40%. Unit economics and customer value are improving, but cash flow acceleration is moderate. The business is growth-oriented and disruptive, but not at the highest velocity, so some scores are conservative.
Varonis (VRNS) Q1 2026: SaaS ARR Jumps 29% as AI Security Demand Accelerates
Varonis demonstrates a long reinvestment runway, disruptive SaaS transition, and strong growth signals (29% SaaS ARR, raised guidance, new logo acceleration). Some scores are not maxed due to margin compression and guidance that, while strong, is not at hypergrowth levels. The business is clearly transitioning to a growth phase with high investor relevance.
Grail (GRAL) Q4 2025: Gallery Test Volume Up 36% as Stage 4 Cancer Detection Drops Over 20%
Grail has a long reinvestment runway, disruptive business model, improving unit economics, and is transitioning to commercial scale. The business is not yet showing >40% annual growth or exceptional acceleration, but the clinical and regulatory inflections are significant. Cash flow is improving but not yet accelerating, and some growth metrics are below the highest threshold. Overall, the signal is strong, but not at the absolute maximum due to these nuances.
Surf Air Mobility (SRFM) Q4 2025: On-Demand Charter Up 36% as Platform Pivot Drives 2026 Growth Ambition
SRFM demonstrates a long runway, disruptive platform transition, and strong unit economics in the charter business. The Beta Technologies partnership and software commercialization create significant upside optionality. However, the business is not yet showing exceptional (30%+) growth or cash flow acceleration, and some execution risk remains around software ramp and electrification milestones.
Montrose Environmental (MEG) Q4 2025: Cross-Sell Revenue Jumps to 62%, Signaling Deepening Client Penetration
Montrose demonstrates a long reinvestment runway, compounding cross-sell, improving margins, and a disruptive, integrated business model. Growth is robust but not hyperbolic (not 40%+), and while water tech is a strong growth vector, the business is not quite in a 'massive' inflection phase. Guidance is positive but not exceptional. Signal is high but not at the very top end for a truly explosive or under-followed opportunity.
CoStar Group (CSGP) Q1 2026: Homes.com Revenue Surges 58%, Unlocking Pricing Power
CoStar demonstrates a long reinvestment runway, disruptive business model elements, and strong unit economics, but growth rates are high rather than explosive (>20% but <40%). The business is transitioning to a higher-margin, global SaaS/marketplace model with accelerating cash flow and clear pricing power, but not all signals are at the absolute highest level for an unknown or underappreciated growth story.
Corvus Pharmaceuticals (CRVS) Q4 2025: $189M Financing Extends Cash Runway to 2028 as Socalitinib Clinical Momentum Builds
Corvus shows a long reinvestment runway, disruptive platform potential, and improving unit economics with clinical momentum and capital strength. While growth is high and catalysts are near, a slight deduction is made for not yet demonstrating exceptional future guidance acceleration and only moderate cash flow ramp. Overall, the signal is strong and above average for the sector.
Bandwidth (BAND) Q4 2025: AI-Driven Voice Deals Surge, Software Services Run Rate Hits $15M
Bandwidth shows a long reinvestment runway, high returns on capital, and clear operating leverage. There is strong evidence of accelerating enterprise wins, AI-driven growth, and expanding software margins. While growth is robust, not all metrics point to hypergrowth (>40%), and the business model, while evolving, is not fully disruptive compared to pure SaaS or platform giants. Still, the business is strongly positioned for compounding and margin expansion.
Lincoln Educational Services (LINC) Q4 2025: 21% Revenue Surge Anchored by Skilled Trades Expansion
Lincoln is demonstrating a long reinvestment runway with high returns, clear operating leverage, and a disruptive hybrid model. Growth is strong and consistent, with double-digit revenue and EBITDA expansion, but not quite at the highest acceleration threshold. The business model is self-reinforcing and customer value is increasing. While the growth is substantial, it is not consistently above 40% annually, and some elements (e.g., high school channel, healthcare rebound) are still emerging rather than fully materialized.
Pursuit (PRSU) Q4 2025: EBITDA Margin Expands 500bps as Iconic Asset Model Drives 2030 Growth Targets
Pursuit demonstrates a long reinvestment runway with high returns, significant recent growth, improving unit economics, and a self-reinforcing model based on asset scarcity. Customers are becoming more valuable, and the business is transitioning to a strong growth phase with accelerating cash flow. While guidance is solid, it is not exceptional (not >30% acceleration), and the business model, while highly attractive, is not fully disruptive. Revenue and EPS growth are expected to be double-digit, but not consistently above 40%. The business is clearly in a growth phase and not legacy or stalling.
HeartBeam (BEAT) Q4 2025: 70%+ Margin Subscription Model Targets 30,000 Patients for Breakeven
HeartBeam demonstrates a disruptive, high-margin subscription model with a clear reinvestment runway and evidence of improving unit economics. The business model is self-reinforcing, customer value is increasing, and the company is positioned for high growth, though not all metrics (e.g., immediate cash flow acceleration or >40% growth) are fully de-risked yet. Execution risk and capital constraints remain, slightly tempering the signal score.
CS Disco (LAW) Q4 2025: Generative AI Revenue Jumps 600% as Platform Unifies Under New Pricing Model
CS Disco demonstrates a strong reinvestment runway and disruptive business model, with clear evidence of compounding advantages and improving unit economics. The 600% AI revenue growth and upmarket expansion are highly material, but guidance and future growth, while strong, are not yet exceptional across all metrics. Margins are improving, but cash flow is not yet accelerating. The business is in a growth phase with credible upside.
Weave (WEAV) Q1 2026: Payments Revenue Grows 2x Faster Than Core, Unlocking Margin Expansion
Weave demonstrates a long reinvestment runway (payments and AI), recent business acceleration (payments >2x core), and improving unit economics. The model is self-reinforcing with increasing ARPU and customer retention. The business is moving toward growth, but some metrics (e.g. revenue/EPS growth rates, cash flow) are not yet at the highest acceleration, so scores are conservative on those dimensions. The model is disruptive within vertical SaaS for healthcare, but not a brand-new category. Overall, the signal is strong but not at the absolute maximum due to some metrics still in transition.
Sophia Genetics (SOPH) Q4 2025: 31% Clinical Revenue Surge Signals Platform Expansion
Sophia Genetics shows strong signals of a high-quality growth business: long reinvestment runway, disruptive model, improving unit economics, and deepening customer value. However, while growth is robust (20–31%), it is not yet at hypergrowth levels (>40%), and biopharma ramp is still gradual. Cash flow is improving but not yet accelerating. The business is transitioning toward profitability but not yet a cash machine. Signal is high but not at the very top end.
Wave Life Sciences (WVE) Q1 2026: Cash Position Extends Runway Into 2028 as RNA Platform Advances
Wave Life Sciences demonstrates a long reinvestment runway, disruptive business model, improving unit economics, and a transition to late-stage clinical execution. Clinical catalysts and cash runway support high growth potential, but some uncertainty remains regarding the magnitude and timing of growth inflection and cash flow acceleration, justifying some deductions.
Identiv (INVE) Q4 2025: BLE Smart Label Deal Unlocks 100M Unit Ramp, Margin Profile Transforms
Identiv has a long reinvestment runway (exclusive IFCO deal, IoT-only focus), major recent developments (BLE rollout, manufacturing overhaul), and improving unit economics. The business model is disruptive with self-reinforcing elements. However, near-term growth (guidance) is strong but not yet at exceptional acceleration, cash flow is not yet accelerating, and margin volatility remains a risk. The business is transitioning but positioned for growth.
EH (EH) Q4 2025: Overseas Revenue Set to Double as Commercial Operations Launch
EH is at a major inflection point, launching the world’s first ticketed pilotless passenger flights and moving to a recurring revenue model with global expansion. The business model is disruptive with a long runway, strong margin profile, and evidence of improving unit economics. However, growth guidance is just under 20% for 2026 and cash flow is not yet accelerating, warranting a conservative score on those dimensions.
Evergy (EVRG) Q4 2025: $21.6B Capex Plan Anchors 6% Load CAGR, Data Center Surge Drives 8%+ EPS Growth Path
Evergy displays a rare combination of long reinvestment runway, disruptive regulatory innovation, and clear acceleration in growth from data center contracts. The business model is transitioning to a higher growth, higher visibility profile with strong unit economics and customer value deepening. Some signal is withheld due to the inherently regulated and capital-intensive nature of the utility sector, and because the business is not entirely disruptive compared to tech, but the inflection is clear and material.
PSTG Q4 2026: Hyperscale Momentum Drives 19% Revenue Growth Outlook Amid Supply Volatility
EverPure demonstrates a long reinvestment runway, disruptive business model, improving unit economics, and growing customer value. The business is transitioning to higher-margin, software-driven revenue streams and is positioned for growth, but some uncertainty remains on the magnitude and timing of margin recovery and hyperscaler deal conversion. Growth is high but not at the most exceptional acceleration, and cash flow is strong but not yet rapidly accelerating.
Alchemy Technology (ALKT) Q4 2025: ARR Backlog Hits $71M as Integrated Platform Drives 30% Uplift
Alchemy Technology demonstrates a long reinvestment runway, disruptive SaaS model, improving unit economics, and high customer retention. Recent backlog and ARR growth are strong but not at the most exceptional acceleration levels. The business is transitioning to higher cash flow and margin, but near-term headwinds temper the signal slightly. The model is self-reinforcing with clear lateral opportunities, and the company is positioned for durable growth, though not all signal indicators are at maximum strength.
Axsome Therapeutics (AXSM) Q1 2026: Ovelity Peak Sales Raised to $8B on Alzheimer’s Agitation Expansion
Axsome demonstrates a long reinvestment runway with a disruptive CNS platform, a major new indication, and raised peak sales guidance. While not yet showing 40%+ growth or cash flow acceleration, the dual-indication launch and expanded addressable market provide strong optionality and growth prospects. The business is transitioning to a growth phase, but not all metrics (e.g., cash flow, guidance) are exceptional or at the highest signal threshold.
AAMI Q1 2026: Net Flows Surge $21.4B, Record AUM Signals Systematic Strength
Acadian demonstrates a long reinvestment runway, clear margin expansion, and strong compounding business model characteristics. There is evidence of accelerating flows and profitability, but the business—while high quality—is not disruptive on a scale that would merit a perfect signal score. The growth is robust but not at an exceptional, transformative level across all dimensions.
CytomX (CTMX) Q4 2025: Varsetta-M Delivers 32% ORR at 10mg, Accelerating CRC ADC Path
CytomX demonstrates a disruptive, platform-based business model with a long reinvestment runway, strong clinical inflection, and the potential for multi-indication expansion. The business is not yet at the cash flow machine stage and guidance suggests strong but not yet exceptional acceleration (hence, 1s for those items). The rest of the signal is very high due to the first-in-class nature, pipeline optionality, and clinical data. The business is clearly in a growth, not legacy, phase.
Innoviz (INVZ) Q4 2025: Non-Auto LiDAR Set to Hit 10% of Revenue as Physical AI Demand Surges
Innoviz is at a strategic inflection, with a long reinvestment runway, disruptive business model, and strong automotive and non-automotive growth drivers. Backlog and guidance are improving but not at an exceptional (30%+) rate, and cash flow is not yet accelerating. The business is transitioning to growth, but some metrics (e.g., revenue/EPS growth) are not yet at the highest tier.
NewTex Health (NUTX) Q4 2025: Arbitration True-Up Drives $55M Revenue Hit, But 152% EBITDA Growth Affirms Model Strength
NewTex Health demonstrates a long runway for high-return reinvestment, strong margin and cash flow improvement, and a disruptive, scalable business model. There is evidence of continued organic and inorganic growth, but growth rates, while strong, are not at hypergrowth levels for all segments. The business is not yet a household name, but the platform is clearly compounding and offers significant strategic upside.
Ategrity (ASIC) Q4 2025: Expense Ratio Falls 6.1 Points as AI Drives Underwriting Leverage
Ategrity demonstrates a long reinvestment runway with high returns, significant premium growth, improving unit economics, and a self-reinforcing distribution/AI model. Customer value is increasing, and the business is a growth leader in its segment. However, while growth is strong, it is not at the hyper-accelerated level that would warrant top marks for every signal question. The business is disruptive for insurance, but not a pure tech platform, and growth is robust but not consistently 40%+.
Lightbridge (LTBR) Q4 2025: Cash Position Soars to $202M as Fuel Testing Milestones Accelerate Commercial Path
Lightbridge is at a pivotal inflection with a long reinvestment runway, disruptive advanced nuclear fuel, and a strategic financial position. Technical and regulatory milestones, policy tailwinds, and a quadrupled cash balance provide clear upside. However, while growth signals are strong, cash flow is not yet accelerating, and revenue/earnings growth remains prospective rather than demonstrated, warranting a slightly conservative signal score.
Arlo (ARLO) Q4 2025: Services Revenue Hits 63% of Total, Cementing SaaS Margin Expansion
Arlo shows a long SaaS runway, clear margin and ARPU expansion, and a self-reinforcing model with deepening customer value. Partnerships and adjacencies signal future growth, but near-term guidance is strong rather than exceptional (hence not all 2s). The business is now a growth platform, but not in the hypergrowth or disruptive category that would justify a perfect signal score.
PSQH Q4 2025: 81% Revenue Growth Signals FinTech Pivot, Margin Compression Highlights Platform Shift
PSQH demonstrates a long reinvestment runway with high returns potential, significant business evolution (81% revenue growth, 411% GMV growth), improving unit economics, and a self-reinforcing model via platform bundling and AI. While future growth is strong, guidance does not indicate acceleration above 30% for the next year, and cash flow is improving but not yet fully accelerating. The business is disruptive and transitioning to a growth engine, but not all metrics reach the highest threshold.
Globant (GLOB) Q4 2025: AI Pods Pipeline Jumps 34% as Execution Phase Drives Structural Shift
Globant's business demonstrates a long reinvestment runway, disruptive subscription-based AI model, improving unit economics, and a structural shift in margin profile. While not all guidance is for hypergrowth (>40%), the pipeline and margin expansion are exceptional, and the business is clearly transitioning from legacy to growth. Some caution is warranted on near-term macro and pipeline conversion, but the signal for structural upside is strong.
AAPG Q4 2025: Dual Product Launch Drives 90% Revenue Surge, Global Trial Enrollment Sets 2027 NDA Path
AAPG demonstrates a long reinvestment runway, disruptive dual-product model, and substantial revenue growth. While guidance and backlog are strong, and the business is transitioning to growth, cash flow is not yet accelerating and revenue growth isn't consistently above 40%. The signal is high but not at the absolute maximum due to these moderating factors.
IceCure Medical (ICCM) Q4 2025: U.S. Commercial Team to Triple as FDA Clearance Spurs Demand
IceCure Medical demonstrates a long reinvestment runway, clear disruptive potential, and strong unit economics with accelerating commercial traction. While the business is at a commercial inflection and has significant growth levers, the near-term growth guidance and backlog do not yet signal >40% acceleration, and cash flow is not yet fully ramped. The business is not yet a household name, but the signal is strong for investors seeking inflection-stage medtech opportunities.
Blackstone (BX) Q1 2026: AI Infrastructure Drives $150B Portfolio, Offsetting Private Wealth Outflows
Blackstone demonstrates a long reinvestment runway, major AI/data center developments, improving unit economics, and a self-reinforcing business model. Customer value is increasing, and the business is growth-oriented with strong cash flow. However, growth rates are strong but not consistently above 40%, and while disruption and innovation are evident, the asset management model is not as disruptive as true tech platforms.
PACS (PACS) Q4 2025: 31% Revenue Growth Anchored by 106-Facility Acquisition Surge
PACS demonstrates a long reinvestment runway with high returns via disciplined M&A and integration, and the recent surge in acquisitions is a significant business evolution. Unit economics are improving, the business model has self-reinforcing elements, and customer value is deepening. The future outlook is strong but not yet exceptional (guidance is up, but not at hypergrowth levels). The business is semi-disruptive within the sector, and cash flow is accelerating. Revenue and EPS growth is strong but not over 40%. This is a growth business with embedded upside but not an undiscovered or truly exceptional signal for a well-followed sector.
Tradeweb (TW) Q1 2026: International Drives 60% of Revenue Growth, Swaps Market Share Hits 24.1%
Tradeweb demonstrates a long reinvestment runway, accelerating international and swaps growth, improving unit economics, and a self-reinforcing business model. Customer value is rising with cross-sell and engagement, and cash flow is robust. While digital assets and AI are early-stage, the core business is compounding. Growth is strong but not consistently above 40%, and the business is not fully disruptive yet, so a perfect score is not warranted.
HealthEquity (HQY) Q4 2026: Gross Margin Jumps 700bps as AI and Scale Drive Operating Leverage
HealthEquity demonstrates a long reinvestment runway, strong margin and EBITDA expansion, improving unit economics, and a self-reinforcing platform. However, while growth is robust, some levers (marketplace, retail HSA) are still early and not fully reflected in guidance, limiting the score slightly. The business is not highly disruptive or growing at hyper-scale rates, but it is a clear growth story with multiple compounding advantages.
NeuroPace (NPCE) Q4 2025: RNS System Revenue Jumps 26% as Core Growth Engine Accelerates
NeuroPace demonstrates a long reinvestment runway with high returns, clear business model advantages, and improving unit economics. There is a significant growth catalyst with the IGE indication and AI tools, but not all guidance or backlog revisions are exceptional, so some scores are conservative. The business is disruptive, margins are expanding, and the company is transitioning into a growth phase, but not all metrics (like revenue growth rate) are at the highest threshold for a perfect score.
Cognite (CGNT) Q4 2026: Gross Margin Hits 74.7% as Subscription Mix and AI Tailwinds Deepen
Cognite demonstrates a long reinvestment runway, improving unit economics, and a self-reinforcing business model with high recurring revenue and strong margin expansion. Backlog and guidance support a growth trajectory, though not at hypergrowth (40%+) levels, and the business is not fundamentally disruptive but semi-disruptive. Cash flow is accelerating, and the company is transitioning to a higher quality recurring model, supporting a high but not perfect signal score.
Alkermes (ALKS) Q4 2025: Avidel Acquisition Adds $315M Lumerize Upside, Shifts Growth Trajectory
Alkermes demonstrates a strong reinvestment runway, disruptive business model, and self-reinforcing dynamics with the Avidel acquisition and orexin-2 pipeline. Unit economics and customer value are improving, and the business is clearly in a growth phase. However, growth guidance is strong but not at the highest acceleration threshold, and cash flow is robust but not yet rapidly accelerating. The signal is high, but not at the maximum due to some execution and integration risks.
Maze Therapeutics (MAZE) Q4 2025: MZE829 Delivers 36% UACR Reduction, Unlocking Broad AMKD Proof-of-Concept
Maze Therapeutics demonstrates a disruptive model with a long runway, high returns, and strong clinical momentum. The business is not yet showing >40% revenue/earnings growth or cash flow acceleration, but the inflection is clear and the opportunity is significant.
Galaxy Digital (GLXY) Q1 2026: Data Center Phase One Delivers 133MW, Anchoring Multi-Billion Dollar Platform Buildout
Galaxy Digital demonstrates a long reinvestment runway with high returns on capital through its data center platform and institutional infrastructure buildout. The business is at a major inflection point with significant recent developments (data center delivery, new revenue streams). Unit economics and business model quality are improving, with clear signs of self-reinforcement and customer value deepening. While future guidance is bullish, growth acceleration is not yet exceptional, and cash flow is ramping but not yet fully accelerating. Revenue and EPS growth are likely strong but not consistently over 40%. The company is a growth business, not legacy or just transitioning.
Golar LNG (GLNG) Q4 2025: $1.7B in New Financing Unlocks Aggressive FLNG Growth Path
Golar LNG demonstrates a long reinvestment runway, strong recent developments, improving unit economics, and a self-reinforcing business model. Customer value is deepening, and the business is transitioning to a high-cash flow model. However, growth is not yet exceptional (guidance is strong but not over 40% growth), and while disruptive, the business model is not fully transformative. The strategic review and backlog support a high signal score, but not the maximum.
EverQuote (EVER) Q4 2025: Operating Expenses Flat as Revenue Doubles, AI Leverage Drives Margin Expansion
EverQuote shows strong signs of a durable, high-return growth runway, with disruptive AI-driven operating leverage and margin expansion. While growth is robust and the model is evolving, some metrics (like future growth guidance and business model disruption) are not at the absolute highest tier, and the business is not a newly discovered compounder, justifying a slightly lower signal score.
Wix (WIX) Q4 2025: Base44 ARR Surges to $100M, Unlocking New AI-Driven Market Reach
Wix demonstrates a long reinvestment runway, disruptive business model evolution, improving unit economics, and strong customer value expansion. Base44's ARR surge is a material development, and the business is transitioning to higher-value, AI-driven solutions. However, guidance for mid-teens growth (not 30%+) and some margin compression limit the exceptional growth signals. Still, the platform's evolution and capital allocation strategy signal significant upside potential.
Weave (WEAV) Q4 2025: Specialty Medical Adds 29% of New Locations, Expanding Vertical TAM
Weave demonstrates a long reinvestment runway, disruptive business model, strong vertical expansion, and improving unit economics. However, while growth is robust, some metrics (like cash flow and forward guidance) are not yet at exceptional levels, and annualized growth is likely in the 20-40% range, not above 40%. The business is clearly growth-oriented but not at the most extreme end of signal.
STXS Q4 2025: Average Procedure Revenue Jumps 5x as Proprietary Catheter Ramp Reshapes Model
STXS is undergoing a major business model transformation with clear evidence of a long reinvestment runway, disruptive model, and improving economics. There is a significant increase in per-procedure revenue and a shift to recurring, high-margin revenue streams. However, manufacturing constraints and risk to execution moderate the outlook for near-term acceleration, and guidance points to growth but not at an exceptional (40%+) rate.
Alignment Healthcare (ALHC) Q4 2025: Membership Jumps 25% as Margin Expansion Outpaces Industry
Alignment Healthcare demonstrates a long reinvestment runway, strong recent growth, improving unit economics, and a self-reinforcing business model. Customer value is increasing, and the business is shifting toward cash flow generation. However, while the growth is robust and margins are expanding, the business does not show the kind of breakout acceleration (e.g., >40% revenue/EPS growth or industry-defining disruption) that would warrant a perfect signal score. The business is a growth story with clear strategic levers and some disruptive elements, but with execution and regulatory risks that temper the signal slightly.
Apellis (APLS) Q4 2025: Empaveli Penetration Tops 5%, Signaling Rare Disease Launch Outperformance
Apellis demonstrates a long reinvestment runway with high returns, disruptive business model, and strong early growth in Empaveli. There are clear signals of improving unit economics, customer value, and franchise resilience. However, growth outlook is solid but not extreme (20-40%), and cash flow acceleration is moderate rather than dramatic. The business is firmly in growth mode but not at a hypergrowth inflection.
MIRM Q4 2025: Net Product Sales Jump 55% as Four Registrational Readouts Approach
Mirim shows strong signal: a long reinvestment runway, disruptive rare disease platform, improving margins, and clear commercial leverage. Four pivotal readouts create a material business evolution. However, near-term cash flow will be pressured and growth, while strong, is not yet at the highest acceleration. The business is not yet a cash flow machine, and future guidance is positive but not exceptional. Overall, the signal is high for a late-stage biotech, but not at the absolute maximum.
MediaAlpha (MAX) Q1 2026: Open Marketplace Drives 28% Core Growth as Carrier Spend Broadens
MediaAlpha is a growth business with a long reinvestment runway, high margins, and clear network effects. Recent results show strong core growth (28%), improving unit economics, and compounding business model advantages. LLM/AI channel expansion is a potential future lever, but not yet exceptional in scale. Growth is set to normalize, so some upside is capped, but the company remains highly investable.
iRhythm (IRTC) Q4 2025: ZOAT Growth Tops 50%, Margin Expansion Signals Durable Scale
iRhythm exhibits a long reinvestment runway, disruptive business model elements, clear margin and unit economic improvement, and a shift to positive cash flow. However, while growth is strong and there is upside optionality, the near-term guidance is conservative and not all segments are compounding at the highest rates. International and new channels are early-stage, tempering the maximum signal.
Atlassian (TEAM) Q3 2026: Cloud Revenue Jumps 29% as Rovo AI Doubles Customer Growth
Atlassian demonstrates a long reinvestment runway, disruptive AI-native business model, and strong cloud/AI growth. There is clear evidence of improving unit economics, self-reinforcing platform dynamics, and increasing customer value. However, some caution is warranted on growth acceleration (not above 40%), cash flow, and near-term revenue volatility, so scores are conservative.
Povella Therapeutics (PVLA) Q4 2025: $230M Raise Extends Runway Through First-Line Launch
Povella has a long reinvestment runway, disruptive platform, and strong evidence of compounding advantages (platform leverage, indication expansion, regulatory designations). The recent $230M raise, positive pivotal data, and pipeline progress are significant developments. Unit economics and customer value are likely to improve as the company scales, but commercial cash flow acceleration and 40%+ growth are not yet proven, so those scores are conservative. The business is positioned as a growth platform, but near-term commercial execution and regulatory risks temper the highest signal marks.
Perma-Fix (PESI) Q4 2025: Treatment Backlog Jumps 51% as Hanford Ramp Drives Visibility
Perma-Fix demonstrates a long reinvestment runway, disruptive technology, and a clear strategic inflection with a 51% backlog increase and capacity expansion. Double-digit segment growth, backlog visibility, and regulatory tailwinds (Hanford, PFAS) support the signal. Some metrics (customer value, cash flow) are improving but not yet exceptional, and guidance is directional rather than quantified, so full marks are not warranted.
ADMA (ADMA) Q4 2025: Ascentive Drives 51% Growth, Margin Expansion Signals Durable Upside
ADMA demonstrates a long reinvestment runway with high returns, transformative growth in its core product, improving unit economics, and a self-reinforcing model through manufacturing innovation and supply chain control. Customer value is rising, and the business is transitioning to a cash flow machine. However, while growth is strong, forward guidance does not clearly support 40%+ growth, and pipeline optionality is not yet realized. The business is disruptive within its niche but not broadly so, and some risk remains around working capital normalization and execution.
PureCycle (PCT) Q4 2025: Denver Feedstock Ramps 44%, Unlocking Commercial Pipeline for 2026
PureCycle demonstrates a long reinvestment runway, disruptive business model, improving unit economics, and deepening customer value. Regulatory and technical milestones create strong optionality. However, the revenue and cash flow ramp, while promising, is still gated by adoption cycles and regulatory timing, tempering the signal score slightly. Growth is strong but not yet at the exceptional acceleration threshold.
Full Truck Alliance (YMM) Q4 2025: Transaction Service Revenue Climbs 38% as AI and Governance Reshape Platform
YMM demonstrates a long reinvestment runway, a disruptive and self-reinforcing business model, improving unit economics, and increasing customer value. There is a clear shift to high-quality, high-margin growth, and AI integration creates a defensible moat. The business is transitioning to a higher margin, growth-oriented model, but the growth rates are not consistently above 40% and overseas expansion is still in early stages, capping the score.
Planet Labs (PL) Q4 2026: Backlog Jumps 79% to $900M, Unlocking Multi-Year Growth Visibility
Planet Labs demonstrates a long reinvestment runway, disruptive business model, and accelerating growth with a 79% backlog jump and a clear pivot to sovereign/AI markets. However, guidance signals some conservatism and margin/cash flow acceleration is not yet exceptional, so a few points are deducted. The business is high growth but not yet explosive enough for a perfect score.
Mink Therapeutics (INKT) Q4 2025: Operating Costs Down 40% as Pipeline Advances to Randomized Trials
Mink Therapeutics demonstrates a disruptive, capital-efficient business model with a long runway and strong clinical momentum. While growth is strong and the business is transitioning to later-stage trials, the near-term acceleration is not yet at the highest tier, and cash flow is not yet rapidly accelerating. The company is, however, positioned for high growth and value creation if clinical milestones are met.
Recursion (RXRX) Q4 2025: 35% OpEx Cut Extends Runway, AI Platform Delivers First Clinical Proof
Recursion demonstrates a long reinvestment runway, disruptive AI-enabled business model, and strong external validation through partnerships and milestones. Clinical proof and cost discipline are positive signals. However, while growth is strong, it is not yet at the exceptional/accelerating level across all metrics, and some program risks remain. The business is transitioning to growth but is not yet fully de-risked or at the highest trajectory.
AppFolio (APPF) Q1 2026: AI-Driven Platform Lifts Revenue 20% as Premium Tier Adoption Accelerates
AppFolio demonstrates a long reinvestment runway, improving unit economics, and a self-reinforcing business model with strong customer value expansion. There is a significant uptick in AI adoption and premium tier upgrades, but growth guidance for the year is under 20%, limiting the score for questions 6 and 9. The business is not entirely disruptive but is semi-disruptive within its vertical. Cash flow is accelerating, and the company is firmly in the growth phase.
ThredUp (TDUP) Q1 2026: Active Buyers Surge 25%, Fueling Supply and AI-Driven Marketplace Expansion
ThredUp demonstrates a long reinvestment runway and high ROIC potential, with double-digit buyer and seller growth and a disruptive, self-reinforcing marketplace model. Unit economics are improving, and customer value is deepening. The business is not quite showing exceptional acceleration (over 30% growth) in all metrics, and cash flow is only moderately accelerating, which tempers the signal score. Still, the business is clearly in growth mode with strong optionality and competitive moats.
Opendoor (OPEN) Q4 2025: Acquisition Velocity Up 300% as Opendoor 2.0 Drives Margin Turnaround
Opendoor demonstrates a long reinvestment runway, disruptive AI-driven model, and improving unit economics. The October cohort's margin and velocity inflection are strong signals, but guidance for only moderate growth and some ongoing losses temper the score. The business is transitioning into a growth phase, but still faces execution and macro risks, justifying a conservative approach on cash flow and growth acceleration.
SGHC (SGHC) Q4 2025: 57% EBITDA Growth Highlights Africa and Tech Leverage
SGHC demonstrates a long reinvestment runway, clear operating leverage, and improving unit economics. Recent results show strong growth and margin expansion, with technology and regional diversification providing compounding advantages. However, growth guidance for 2026 is strong but not exceptional, and the business model, while innovative, is not fundamentally disruptive at a global scale. The company is a clear growth business but not in hypergrowth territory, and some risks around regulation and product adoption temper the overall signal.
LifeZone Metals (LZM) FY25: Kabanga Valuation Anchors $1.6B NPV as FID Nears
LifeZone Metals has a long reinvestment runway with clear high-return avenues (Kabanga, Burundi, downstream), significant recent developments (FID, partner offers), improving unit economics, and a self-reinforcing model via technology and supply chain integration. Customer value is deepening with offtake competition. The future is good but not yet exceptional (FID pending, not yet >30% growth), and cash flow is not yet accelerating. The business is clearly disruptive and transitioning to growth, but some upside is still contingent on execution.
HIMS Q4 2025: International Revenue Jumps 400% as Platform Diversifies Beyond GLP-1s
Hims & Hers demonstrates a long reinvestment runway, rapid international growth, improving unit economics, and a self-reinforcing platform model. Customer value is deepening, and the business is transitioning to a diversified, global growth story. While growth rates are strong, they are not at the extreme levels for the highest marks. The business is disruptive with lateral opportunities, though near-term cash flow and revenue growth are just below the highest thresholds.
Lifetime (LTH) Q4 2025: Growth CapEx Jumps to $915M as Club Ramp Accelerates
Lifetime is accelerating expansion with strong club ramp dynamics, improving unit economics, and a robust capital return plan. There is clear evidence of a long reinvestment runway, improving customer value, and a self-reinforcing premium model. However, growth guidance is not exceptional (not >30%), and while the business is premium and semi-disruptive, it is not a true disruptor. Revenue growth is strong but not at the highest threshold, and the business is positioned solidly as a growth company.
Amer Sports (AS) Q4 2025: Salomon Footwear Soars 35%, Fueling Global Expansion Play
Amer Sports demonstrates a long reinvestment runway, significant growth in key segments, improving unit economics, and a self-reinforcing business model. Customers are becoming more valuable, and the business is positioned for continued growth. Some elements (like guidance) are strong but not exceptional, and while the business is highly attractive, it is not uniquely disruptive compared to other global consumer brands.
Amazon (AMZN) Q1 2026: AWS Backlog Hits $364B as AI and Custom Silicon Fuel Next Growth Wave
Amazon demonstrates a long reinvestment runway, disruptive business model, and improving unit economics, with massive AI and custom silicon momentum. However, some signal is tempered by capital intensity, near-term cash flow pressure, and the company's already large scale, which makes further upside less explosive than for a smaller disruptor.
CLSQ (LAES) Q1 2025: Pipeline Expands to $200M as Regulatory Urgency Accelerates Post-Quantum Adoption
CLSQ demonstrates a long reinvestment runway, disruptive business model, expanding margins, and strong customer engagement driven by regulatory urgency. The pipeline and backlog are large and growing, but some growth is dependent on future certification and integration milestones, tempering the signal on near-term acceleration and cash flow. Still, the business is clearly in a high-growth, inflection phase with strong strategic positioning.
Cardiff Oncology (CRDF) Q4 2025: 72% ORR in RAS-Mutated mCRC Sets Stage for Pivotal Phase 3
Cardiff Oncology demonstrates a potentially long reinvestment runway with a disruptive asset in a high-unmet-need segment. The business has shown a step-change in efficacy (72% ORR), improving unit economics, and a self-reinforcing model if successful. However, the lack of mature PFS data and the funding gap for Phase 3 temper the signal. Growth is strong but not yet at extreme levels, and the business is transitioning from clinical to pivotal-stage, with some uncertainties remaining.
Waystar (WAY) Q1 2026: AI Drives 40% of New Bookings, Expanding Platform TAM
Waystar demonstrates a long reinvestment runway, disruptive AI-driven business model, improving unit economics, and strong customer value expansion. The company is not yet seeing >40% revenue growth or backlog acceleration, and cash flow is improving but not rapidly accelerating. The signal is strong but not at the absolute highest level due to these moderating factors.
Mesoblast (MESO) Q2 2026: Ryonsel Launch Drives $49M Revenue as Adult Label Expansion and BLA Filings Advance
Mesoblast exhibits a long reinvestment runway, disruptive business model, improving unit economics, and strong commercial traction with Ryonsel. Backlog and pipeline catalysts are significant but not yet at the highest acceleration threshold. Cash flow is improving but not yet accelerating, and revenue growth is strong but not at hypergrowth rates. The business is clearly in a transition to a growth stage with substantial optionality.
Trip.com (TCOM) Q4 2025: International OTA Bookings Surge 60% as Inbound Travel Doubles
Trip.com demonstrates a long reinvestment runway, disruptive AI-driven business model, and clear international expansion with double-digit growth and a major mix shift. Unit economics and customer value are improving, and the platform is self-reinforcing with network effects. However, while growth is strong, not all signals point to exceptional acceleration (Q6, Q8, Q9), and regulatory overhang tempers the overall signal. Still, the business is clearly in a high-growth, strategic transition with substantial upside potential.
SARO Q4 2025: Free Cash Flow Surges 75% as LEAP, CRS Expansion Drive Margin Upside
SARO demonstrates a long reinvestment runway with high ROIC, recent significant business developments, improving unit economics, and a self-reinforcing business model. Customers are becoming more valuable, and the business is transitioning into a high-cash-flow, growth-oriented company. However, while growth is strong, it is not consistently above 20%+ for all metrics, and the model is not fully disruptive, warranting a slightly conservative signal score.
Braze (BRZE) Q4 2026: Bookings Surge 50% as AI-Driven Platform Expands Enterprise Foothold
Braze demonstrates strong signal: a long reinvestment runway, disruptive AI-driven business model, improving unit economics, deepening customer value, and robust enterprise expansion. While guidance is strong, YoY growth is moderating toward 20%, and cash flow is improving but not yet accelerating, which slightly tempers the signal score.
KURA Q4 2025: ComSifty Launch Drives $2.1M Revenue, Step-Edit Access Signals Class Leadership Shift
Kura demonstrates a long reinvestment runway, disruptive business model, and strong initial commercial traction with payer and prescriber validation. There is clear evidence of improving unit economics, self-reinforcing model, and customer value deepening. However, while growth is strong, not all metrics hit the 'exceptional' threshold yet (e.g., future cash flow acceleration and revenue growth are promising but not yet at the highest tier).
PODD Q4 2025: Omnipod Drives 29% Revenue Growth as Type 2 Penetration Accelerates
Insulet demonstrates a long reinvestment runway, high ROIC, and a durable, self-reinforcing business model with strong recurring revenues. There is clear evidence of margin and unit economics improvement, and customers are becoming more valuable over time. Growth is robust but moderating, so some questions (notably 6, 7, and 9) are marked down as growth decelerates from peak levels and the business is not fully disruptive or delivering 40%+ growth. The company remains a growth business, but not at the most extreme levels of signal.
Lantern Pharma (LTRN) Q4 2025: R&D Spend Down 29% as AI Pipeline Hits Clinical Inflection
Lantern Pharma demonstrates a long reinvestment runway with a disruptive, AI-driven drug development model and clear platform optionality. All lead molecules are now in clinical trials, with early efficacy signals and cost discipline supporting business model scalability. Commercialization of the AI platform is underway but not yet proven at scale, and funding needs present some risk. Growth is strong but not yet at the highest acceleration tier, and cash flow is not yet accelerating. However, the business is clearly transitioning from validation to growth, with multiple near-term catalysts.
Fractal Health (GUTS) Q4 2025: 16cm Ablation Threshold Sharpens Pivotal Success Odds
Fractal Health shows a long reinvestment runway, disruptive and scalable business model, and clear inflection with dose-response clarity. Backlog and growth signals are strong, but not yet at the 'exceptional' level for some metrics (e.g., future growth is anticipated but not yet proven at 40%+ rates). Cash flow is improving but not yet accelerating. The business is positioned for growth, but pivotal data remains a gating variable.
Sprott (SII) Q4 2025: ETF AUM Surges 94% as Metals Flywheel Accelerates
Sprott is showing a long reinvestment runway with high returns on capital, a major recent AUM surge, improving unit economics, and a self-reinforcing model (especially in ETFs/physical trusts). Customer value is deepening, and the business model is semi-disruptive with government and institutional tailwinds. Cash flow is accelerating. However, growth rates are strong but not consistently above 40%, and the business, while a leader in its niche, is not a totally new disruptor or a hypergrowth story. Still, signal is high for the sector.
LandBridge (LB) Q4 2025: SUEE Jumps 21% as Active Land Model Drives Compounding Value
LandBridge demonstrates a long reinvestment runway, improving unit economics, and a self-reinforcing, capital-light model. There is clear evidence of compounding value and optionality. While growth is strong and the model is disruptive for the land management space, the guidance for 2026 is conservative, and revenue/earnings growth, while above-market, does not yet exceed the 40% threshold for the highest marks. The business is not yet at the most exceptional growth inflection, but the signal is very high.
Audia (ADEA) Q4 2025: Non-Pay TV Revenue Jumps 30% as OTT and Semiconductor Deals Reshape Mix
Audia demonstrates a long reinvestment runway (OTT, semiconductors), recent significant growth (non-pay TV up 30%, semiconductor up 40%), improving unit economics, and a self-reinforcing licensing model. Customer value is increasing, but future growth, while strong, is not yet at an 'exceptional' acceleration level. The business is transitioning but not fully disruptive, and cash flow is robust. Revenue/EPS growth is strong but not consistently over 40%. Overall, the business is a growth platform with clear optionality but not quite at the highest possible signal level.
PCVX Q4 2025: $600M Equity Raise Extends Runway, Pivots to Late-Stage Vaccine Execution
PCVX demonstrates a long reinvestment runway with high ROIC potential, significant recent developments (large equity raise, pipeline restart), improving unit economics as scale is reached, and a disruptive, self-reinforcing business model. Customer value is increasing, but future growth, while strong, is not yet exceptional (>30% acceleration). Cash flow is improving but not yet accelerating. Revenue/EPS growth is likely above 20% but not 40%. The business is clearly in a high-growth phase.
GEVO (GEVO) Q4 2025: North Dakota Acquisition Drives 849% Revenue Surge, Sets Stage for $40M EBITDA Target
GEVO demonstrates a long reinvestment runway, a disruptive and evolving business model, and improving unit economics with clear operational leverage. While growth is strong, it is not quite at the highest acceleration tier, and some optionality (ATJ platform) remains unproven. The business is transitioning into a growth phase with visible cash flow and margin expansion, but a few elements—such as full ATJ scaling and carbon market maturity—are not yet fully de-risked.
Ouster (OUST) Q4 2025: Software-Attached Bookings Jump 120%, StereoLabs Acquisition Expands Physical AI Platform
Ouster demonstrates a long reinvestment runway, disruptive business model, improving unit economics, and strong customer value expansion. Software-attached bookings and recurring revenue are accelerating. However, while growth is robust, it is not yet at an 'exceptional' (30%+ acceleration) level, and cash flow is only moderately accelerating, not yet at full breakout. Revenue growth is above 20% but not consistently above 40%.
EVEX Q1 2026: $500M Order Book Anchors Production, Embraer Synergies Sharpen Cost Edge
Eve Air Mobility demonstrates strong signal: a long reinvestment runway, disruptive business model, improving unit economics, and clear cost/operational synergies from Embraer. The $500M order book and staged payments are evidence of market validation and liquidity discipline. However, growth guidance is not yet exceptional, and cash flow acceleration is not fully proven, so scores are slightly capped. The business is early-stage but positioned for high growth and leverage, with material upside if execution and certification milestones are met.
LIF (LIF) Q4 2025: Advertising Platform Drives 86% “Other Revenue” Surge, Unlocking Multi-Engine Growth
Life360 demonstrates a long runway with multiple growth engines, strong unit economics, and a disruptive, data-driven model. The advertising platform and AI adoption are clear inflections, though some guidance and growth rates are strong but not exceptional across every metric. The business is transitioning to higher margin and diversified growth, justifying a high but not perfect signal score.
BrightSpring Health (BTSG) Q4 2025: EBITDA Jumps 41% as Specialty Pharmacy and Home Health Scale
BrightSpring Health demonstrates strong signal: long reinvestment runway, recent double-digit EBITDA growth, improving unit economics, and a self-reinforcing model with operational leverage and M&A. Customer value and cash flow are rising, and the business is positioned for growth, though guidance is strong but not at an exceptional acceleration level. The model is semi-disruptive with tech and AI investments, but not fully disruptive. Revenue growth is in the 12-16% range, so not at the highest signal tier for growth, but the company is clearly a growth business, not legacy or stalling.
Comfort Systems USA (FIX) Q1 2026: Backlog Surges $5B as Tech Demand Drives Record Margins
FIX is exhibiting a rare combination of record backlog expansion, margin improvement, and high visibility into multi-year growth, driven by secular tech and data center demand. The business model is becoming more self-reinforcing with modular and automation investments, and customer value is increasing. However, while growth is very strong, it is not at the extreme acceleration level (over 40% annualized for the whole business) and the model, while robust, is not as disruptive as true platform businesses. Still, the signal is very high for a specialty contractor.
LOAR (LOAR) Q4 2025: Margin Expands 320bps as Proprietary Product Mix Drives Double-Digit Organic Growth
LOAR shows strong reinvestment runway, clear margin and growth expansion, and a highly proprietary, self-reinforcing business model. The growth outlook is robust but not explosive enough for top scores on all growth acceleration questions. The business is differentiated and compounding, with some moderate risk around integration and guidance not being exceptional (rather, very strong).
Clean Capital Energy Carriers (CCEC) Q4 2025: LNG Orderbook Climbs to 20% Market Share as Fleet Pivot Accelerates
CCEC demonstrates a long reinvestment runway with high ROIC potential and a disruptive business model pivot. There are significant developments (20% orderbook share, new vessel types), improving unit economics, and self-reinforcing advantages. However, growth is not yet at the 40%+ level, and cash flow acceleration is moderate rather than exceptional. Still, the business is positioned for strong future growth and industry leadership.
SES (SES) Q1 2026: ESS Revenue Jumps 47% as ATG ePower Deal Expands North American Reach
SES demonstrates a long reinvestment runway, disruptive business model, and clear self-reinforcing dynamics (hardware/software/data). Growth is strong but not yet at a hyper-accelerated level, and cash flow is improving but not yet rapidly accelerating. The company is transitioning from proof-of-concept to commercial scaling, showing strong optionality and early traction, but some metrics (like recurring software revenue and defense order ramp) are still emerging.
Venue (VENU) Q4 2025: Fire Pit Suite Sales Jump 62% as Triple Net Model Hits 25% of Mix
Venue demonstrates a long reinvestment runway, disruptive business model, and clear operational inflection with the triple net leaseback scaling rapidly. Unit economics, customer value, and platform effects are all improving. However, while growth is strong, some metrics (e.g., revenue and EPS growth) are not yet at the highest acceleration threshold, and cash flow is not yet clearly accelerating. The business is in transition to growth, with significant optionality and upside, but not every indicator is at the maximum.
HOVR Q3 2026: X-7 Projected to Cut Operating Costs by 75%, Securing Hybrid Edge
HOVR demonstrates a long reinvestment runway, disruptive hybrid-electric architecture, improving unit economics, and strong customer value potential. The business model is self-reinforcing and positioned for growth, with government and defense tailwinds. However, near-term growth rates and cash flow are not yet exceptional (prototype stage), so scores are slightly reduced in those areas. Overall, the signal is very high for investors seeking early-stage, high-upside industrials.
Lithium Argentina (LAR) Q4 2025: Cash Costs Drop 30% as Production Hits 97% Capacity
Lithium Argentina demonstrates a long reinvestment runway, cost leadership, and strong cash flow generation. While the business model is not highly disruptive and growth outlook is strong but not hyper-growth, the company displays significant operational and financial progress, positioning it as a credible growth story with risk-mitigated expansion potential.
Analog Devices (ADI) Q1 2026: Data Center and ATE Surge Powers 30% Revenue Growth, Industrial Up 20%+ Sequentially
ADI demonstrates a long reinvestment runway, strong unit economics, and self-reinforcing business model. Recent growth in ATE and data center is significant but not at the highest possible acceleration. The business is not fully disruptive, and while revenue/EPS growth is robust, it does not consistently exceed 40% for the highest score. Still, the signal is strong due to secular AI/industrial tailwinds and margin expansion.
UMAC Q4 2025: Enterprise Mix Reaches 81% as Domestic Drone Components Scale
UMAC demonstrates a long reinvestment runway, disruptive business model, and strong regulatory moat, with clear evidence of rapid enterprise growth and margin improvement. While the growth outlook is strong, the guidance for margin compression and dependence on government programs tempers the score. The business is not yet at the extreme acceleration threshold for all signal questions, but the overall profile is highly attractive for investors seeking growth and inflection.
Cadence (CDNS) Q4 2025: $7.8B Backlog Anchors AI-Driven Demand Surge Into 2026
Cadence demonstrates a long reinvestment runway, clear compounding business model advantages, and strong recurring revenue growth. The backlog and recurring revenue base provide multi-year visibility, and the business is clearly in a high-growth phase, though guidance for acceleration is prudent rather than exceptional. The business is not disruptive in the classic sense, but agentic AI adoption and platform expansion do create semi-disruptive opportunities. Cash flow is strong and accelerating, and the company is a clear growth business, though not likely to post >40% topline growth.
Sharplink (SBET) Q4 2025: ETH Holdings Surge to 868,699 as Institutional Adoption Accelerates
Sharplink demonstrates a long reinvestment runway at high returns, recent significant growth in ETH holdings, and improving unit economics. The business model is disruptive, with self-reinforcing features and deepening customer value. While growth is strong, it is not yet exceptional in the near term (guidance is for continued discipline rather than acceleration), and cash flow is improving but not rapidly accelerating. The company is clearly transitioning into a growth business with institutional adoption, but some metrics (e.g., revenue/EPS growth) are not yet at the highest tier.
Repositrak (TRAK) Q2 2026: SaaS Revenue Hits 98% as Traceability Patents Expand Moat
Repositrak demonstrates a long reinvestment runway through its SaaS model and patent-driven moat. There is a material business evolution with traceability and regulatory catalysts, but growth is not yet at a 'very high' level (hence Q6 and Q9 are not maxed out). Unit economics are clearly improving, and the business model is self-reinforcing with network effects and switching costs. Customer value is deepening through cross-sell and integration. While growth is strong and accelerating, it is not (yet) at a hypergrowth (40%+) level. The model is disruptive but not a pure platform, and cash flow is accelerating. The business is a clear growth story, but not an unknown or underfollowed name, so signal is strong but not perfect.
Beta Bionics (BBNX) Q4 2025: Pharmacy Channel Mix Climbs to 32%, Reshaping Pump Market Access
Beta Bionics exhibits a long reinvestment runway, disruptive business model, and improving unit economics, with strong recurring revenue growth and expanding pharmacy channel penetration. There are clear compounding advantages and increasing customer value. However, near-term growth guidance is not exceptional and cash flow is not yet accelerating, tempering the signal score slightly.
Opera (OPRA) Q1 2026: AI-Driven Query Revenue Jumps 23%, Propelling Margin Expansion
Opera demonstrates a long reinvestment runway with high ROIC, recent double-digit growth, improving unit economics, and a self-reinforcing business model. Customers are becoming more valuable and the business is a clear growth story. However, guidance and backlog are not exceptional enough for a perfect score, and the business model—while innovative—is not fully disruptive.
Insight (INCY) Q1 2026: Core Portfolio Ex-Jakafi Jumps 63%, Accelerating HemOnc & I&I Transition
Insight is transitioning to a high-growth, multi-asset model with strong reinvestment prospects and accelerating non-Jakafi sales. The pipeline is rich with near-term catalysts, and unit economics are improving. The business model is becoming self-reinforcing, and customer value is increasing. While the model is not fully disruptive and cash flow is not yet accelerating, the business is positioned as a growth story with significant upside optionality.
Rush Street Interactive (RSI) Q1 2026: North America iCasino MAUs Surge 62% as Casino-First Model Scales
RSI demonstrates a long reinvestment runway with high returns, significant recent growth (e.g., 62% MAU surge, 134% LatAm revenue), improving unit economics, and a self-reinforcing business model. Customer value is increasing, and the business is transitioning to a cash flow machine. However, guidance revision is not yet exceptional (>30% acceleration), disruption is present but not at the level of a platform business, and growth is robust but not consistently above 40% annualized. The business is clearly in a growth phase, but some metrics, while strong, are not at the very top end of the rubric.
TE Connectivity (TEL) Q2 2026: $1B Order Surge Signals AI and Grid Tailwinds
TE Connectivity demonstrates a long runway with high returns, strong recent growth, improving unit economics, and self-reinforcing business dynamics. While the business is not a pure disruptor and growth, though strong, is not hyperbolic, the secular tailwinds and backlog strength provide notable signal. Some moderation is warranted on guidance acceleration and disruptive potential.
FIP (FIP) Q4 2025: Rail Integration Delivers 34% EBITDA Lift, Monetization and M&A in Focus
FIP demonstrates a long reinvestment runway with high returns on capital, particularly through rail integration and terminal expansion. There is a material uptick in EBITDA and clear business evolution, but not at a hypergrowth pace. Unit economics are improving, and the business model is becoming more self-reinforcing, though not yet at the level of a dominant platform. Customer value is increasing, and cash flow is accelerating. The business is transitioning into a growth phase, but annual growth rates are not consistently above 40%. The model is semi-disruptive with some lateral opportunities, but not fully disruptive. Overall, the signal is strong for a scaled infrastructure platform with upside, but not at the level of a breakthrough tech or platform business.
Slide Insurance (SLDE) Q1 2026: Gross Written Premiums Surge 49% as Voluntary Expansion and Buybacks Accelerate
Slide Insurance is exhibiting high growth, strong returns on capital, and improving unit economics with a disruptive, technology-driven model. The business is not entirely unknown, but the growth trajectory and capital deployment are notable. While the guidance and backlog are strong, they are not exceptional enough to score a perfect 2 on all forward-looking measures. The company is not yet in the hypergrowth (>40%) category for future guidance but is clearly a growth business with significant investor signal.
DCO Q4 2025: Missile Orders Drive $75M RPO Surge, Defense Capacity Positioned for 30% Growth
DCO demonstrates a long reinvestment runway and strong ROIC prospects due to defense demand and available capacity. Missile bookings and backlog surged, signaling an important business evolution. Unit economics and margins are improving with scale and engineered content. The business model is becoming more self-reinforcing, with growing aftermarket/engineered share and cost advantages. Customer value is increasing (aftermarket, defense primes). Growth is strong but not yet exceptional (over 40%), and guidance is for mid- to high-single-digit revenue growth, not an outright acceleration. The model is semi-disruptive due to mix shift but not fully disruptive. Cash flow is accelerating. Revenue/EPS growth is likely in the 10-20% range. DCO is a growth business, not a legacy or stalling one.
Autolist (AUTL) Q4 2025: 92% Real-World Remission Validates $120M+ Guidance and Expansion Ambitions
AUTL demonstrates a long reinvestment runway, disruptive pipeline, improving unit economics, and compounding business model. Real-world data and pipeline readouts are significant, but near-term growth is strong rather than explosive, and cash flow is not yet accelerating. The business is clearly in a growth phase, but some upside is dependent on future execution.
APYX Q4 2025: Aon Drives 38% Aesthetics Surge, Setting Stage for 19% Segment Growth in 2026
Apyx demonstrates a long reinvestment runway, disruptive platform potential, and improving unit economics. There is clear evidence of business model evolution (Aon launch, GLP-1 tailwind, label expansion). However, growth guidance is below the 20%+ threshold for some metrics, and cash flow acceleration, while improving, is not yet exceptional. Overall, the business is transitioning to a high-growth, platform-based model, but some upside levers are not yet realized.
Amplitude (AMPL) Q4 2025: AI Agent Queries Jump to 25%, Catalyzing Enterprise Expansion
Amplitude demonstrates a long reinvestment runway, disruptive business model, and strong customer expansion. AI adoption is a structural tailwind, and enterprise growth is robust. However, growth rates are not at hypergrowth levels and cash flow, while improving, is not yet accelerating. The outlook is strong but not exceptional, warranting a slightly conservative signal score.
On Holding (ONON) Q4 2025: D2C Share Climbs to 41.8% as Premium Strategy Drives Global Expansion
ONON shows a strong reinvestment runway, improving unit economics, and a disruptive, premium D2C model with global optionality. Growth is robust but not at the absolute highest tier (over 40%). Margins and cash flow are accelerating, and the business is clearly transitioning from breakout to sustained premium growth. Some elements (guidance revision, business model disruption) are strong but not at the most extreme level, justifying a slightly conservative signal score.
NetPower (NPWR) Q4 2025: Project Permian Ups Output 33%, Accelerating Carbon Capture Path
NetPower demonstrates a long reinvestment runway with modular, scalable design and capital-light financing. There is a recent 33% output increase and commercial pivot, but not yet a massive backlog surge or double-digit revenue growth. Unit economics are improving with scale, and the business model has emerging self-reinforcement via standardization and procurement leverage. Customers are becoming more valuable, and future growth is good but not yet exceptional. The model is disruptive for the sector, with some acceleration in cash flow likely as offtake agreements are signed. The business is transitioning to growth, but not yet at hypergrowth levels.
Rivian (RIVN) Q1 2026: R2 Platform BOM Halved, Unlocking Cost Leverage for 300K-Unit Georgia Expansion
Rivian shows a very strong signal profile: the R2 platform and Georgia expansion provide a long reinvestment runway, with disruptive cost-down and scaling. There is significant growth in software/services and autonomy, and the business is transitioning into a high-volume, potentially high-margin model. However, some caution is warranted as cash flow is not yet accelerating and topline growth is not yet over 40%—hence, scores are conservative on those fronts. The business is not yet at the highest possible growth inflection, but the strategic levers and optionality are clear.
Harmony Biosciences (HRMY) Q4 2025: WAKIX Revenue Surges 21% as Blockbuster Status Beckons
Harmony Biosciences demonstrates a long reinvestment runway, unit economics improvement, a self-reinforcing business model, and increasing customer value. While the business is transitioning toward a multi-asset story, most growth is anchored in a single asset, and pipeline execution risk remains. The business model is only semi-disruptive, and while growth is strong, it is not yet exceptional across all dimensions.
IONIS (IONS) Q4 2025: Olazarsen Peak Revenue Raised Above $2B as Launch Readiness Accelerates
IONIS is at an inflection point with a long reinvestment runway, blockbuster drug potential, and improving unit economics. The business model is self-reinforcing and disruptive in RNA therapeutics, with growing commercial revenue and strong customer metrics. While growth is strong, some guidance and cash flow metrics are not yet exceptional, and future acceleration is implied rather than fully realized.
SOPH Q1 2026: Net Dollar Retention Climbs to 117% as Platform Expansion Drives Upsell Momentum
SOPH demonstrates a long reinvestment runway, high net dollar retention, improving unit economics, and clear network effects. The business model is disruptive with recurring revenue and global scale. While growth is strong, guidance is for 20-22% revenue growth, so not quite at the highest acceleration tier. Cash flow is improving but not yet accelerating. The business is firmly in growth mode, with some metrics (like biopharma acceleration) not yet at exceptional levels.
EVLV Q4 2025: ARR Climbs 21% as Direct Fulfillment Model Drives Recurring Revenue Leverage
Evolve demonstrates a long reinvestment runway, disruptive model, improving unit economics, and deepening customer value. Growth is strong but not hyperbolic, and while cash flow is improving, it's not yet accelerating. Guidance is robust but not exceptional (>30% acceleration), and revenue/EPS growth is in the 20-40% range. The business is clearly transitioning to a growth phase with high signal, but not at the absolute highest level of upside.
MediaAlpha (WTM) Q4 2025: P&C Transaction Value Jumps 38% as Open Marketplace Mix Expands
MediaAlpha demonstrates a long reinvestment runway in its core P&C business with high returns on capital and a disruptive, AI-driven marketplace model. The recent 38% jump in P&C transaction value and open marketplace mix shift are material, and unit economics are improving. The business model is self-reinforcing with deepening network effects and customer value, but health vertical drag and lack of >40% revenue/EBITDA growth cap the score. The business is growth-oriented, but not at the highest acceleration tier.
EVLV Q4 2025: 32% Revenue Growth Anchored by Direct Fulfillment Shift and Expanding Recurring Base
Evolve demonstrates a strong growth profile, disruptive business model, improving unit economics, and expanding recurring revenue base. The business is not yet showing >40% growth in all metrics, and cash flow is not yet accelerating at the highest level, but the overall signal is high due to the inflection in business model and regulatory tailwinds.
CryoPort (CYRX) Q1 2026: Commercial Cell & Gene Therapy Revenue Jumps 26% as Pipeline Matures
CryoPort demonstrates a long reinvestment runway, recent major business evolution, improving unit economics, and a self-reinforcing business model. Customer value is deepening, and the business is positioned as a growth company. However, while growth is strong, it is not accelerating at the highest tier. The business model is semi-disruptive, and cash flow is improving but not yet rapidly accelerating. Revenue and EPS growth are above 20% but below 40%.
MDB Capital Holdings (MDBH) Q4 2025: AI-Driven Diligence Compresses Launch Timelines by 66%
The business model is disruptive, AI-driven, and has a long reinvestment runway. There is a major inflection in throughput and asset monetization, but customer value deepening and cash flow acceleration are not yet proven. Growth outlook is strong but not yet at the highest tier, and some execution risk remains.
Sezzle (SEZL) Q4 2025: Subscription Users Jump 30%, Fueling Ecosystem Margin Gains
Sezzle has a long reinvestment runway, strong margin and revenue growth, improving unit economics, and a business model shifting toward self-reinforcing ecosystem effects. However, while growth is strong, guidance is for 25–30% revenue growth (not >40%), and some elements (AI leverage, new products) are promising but not yet proven to be exceptional or disruptive at scale. The business is not yet at the highest signal level for disruptive growth or cash flow compounding.
BWXT (BWXT) Q4 2025: Commercial Backlog Climbs 85%, Locking in Multi-Year Growth Visibility
BWXT demonstrates a strong reinvestment runway, major backlog growth, improving unit economics, and a compounding business model. Customer value is increasing, and the future outlook is positive, though not yet exceptional. The business model is semi-disruptive, and cash flow is improving but not yet accelerating. Growth rates are strong but not over 40%, and the company is clearly a growth business. Signal is high, but not at the absolute maximum due to some moderate rather than exceptional metrics.
Penguin Solutions (PENG) Q2 2026: Memory Segment Surges 63%, Anchoring AI Infrastructure Pivot
Penguin Solutions is undergoing a strong strategic pivot with high growth in the memory segment and clear AI infrastructure tailwinds. There is a long reinvestment runway, improving unit economics, and evidence of compounding business advantages. However, some elements—such as cash flow acceleration and disruptive business model status—are still developing, and the business is not yet at the very highest level of signal due to transitional volatility and some dependency on supply constraints.
Kurosushi USA (KRUS) Q2 2026: Labor Leverage Surges 410bps, Technology and IP Drive Momentum
KRUS displays a long reinvestment runway, strong unit economics, and a self-reinforcing business model driven by technology and IP partnerships. While growth is robust and the business is transitioning into a cash flow machine, some areas (future growth acceleration, disruptive potential, and cash flow velocity) are present but not at the highest magnitude. The business is clearly in a growth phase with above-average signal, but not an undiscovered or highly disruptive story.
GameSquare (GAME) Q4 2025: Agency Revenue Soars 142% as Platform Integration Unlocks Margin Expansion
GameSquare demonstrates a strong reinvestment runway and significant recent growth, with clear improvement in unit economics and a self-reinforcing business model. Customers are becoming more valuable, and the business is transitioning into a high-margin, growth-oriented platform. However, while the growth outlook is strong, it does not reach the exceptional acceleration threshold in all areas, and some elements (such as disruption and cash flow) are present but not at the highest possible level. The company is a growth business with above-average signal but not at the absolute top tier.
MannKind (MNKD) Q4 2025: Furosix Sales Surge 91% as Pediatric Afrezza and Auto-Injector Catalysts Approach
MannKind demonstrates a long reinvestment runway, significant recent growth, improving unit economics, and a self-reinforcing business model. Customers are becoming more valuable and the business is transitioning to a growth profile. However, while the future outlook is strong, some elements (like disruptive potential and extreme acceleration) are present but not at the highest threshold, justifying a slightly lower signal score.
NXXT Q1 2026: Fuel Revenue Triples, $750M Microgrid Pipeline Sets Up Next Phase
NXXT demonstrates a long reinvestment runway, strong revenue growth, improving unit economics, and early signs of self-reinforcing business dynamics. Customer value is increasing and the business is transitioning to a growth platform, but the energy infrastructure pipeline is not yet fully converted, and cash flow acceleration is only moderate. The business model is semi-disruptive, and while growth is strong, it is not yet at the highest acceleration tiers. Risks around funding and execution temper the signal score.
Soleno Therapeutics (SLNO) Q4 2025: 40% Sequential Revenue Surge Anchors PWS Franchise Expansion
Soleno demonstrates a strong reinvestment runway, rapid business evolution, improving unit economics, and a self-reinforcing model with increasing customer value. The growth outlook is robust but not yet exceptional due to regulatory and launch risks. The business is clearly in a high-growth phase but faces some uncertainty in EU approval and pipeline expansion, moderating the signal score.
Array Technologies (ARRY) Q4 2025: Order Book Hits $2.2B as Tier 1 Mix and Platform Expansion Drive Visibility
Array Technologies demonstrates a long reinvestment runway, clear business model evolution, and improving unit economics, with a record order book and increasing Tier 1 customer mix. However, while growth is strong and recurring revenue optionality is emerging, the business is not disruptive in the purest sense and some metrics (cash flow, international execution, and margin recovery) remain in transition. The signal is strong, but not at the absolute highest level due to these moderating factors.
MSCI (MSCI) Q1 2026: Index Asset-Based Fee Run Rate Jumps 25% as AI Drives Custom Index Surge
MSCI demonstrates a strong reinvestment runway, clear improvements in unit economics, and a self-reinforcing model, with high-value customers and a disruptive, AI-driven business model. The business is growing robustly, though not at hypergrowth rates, and some segments (e.g., sustainability) are muted, which tempers the overall signal. The business is not undiscovered, but there is clear strategic upside and innovation.
Manhattan Associates (MANH) Q1 2026: Cloud Revenue Jumps 24% as AI Agents Drive Adoption
Manhattan Associates demonstrates a strong reinvestment runway, clear business model transition, and improving unit economics. There is evidence of high-value customer wins, recurring revenue growth, and strategic AI-driven differentiation. However, while growth is robust, the signal is slightly tempered by management's macro caution, the moderate pace of cloud conversion, and the fact that the business, though strong, is not undiscovered or highly disruptive. The outlook is positive but not at the highest level of transformative upside.
Beta Bionics (BBNX) Q1 2026: Pharmacy Channel Mix Hits 39%, Accelerating Margin Expansion Path
BBNX demonstrates a long reinvestment runway (pharmacy channel, pipeline), significant recent developments (margin expansion, guidance raise), improving unit economics, and a recurring revenue model. The business is not fully disruptive or in hypergrowth, but shows strong growth characteristics and some optionality. Cash flow is improving, but not yet accelerating rapidly. Guidance and backlog suggest solid but not exceptional acceleration.
Grid Dynamics (GDYN) Q4 2025: AI Revenue Surges 30% as Platform Shift Drives Margin Expansion
Grid Dynamics is transitioning to an IP-driven, platform-led model with strong evidence of operating leverage, recurring revenue, and improving unit economics. AI revenue is growing rapidly (30% YoY), and the business is compounding via partnerships and vertical expansion. However, while growth is robust, it is not yet at hypergrowth levels (>40%), and legacy vertical headwinds plus FX risk temper the overall signal. The business is clearly in growth mode with a differentiated model, but not yet at the highest possible inflection.
Moody’s (MCO) Q1 2026: Private Credit Ratings Revenue Surges 80%, AI and Workflow Integration Drive Structural Growth
Moody's demonstrates strong growth in private credit ratings and workflow integration, with evidence of margin expansion, recurring revenue focus, and AI-driven operational leverage. However, as a large, well-followed incumbent, its reinvestment runway is somewhat capped, and growth rates, while impressive in private credit, are not at the hypergrowth level for the overall business. The business model is robust but not disruptive in the sense of a new entrant or category creator.
Allot (ALLT) Q4 2025: Cybersecurity ARR Soars 69%, Recurring Revenue Hits 62%
Allot demonstrates a strong business model inflection with a long reinvestment runway, high recurring revenue growth, and improving unit economics. The business model is moving toward self-reinforcement, though network effects are still emerging. Customer value is improving but not dramatically deepening yet. Growth is robust (ARR up 69%), but revenue/EPS growth rates are not above 40%. The company is in a strong transitional phase toward a growth SaaS business, with clear disruptive potential and accelerating cash flow.
ZLAB Q4 2025: Pipeline Drives 17% Revenue Growth, Sets Stage for 2026 Launches
Zai Lab demonstrates a long reinvestment runway, robust pipeline momentum, and improving unit economics. The business model is increasingly self-reinforcing, with growing customer value and a clear transition to global innovation leadership. However, while growth is strong, it is not at the most exceptional levels (over 40%+), and some elements (e.g., cash flow, disruption, and growth rates) are solid but not at the highest possible signal. The business is a growth platform but not a breakout hypergrowth story.
ServiceNow (NOW) Q1 2026: AI Commit Surges 50% to $1.5B, Setting New Platform Trajectory
ServiceNow is showing strong growth, a long reinvestment runway, and clear evidence of a compounding, self-reinforcing platform. The 50% AI commit jump and multi-vertical expansion are significant, but the business is already well-followed and the growth, while impressive, is not at a disruptive, hypergrowth inflection. Some elements (cash flow, future guidance) are solid but not exceptional, and the business model, while evolving, is not fully disruptive. This is a high-quality, high-signal business, but not at the very top of the scale for upside surprise.
Goosehead Insurance (GSHD) Q1 2026: Digital Agent Drives 23% Revenue Growth as Platform Expansion Accelerates
Goosehead demonstrates a long reinvestment runway with high returns, strong revenue growth, and improving unit economics. The business model is self-reinforcing, and customer value is increasing. While growth is robust, future guidance signals acceleration but not at an exceptional (30%+) rate, and the business, while technology-forward, is not fully disruptive. Cash flow is improving but not yet accelerating, and annualized revenue/EPS growth is in the 20-40% range. The company is a clear growth business, but not at the most extreme levels of signal.
NovationBio (NUVB) Q1 2026: First-Line Shift Lifts Ibtrozi Revenue 18% as Patient Mix Rebalances
NovationBio demonstrates a long reinvestment runway, major recent business evolution (first-line shift), improving unit economics, and a self-reinforcing model. Customers are becoming more valuable, and the business is transitioning to a growth phase with a disruptive model. However, while growth is strong, it is not yet in the exceptional (40%+) range, and cash flow acceleration is moderate rather than explosive. Pipeline optionality and international expansion add to the signal, but some elements (testing bottleneck, pipeline risk) temper the overall upside.
NextEra Energy (NEE) Q1 2026: Renewables Backlog Hits 33 GW as Data Center Demand Accelerates
NEE demonstrates a long reinvestment runway, record backlog growth, improving unit economics, and a self-reinforcing business model. Customer value is increasing, and the business is positioned as a growth leader in the sector. However, while growth is strong, the business is still a large, well-known utility, so some signal points are capped. The business model is semi-disruptive, not fully disruptive, and although cash flow and revenue growth are robust, they are not at the most exceptional levels.
BridgeBio (BBIO) Q4 2025: Atruby Prescriber Base Jumps to 1,856, Signaling Deepening Franchise Penetration
BridgeBio is transitioning to a cash-generative, multi-product commercial model with strong runway and pipeline de-risking. However, while the commercial inflection and pipeline launches are notable, the business is not yet a clear outlier for 40%+ growth or disruptive business model, and some optionality remains to be proven. The signal is strong but not at the absolute highest level for a truly exceptional or unknown growth story.
KNSA Q4 2025: Arclist Penetration Reaches 18% as Market Expansion Accelerates
KNSA demonstrates a long reinvestment runway, robust growth, improving unit economics, and a self-reinforcing business model. Customer value is deepening, and the business is firmly in growth mode. However, pipeline execution and future growth rates are not exceptional or disruptive enough for the highest scores, and while cash flow is strong, it's not yet accelerating at the highest possible rate.
Ligand (LGND) Q4 2025: Royalty Revenue Jumps 48% as Portfolio Drives $1B Deployable Capital
Ligand demonstrates a long reinvestment runway, strong recent growth, improving unit economics, and a self-reinforcing model. Customer value and growth outlook are positive, but the business model, while differentiated, isn't disruptive at platform scale, and some growth metrics are just below the highest thresholds. Still, the business is clearly a growth story with substantial optionality and capital deployment capacity.
Spotify (SPOT) Q1 2026: Biddable Ads Top 33% of Revenue, Unlocking New Monetization Levers
Spotify shows strong signs of a long reinvestment runway and improving unit economics, with self-reinforcing business model characteristics and increasing customer value. While growth is robust and strategic inflections are evident, the business is not entirely disruptive and some metrics (growth rate, cash flow acceleration) are solid but not extreme. Signal is strong but not at the highest level for a widely followed, maturing platform.
Amkor Technology (AMKR) Q1 2026: Advanced Packaging Drives 27% Revenue Surge, Setting Stage for Multi-Year Margin Expansion
Amkor demonstrates a long reinvestment runway and clear compounding advantages in advanced packaging, with strong recent growth and improving unit economics. However, while growth is robust, it is not accelerating at the highest possible rate (e.g., 40%+), and some risks around CapEx execution and margin dilution remain. The business is not fully disruptive but is transitioning toward a more strategic position in the semiconductor value chain. The outlook is strong but not at the most exceptional tier for signal.
Connexa (KNSA) Q1 2026: ARCLIS Revenue Jumps 56% as Prescriber Base Expands
Connexa demonstrates strong growth, improving unit economics, a self-reinforcing model, and a long runway. However, pipeline milestones are pending and some lateral/disruptive opportunities are still emerging rather than fully proven. Revenue growth is strong but not yet at the most exceptional levels, and cash flow is only moderately accelerating.
Guidewire (GWRE) Q2 2026: RPO Surges 63% as Cloud and AI Wins Extend Contract Durability
Guidewire demonstrates strong durability, a premium-linked model, high retention, and accelerating backlog, but growth is not hyper-scaling (>40%), and the business model, while strong, is not fully disruptive. Signal is high but not at the absolute maximum due to these factors.
TARS Q4 2025: Xtemvi Drives 50% Sales Growth, $2B+ U.S. Peak Target Unveiled
Tarsus demonstrates a strong reinvestment runway, clear business model leverage, and rapid revenue growth, with Xtemvi showing blockbuster potential. However, the business is not yet at exceptional acceleration (guidance is strong but not >40%+), and pipeline risk remains. The model is disruptive but not at the frontier of platform scale, and cash flow is improving but not yet a machine. The company is transitioning to a growth portfolio but not yet a multi-product giant.
KIDS Q1 2026: 22% International Surge Signals Global Pediatric Platform Leverage
Orthopediatrics shows strong international growth, improving unit economics, and a focused innovation cycle. However, while the growth is robust, it is not yet exceptional or disruptive at the highest level. The runway is long and the business is transitioning toward higher profitability, but near-term guidance and cash flow improvement are not quite at the 'exceptional' threshold. Still, the business is clearly growth-oriented with strong signals for investors.
AAON (AAON) Q4 2025: Basics Backlog Surges 141% as Data Center Demand Drives Capacity Focus
AAON displays a long reinvestment runway with high returns, a disruptive shift into data center cooling, and strong backlog growth. Unit economics are improving, and the business model is compounding with scale. Customer value is deepening, and the business is firmly in growth mode. However, guidance for 2026 points to high but not exceptional growth (18-20%), so not all metrics are at the highest level. Cash flow is improving but not yet accelerating, and the business, while disruptive, is not a pure-play tech platform. Nevertheless, the signal is strong and above average for the sector.
Sens (SENS) Q4 2025: Eversense 365 Drives 103% U.S. Patient Growth as Commercial Control Shifts In-House
Sensonics is transitioning to a direct model with a long reinvestment runway, clear margin expansion, and disruptive elements in CGM. Patient and revenue growth are strong, but not yet at hypergrowth/exceptional levels (>40%+ QoQ). The business is not yet a cash flow machine, and some disruption risk remains. Overall, the signal is high but not at the very top end due to execution complexity and the need to prove European scaling.
Celsius (CELH) Q4 2025: Alani New Drives 136% Growth, Doubling Portfolio Shelf Space
Celsius demonstrates a long reinvestment runway, disruptive distribution, and operational leverage, with clear evidence of compounding brand and shelf presence. Alani New's growth rates are exceptional, but normalization is expected, so not all metrics are at maximum signal. Cash flow and margin improvements are credible but not yet fully realized. The business is clearly in a growth phase, but given category maturity and normalization ahead, signal is strong but not at the absolute maximum.
Vistra (VST) Q4 2025: Nuclear PPAs Add 3.8 GW, Reshaping Long-Term Earnings Mix
Vistra demonstrates a strong reinvestment runway, significant recent developments, improving unit economics, and a self-reinforcing business model. While customer value is improving, it is not consistently deepening yet. Growth is robust but not extreme (not consistently over 40%), and the business is transitioning into a growth-oriented, cash-generative model with some disruptive elements. The signal is high, but not at the absolute maximum due to the scale and maturity of the company.
TG Therapeutics (TGTX) Q4 2025: Brionvi Franchise Grows 92% as Subcutaneous Launch Nears
TG Therapeutics demonstrates a long reinvestment runway with high returns, recent significant growth, improving unit economics, and strong cash generation. The business is transitioning from launch to scaled franchise, but the self-reinforcing aspects are still emerging (score 1 for question 4 and 7). Growth is robust but not at the extreme levels for maximum scores in all categories.
iRhythm (IRTC) Q1 2026: Next-Gen AI Algorithm Targets $100M+ Efficiency as Volume Surges 26%
iRhythm shows strong reinvestment potential, operational leverage, improving unit economics, and a self-reinforcing platform model. However, while growth is robust, guidance implies a moderating pace, and regulatory overhangs temper the signal. The business is not fully disruptive or at hypergrowth, but has clear avenues for continued expansion and margin improvement.
Wingstop (WING) Q4 2025: 493 New Units Fuel 15% EBITDA Growth as Smart Kitchen Rollout Reshapes Operations
Wingstop offers strong unit economics, a long reinvestment runway, and clear evidence of compounding advantages (franchise model, tech rollout, international white space). However, while growth is robust, comps are soft and not all metrics are exceptional; some levers (loyalty, Smart Kitchen) are promising but not yet proven at scale. The business is growth-oriented but not at the disruptive or hypergrowth threshold.
TTI Q4 2025: Completion Fluids Margin Climbs 420 bps as Bromine and Desalination Scale Up
TTI demonstrates a long reinvestment runway, margin expansion, and new secular growth drivers, with evidence of improving unit economics and a self-reinforcing business model. However, some growth areas (desalination, tech-grade chemicals) are still emerging, and near-term growth is moderate rather than explosive. The business is transitioning to higher quality, but not yet at the level of a clear hyper-growth disruptor.
HROW Q4 2025: Vivi Revenue Jumps 216% as Sales Force Doubles to Target Market Leadership
Harrow demonstrates a strong reinvestment runway, clear business model evolution, improving unit economics, and deepening customer value, with several disruptive and pipeline-driven growth vectors. However, the business, while showing accelerating growth and diversification, is not a true outlier in terms of magnitude or uniqueness, and some forward signals are still moderate rather than exceptional.
Amneal (AMRX) Q1 2026: Biosimilars to Surpass $1B by 2030 as Kashiv Deal Reshapes Growth Trajectory
Amneal’s acquisition and strategic pivot to biosimilars provides a long reinvestment runway, improved unit economics, and a clear growth trajectory. The business model is becoming more self-reinforcing, and the future outlook is strong but not explosive (hence some 1s instead of 2s). The company is not yet showing over-40% growth or full disruptive status, but is transitioning into a growth business with above-market potential.
FloCo (FLOC) Q4 2025: Rental Revenue Surpasses $110M as Platform Expansion Drives Margin Gains
FloCo demonstrates a long reinvestment runway with high ROIC, significant recent developments (notably the Valiant acquisition), improving unit economics, and a self-reinforcing rental platform. Customer value is increasing, and the business is transitioning to a higher-margin, recurring model. However, while the growth is strong, it does not yet reach the exceptional/accelerating levels in every dimension (e.g., guidance is solid but not explosive, and international expansion is early stage), so scores are slightly conservative.
Ardelyx (ARDX) Q1 2026: Ibsrella Revenue Jumps 58% as Specialty Channel Drives Prescription Fulfillment
Ardelyx demonstrates a strong growth trajectory, high returns on capital, and improving unit economics, with self-reinforcing business model elements and deepening customer value. While growth is robust, it falls just short of extraordinary acceleration, and the business model, while attractive, is not fully disruptive. The signal is strong but not at the absolute highest level.
TKO (TKO) Q4 2025: Media Rights Jump Drives 600bps Margin Expansion, Execution Focus Locks In 2026 Visibility
TKO demonstrates a long reinvestment runway, transformative media rights deals, and improving unit economics. The business model is increasingly self-reinforcing with recurring high-margin revenue, and customer value is deepening via partnerships. While growth is strong, it's not at the most extreme levels, and some aspects (like disruptive potential and cash flow acceleration) are solid but not exceptional. The business is clearly in growth mode, but not at the highest signal threshold for every dimension.
VersaBank (VBNK) Q1 2026: U.S. SRP Portfolio Jumps 29%, Unlocking Operating Leverage
VersaBank demonstrates a long reinvestment runway, improving unit economics, and a self-reinforcing business model via its U.S. SRP platform and digital asset initiatives. The business is transitioning into a high-growth phase with accelerating U.S. asset growth, but the digital asset optionality is not yet proven to be exceptional (hence some 1s instead of 2s). Revenue and EPS growth are strong but not yet at the most aggressive tier. Overall, the signal is high, but not at the absolute maximum due to some execution and adoption risks.
Repligen (RGEN) Q4 2025: Analytics Grows 37%, Multi-Year Upgrade Cycle Accelerates Margin Upside
Repligen demonstrates a long reinvestment runway, strong recent growth in analytics, improving unit economics, and a self-reinforcing model. Customers are becoming more valuable, and the business is a clear growth story. However, guidance is prudent and not exceptional, the disruption is moderate, and growth is strong but not hyper-growth. The article accurately signals the business's upside but tempers the score due to macro caution and lack of explosive near-term acceleration.
Rigetti (RGTI) Q4 2025: 99.9% Gate Fidelity Achieved, Charting Path to 1,000-Qubit Scale
Rigetti demonstrates long-term reinvestment potential, disruptive technology, and significant technical milestones. However, customer value deepening and growth acceleration are moderate due to the early-stage, government/research-centric market. The business is a clear growth story but not yet showing exceptional commercial inflection.
Veristem Oncology (VSTM) Q4 2025: COPAQ Launch Drives $17.5M Revenue, Pipeline Progress Sets Up 2026 Catalysts
Veristem demonstrates a strong reinvestment runway, rapid adoption of a newly launched drug, and a clear path to commercial self-sufficiency, supported by pipeline progress and disciplined capital allocation. While growth is strong, not all future guidance is exceptional, and some elements (e.g., cash flow, disruptive model) are promising but not yet fully proven.
Vermilion Energy (VET) Q4 2025: 36% 2P Reserve Growth Signals Deep Basin and European Gas Upside
Vermilion's results and outlook signal a strong growth and capital efficiency profile, with a long reinvestment runway, premium pricing, and improving unit economics. However, while growth is robust and the business is transitioning to a higher-quality model, it does not reach the most exceptional levels (e.g., >40% growth rates or truly disruptive business model), and there are some moderating factors such as commodity exposure and regulatory risk.
Rumble (RUM) Q4 2025: MAUs Jump 11% as Shorts and Cloud Bet Redefine Growth Trajectory
Rumble demonstrates a long reinvestment runway with disruptive growth levers (Shorts, cloud), clear business model evolution, and improving unit economics. However, monetization per user outside the US is still lagging, and while guidance is positive, it is not yet exceptional. Cash flow is improving but not yet accelerating, and revenue growth is not projected above 40%. The business is transitioning into a growth phase, but some key metrics remain to be proven out.
Targa Resources (TRGP) Q4 2025: Permian Volumes Up 11% as Multi-Year Growth Pipeline Expands
Targa demonstrates a long reinvestment runway, strong growth in core volumes, improving unit economics, and a self-reinforcing business model. Customer value is increasing, and the business is transitioning to higher cash flow. However, while growth is robust, it is not at truly exceptional levels (>40%), and the model, while advantaged, is not fundamentally disruptive. Guidance is strong but not extraordinary. The business is a leader in a core sector but not a new disruptor.
Sunoco (SUN) Q4 2025: Parkland Deal Drives 54% Fuel Volume Surge, Sets Stage for Multi-Year Growth
Sunoco's transformative acquisition and resulting structural changes provide strong signals of a growth business with improved margins, cash flow, and scale. While the reinvestment runway and unit economics are compelling, the business model, while scaling and integrating, is not fundamentally disruptive or self-reinforcing at a tech-platform level. Growth rates and guidance are robust but not at the highest tier. The article signals upside, but the business remains in a consolidator phase rather than a disruptive, runaway growth model.
Slide Insurance (SLDE) Q4 2025: Gross Premiums Written Surge 57% as Geographic Expansion Accelerates
Slide Insurance demonstrates a long reinvestment runway, significant growth (57% YoY premiums), improving unit economics, and strong customer value growth. The business model is partially self-reinforcing (tech/data-driven, but not pure network effects), and while not fully disruptive, it is semi-disruptive in the context of insurance. Cash flow and profitability are accelerating, but the growth rate is below the 40% threshold for the highest signal. The business is clearly transitioning to a multi-state growth story, but faces regulatory and reinsurance cost risks.
DoorDash (DASH) Q4 2025: New Verticals Set to Turn Gross Profit Positive in H2
DoorDash is at a structural inflection with new verticals turning profitable, strong subscription and international momentum, and a clear multi-category platform strategy. However, while growth is robust, not all metrics (e.g., future guidance and cash flow acceleration) are at the highest threshold, and the business is well-known, slightly muting the signal score.
GOTU Q4 2025: Offline Revenue Set to Surpass Peers as AI Drives 21% Growth
GOTU shows strong reinvestment potential, improving unit economics, and a self-reinforcing hybrid business model. Offline expansion and AI integration signal business evolution, but growth guidance is moderate for the near term and regulatory risks temper the signal. The business is transitioning toward growth, but not at a rate warranting a perfect signal score.
AudioEye (AEYE) Q4 2025: 40 Straight Quarters of Growth Sets Stage for 30%+ Cash Flow Acceleration
AEYE shows strong signs of a durable, high-growth SaaS business with a defensible moat and expanding margins. The company has a long reinvestment runway, recent channel wins, and is positioned for regulatory-driven upside. However, while ARR and cash flow are accelerating, some metrics (unit economics, customer value) are improving but not yet exceptional. The growth outlook is strong but not hyper-scale, and some risks around regulatory timing and channel execution temper the signal.
Inspired Entertainment (INSE) Q4 2025: Interactive Surges 53% as Digital Now Drives 51% of EBITDA
INSE demonstrates a long digital reinvestment runway, exceptional recent growth, improving unit economics, self-reinforcing business model, and deepening customer value. However, while growth is strong, future acceleration is not guaranteed, and the business—though attractive—is not a truly disruptive category leader, thus warranting a conservative score.
Waystar (WAY) Q4 2025: AI-Driven Bookings Double, Securing Platform Leadership in Healthcare RCM
Waystar demonstrates a long reinvestment runway, clear business model compounding, improving unit economics, and strong customer value expansion. Growth is high but not at the 'exceptional' (40%+) threshold, and while disruptive, the business model is not entirely unique. Cash flow and EPS growth are strong but not hyper-accelerating. The signal is high but not maximal due to the business's size and relative maturity.
GBTG (GBTG) Q4 2025: AI-Driven Margin Expansion Targets 150–200bps Annually Through 2030
GBTG demonstrates strong signals: long reinvestment runway, significant recent developments (CWT integration, AI adoption), improving unit economics, and a self-reinforcing business model via platform partnerships. Customer value is increasing and the business is positioned for growth, but the signal is limited by the partially disruptive nature of the model, only moderate acceleration in cash flow, and revenue/EPS growth just under the highest tier. The business is not a pure high-growth disruptor, but signal remains strong.
Integrity (ASIC) Q1 2026: Expense Ratio Drops 2.5 Points as Regional Playbook Drives 23% Premium Growth
Integrity demonstrates strong premium growth, margin expansion, and a clear reinvestment runway with regional and technological initiatives. However, the business model, while differentiated, is not highly disruptive and some self-reinforcing aspects are emerging but not yet fully compounding. Growth rates are impressive but not at the extreme end of the spectrum. Still, the signal is strong for investors seeking compounding, high-return insurance models.
Goosehead Insurance (GSHD) Q4 2025: Franchise Gross Payments Climb 29% as Consolidation Drives Producer Scale
Goosehead demonstrates a long reinvestment runway, improving unit economics, and a self-reinforcing business model with rising customer value. There are significant developments (franchise consolidation, tech/AI rollout, enterprise channel ramp), but near-term growth is moderate rather than exceptional. The business is transitioning toward a more scalable, tech-enabled model, but is not yet in hypergrowth territory. Signal is high, but not at the very top end due to the pace of change and some uncertainties.
Ardelyx (ARDX) Q4 2025: Ibsrella Surges 73% as Pipeline and IP Expansion Anchor $1B Ambition
Ardelyx demonstrates a strong runway with Ibsrella’s growth, improving unit economics, and a self-reinforcing model. However, it does not reach the highest bar for multiple questions (e.g., guidance is strong but not exceptional, disruption is moderate, and revenue/EPS growth is high but not at the most extreme level).
AT Renew (RERE) Q4 2025: 88% 1P2C Retail Surge Reshapes Margin and Channel Mix
AT Renew demonstrates a long reinvestment runway, significant recent growth, improving unit economics, and a self-reinforcing business model. Customer value is increasing, and the business is transitioning to a growth profile with some disruptive elements. However, while growth is strong, it is not yet at the most exceptional level in all metrics, and some elements (cash flow, guidance) are solid but not outstanding. The business is highly investable but not in the very top percentile for signal.
Willis Lease Finance (WLFC) Q4 2025: Asset Management Funds Unlock $1.6B Platform Expansion
WLFC is at a pivotal inflection: launching $1.6B in funds, expanding fee income, and leveraging a supply-constrained engine market. The business model is evolving, with high returns on capital and clear reinvestment runway, but some metrics (growth rate, cash flow acceleration, disruptive potential) are not at the highest possible level, and the asset management pivot—while promising—still requires execution. The business is attractive and evolving but not yet in the highest growth/disruption cohort.
Triple Flag (TFPM) Q4 2025: $350M Deployed, 45% Cash Flow Growth Signals Expanding Long-Term GEO Pipeline
Triple Flag demonstrates a long reinvestment runway, robust growth, and improving unit economics. The model is self-reinforcing with compounding potential, and customer (operator) value is deepening. However, near-term growth is strong but not hyper-accelerating, and while the model is disruptive for mining finance, it is not unique to Triple Flag. Cash flow and growth are both strong but not at the highest level of acceleration. The business is a clear growth compounder, but not a new or underappreciated story in the sector.
Royal Gold (RGLD) Q4 2025: Acquisitions Drive 85% Revenue Surge, Portfolio Diversification Accelerates
Royal Gold demonstrates a long reinvestment runway, strong recent growth (85% revenue surge), improving unit economics, and a self-reinforcing business model via portfolio diversification. Customer value is increasing with more diversified streams. Near-term growth is strong but not yet accelerating at an exceptional rate, and the business is not highly disruptive (royalty/streaming is established). Cash flow is improving, but not yet described as accelerating. Guidance and organic growth are positive, but not at hypergrowth levels. The business is a clear growth leader in its sector.
Iron Mountain (IRM) Q1 2026: Data Center Revenue Jumps 47% as ALM and Digital Surpass 50% Growth
Iron Mountain is showing a strong pivot to growth with multiple high-performing segments and clear reinvestment opportunities, but the business is neither undiscovered nor likely to deliver truly explosive upside. While growth is robust, it is not at the 'exceptional' 30%+ acceleration level for the whole business, and some legacy/transition risk remains. Still, the signal is strong for a large-cap REIT.
Futu (FUTU) Q4 2025: Operating Margin Jumps to 64% as Overseas Growth and Product Expansion Drive Leverage
Futu demonstrates a long reinvestment runway, high margins, improving unit economics, and a self-reinforcing global platform with growing ARPU and client stickiness. However, while growth is strong, it is not currently at an exceptional (40%+) acceleration, and some areas (e.g., disruption and cash flow) are solid but not at the highest inflection. The business is a growth story with international optionality, but not an undiscovered or truly exceptional signal.
Aurora Mobile (JG) Q4 2025: Engagelab ARR Soars 186% as Global SaaS Pivot Delivers First Full-Year Profit
Aurora Mobile is showing strong signals of a growth business with a long reinvestment runway, high ARR growth, improving unit economics, and a sticky SaaS model. However, while growth is strong, the guidance for 2026 is for 20-28% YoY revenue growth, which is not exceptional. AI-driven growth is emerging but not yet proven at scale, and while cash flow is improving, it is not yet a cash flow machine. The business is transitioning to global SaaS leadership but is not yet in the highest signal tier for explosive upside.
Belden (BDC) Q1 2026: Ruckus Networks Deal to Lift Solutions Mix Above 20%
Belden is undergoing a significant transformation with a long reinvestment runway and improving unit economics, supported by a high-margin, full-stack acquisition. The move is disruptive for its industry segment, with recurring revenue and software expansion, but the overall growth outlook is strong rather than exceptional. The business is not yet in hypergrowth territory, and some risks remain around integration and execution.
NovoCure (NVCR) Q1 2026: Optune Pax Launch Drives 868 Provider Certifications, Accelerating Oncology Pipeline
NovoCure demonstrates a long reinvestment runway with expanding indications, robust early launch metrics, improving unit economics, and a self-reinforcing business model. Customer value is increasing and the business is transitioning to growth, but not all signal criteria are maxed: future growth is strong but not yet exceptional (>30% acceleration), business model is innovative but not fully disruptive, and cash flow is improving but not yet accelerating. Revenue and EPS growth are above 20% but not 40%.
Fathom Pharmaceuticals (PHAT) Q1 2026: New-to-Brand Share Hits 45% Among Top GI Prescribers, Reinforcing First-Mover Advantage
Fathom demonstrates a strong reinvestment runway, disruptive model, compounding economics, and high growth, but the signal is slightly muted by the business still being in ramp mode, with some uncertainty around the magnitude of future growth and competitive risk. The business is not yet showing accelerating cash flow or over-40% growth in the near term, and the primary care opportunity is still prospective.
BioMarin (BMRN) Q4 2025: Voxogo Surges 26% as Pipeline and Amicus Integration Set Up 2026 Inflection
BioMarin demonstrates a strong reinvestment runway, clear growth in core and pipeline assets, and improving unit economics. However, while growth is robust, it is not at hypergrowth levels (over 40%), and the business model, while durable and expanding, is not fully disruptive. Some risks around competitive threats, order timing, and integration temper the overall signal.
Oncology Institute (TOI) Q4 2025: Pharmacy Revenue Jumps 71%, Accelerating Capitated Platform Leverage
TOI demonstrates a strong reinvestment runway, material business evolution (notably in pharmacy and delegated capitation), improving unit economics, and a self-reinforcing hybrid model. Customer value is increasing, but future growth, while good, is not yet exceptional or hyper-growth. The business is not fully disruptive but is semi-disruptive, and cash flow is improving but not yet accelerating. Revenue/EPS growth is strong but not above 40%. Overall, the business is transitioning rapidly toward growth, but not all signal metrics are at the highest threshold.
TechnipFMC (FTI) Q1 2026: Subsea Opportunity Pipeline Expands 30%, Powering Margin Upside Into 2027
TechnipFMC demonstrates a long reinvestment runway, strong margin and cash flow expansion, and a disruptive business model in Subsea 2.0. Backlog and order growth are robust, but not at hypergrowth rates (>40%), and the business is not entirely unique or unknown—thus, scores are conservatively rounded down. The future is strong, but not exceptional on every signal dimension.
RLX (RLX) Q4 2025: International Revenue Hits 76.5%, Cementing Global Expansion Blueprint
RLX shows a long reinvestment runway, strong recent growth (44% YoY, international shift), improving unit economics, and a self-reinforcing model (regulatory/compliance moat, AI leverage). Customer value and cash flow are improving. However, while the growth is strong, it is not accelerating above 40%, and the business model, while modern, is not fully disruptive. The business is a clear growth story but not at the level of an early-stage hypergrowth disruptor.
Tiendas 3B (TBBB) Q4 2025: 574 Net Store Openings Accelerate Discounter Scale, Margin Leverage in Focus
Tiendas 3B demonstrates a long reinvestment runway, disruptive hard discounter model, and strong growth. However, the signal is tempered by margin compression, rising CapEx, and a maturing phase that could limit further upside. The business remains high-growth but faces emerging capital intensity and efficiency challenges.
Synovus Energy (CVE) Q4 2025: MEG Integration Delivers $3B Net Debt Uptick, Unlocks Oil Sands Scale
Synovus demonstrates a long reinvestment runway, strong recent business evolution, improving unit economics, and a self-reinforcing model with deepening customer value. The business is transitioning to a larger, more complex platform with above-average growth prospects, though not yet at the highest acceleration levels. Some elements (e.g., brownfield focus, moderate guidance) limit the highest scores for future exceptional growth, disruption, and cash flow acceleration, but the overall signal is strong and well above average.
VNET (VNET) Q4 2025: Wholesale IDC Revenues Jump 47%, Capacity Pipeline Expands Amid AI Surge
VNET demonstrates a long runway, strong growth, and improving unit economics, but some signal questions (guidance, disruption, cash flow) are not at the highest bar. The business is clearly in a high-growth phase with major inflections, though not all aspects are exceptional or disruptive enough for top marks.
Babcock & Wilcox (BW) Q4 2025: Backlog Surges 470% on $2.4B AI Data Center Win
BW demonstrates a long reinvestment runway and a massive backlog increase from a transformational contract, indicating a major business evolution. Unit economics and profitability are improving, but there is some uncertainty about the depth of self-reinforcing advantages and customer value expansion. The business is transitioning to a growth profile, but execution complexity and risk temper the signal score.
Paymentus (PAY) Q4 2025: Enterprise Billers Lift Revenue Per Transaction 11%, Expanding Margin Leverage
Paymentus demonstrates a long reinvestment runway, significant enterprise client wins, improving unit economics, and a self-reinforcing model. Customer value is increasing, and the business is transitioning to a growth enterprise. However, guidance and growth rates are strong but not at the highest acceleration, and while the model is innovative, it is not fully disruptive. Cash flow is improving but not yet accelerating at the highest level.
ClearPoint Neuro (CLPT) Q4 2025: Biologics and Drug Delivery Jumps 23% as Pipeline Diversifies
ClearPoint Neuro demonstrates a long reinvestment runway with high returns, significant recent growth in its biologics and drug delivery segment, and improving unit economics as it scales. The business model is increasingly self-reinforcing due to its partner ecosystem and recurring revenue. Customer value is deepening with more clinical trials and partner programs. While the future outlook is strong, guidance remains conservative and not exceptional, and the business model, though innovative, is not fully disruptive. Cash flow is improving but not yet accelerating, and expected growth is strong but not hypergrowth. The company is firmly in growth mode, but the signal is somewhat tempered by execution and regulatory risks.
WTTR Q4 2025: Water Infrastructure Revenue Surges 800% Over Five Years, Anchoring Margin Expansion
WTTR demonstrates a long reinvestment runway, major business mix inflection, improving unit economics, and self-reinforcing infrastructure model. Customers are becoming more valuable and the business is transitioning to high-margin, contract-backed growth. While the model is not fully disruptive and future growth, while strong, is not at hypergrowth levels, the signal is high for a mid-cap infrastructure transition story.
Talkspace (TALK) Q4 2025: Payer Sessions Up 36%, AI and Directory Integrations Expand Growth Runway
Talkspace demonstrates a long reinvestment runway, strong growth in core metrics, and improving unit economics. The payer-first model and emerging AI products provide durable optionality, but some questions remain on the magnitude of future acceleration and the disruptive potential of AI. Risk of execution and competitive pressure tempers the upside signal.
Diamondback Energy (FANG) Q4 2025: Barnett Wells Project 50% Higher Oil Recovery, Reshaping Resource Narrative
Diamondback is showing a long reinvestment runway and clear improvements in resource quality and unit economics. The Barnett program is a significant business evolution, but not yet delivering 40%+ growth or fully disruptive; execution risk remains. The business is transitioning toward higher growth and returns, but not at the highest possible acceleration.
One Stop Systems (OSS) Q4 2025: Gross Margin Hits 58.5% as Edge AI Platform Focus Drives Profitability
OSS has a long reinvestment runway in edge AI compute, with clear high-ROIC opportunities. The business is showing strong growth (70% YoY), improved margins, and multi-year contract wins. Unit economics and customer value are improving, and the business model is self-reinforcing, though not a pure network effect. Guidance is for 20-25% growth, but not >40%, so some scores are capped. There is evidence of disruption and transition to a growth model, but the company is not yet a giant or category-definer.
Audia (ADEA) Q1 2026: AMD Deal Drives 28% Non-Pay TV Recurring Revenue Growth, CEO Transition Looms
Audia demonstrates a long reinvestment runway, disruptive IP model, improving unit economics, and clear business mix shift. However, while growth is strong, it is not yet at the highest acceleration levels (30%+), and some business model risks remain due to legacy exposure and leadership transition. The signal is high, but not at the absolute peak for an unknown or truly exceptional growth story.
XOMA (XOMA) Q4 2025: Royalty Receipts Jump 68% as Portfolio Diversification Drives Cash Flow Inflection
XOMA demonstrates a long reinvestment runway, clear business model evolution, improving unit economics, and compounding effects from portfolio scale. While the growth is strong and the business is transitioning to a self-funding model, it is not yet at the level of an exceptional, hyper-growth platform. Some metrics (e.g., future growth rates, cash flow acceleration) are promising but not at the highest threshold.
uCloud Link (UCL) Q4 2025: New Growth Engines Drive 616% User Surge Amid 14.6% Top-Line Drop
uCloud Link is transitioning to a platform model with exponential user growth in new business lines, improving unit economics, and a disruptive model in IoT and digital ecosystems. However, some elements (cash flow, future growth) are not yet fully exceptional, and network effects are only emerging. The business is not yet a giant, but the signal is strong and above average for a small-cap tech pivot.
Accelerate Energy (EE) Q4 2025: Iraq Project Lifts 2026 EBITDA Outlook by $80M as Regasification Wave Builds
Accelerate Energy demonstrates a long reinvestment runway, strong recent developments (Iraq and Jamaica), improving unit economics, and a self-reinforcing business model. Customer value is deepening, and the outlook is strong, though not at the most exceptional level. The business model is moderately disruptive, with cash flow and growth accelerating but not at hypergrowth rates. The company is positioned as a growth business, though the scale of upside is not 'giant' or highly disruptive.
Flywire (FLYW) Q4 2025: EBITDA Margin Expands 190bps as Enterprise Penetration Deepens
Flywire demonstrates a strong reinvestment runway, improving unit economics, and a self-reinforcing business model. Recent growth is robust but not at the highest acceleration threshold, and while the business is disruptive and increasingly cash generative, it is not in the hypergrowth category. The company is transitioning from a growth to a compounding platform, warranting a high but not perfect signal score.
LPA (LPA) Q4 2025: Mexico Expansion Adds 36% Pipeline, Full Occupancy Unlocks Pricing Power
The business demonstrates a strong reinvestment runway, recent significant expansion, improving unit economics, and a self-reinforcing platform model. Customer value is increasing, but future growth, while visible, is not clearly exceptional or disruptive enough for a perfect score. Revenue and EPS growth are strong but not at the highest threshold. The business is solidly in growth mode.
VSE (VSEC) Q4 2025: Aviation Margins Expand 260bps as Pure-Play Transformation Accelerates
VSE is a growth business with a long reinvestment runway, strong margin expansion, and a disruptive pivot to a pure-play aviation model. Recent acquisition and organic growth are strong, but not yet at the exceptional/acceleration level for all metrics (e.g., guidance is high but not >40% growth). Some lateral opportunities and cash flow acceleration are present but not yet fully proven. The business is highly investable but not at the highest possible signal tier.
FormFactor (FORM) Q1 2026: Gross Margin Jumps 510bps as Capacity, AI, and HBM Demand Drive Outperformance
FormFactor demonstrates a long reinvestment runway with high returns, recent significant growth in HBM and AI-related demand, and improving unit economics. The business model has some self-reinforcing aspects, and customer value is increasing. However, while growth is strong, future acceleration is somewhat constrained by capacity limits and customer concentration, and the overall business is not as disruptive or high-growth as the top decile of opportunities.
Rush Street Interactive (RSI) Q4 2025: Online Casino MAUs Surge 51%, Unlocking Operating Leverage
RSI demonstrates a long reinvestment runway, clear operating leverage, and improving unit economics, with a differentiated and partially disruptive business model. While growth is strong, it is not at the most exceptional levels for all metrics, and some upside drivers (like Alberta) remain optionality rather than certainty. The business is clearly in growth mode, but not all signals point to hyper-growth or extreme disruption.
Hagerty (HGTY) Q4 2025: Written Premiums Accelerate 19% as Markel Fronting Adds Profit Leverage
Hagerty demonstrates a long reinvestment runway, double-digit growth, improving unit economics, and a self-reinforcing business model with strong customer value expansion. The transition to full-risk retention is disruptive and margin-accretive, but accounting noise and some lumpiness in Marketplace revenue temper near-term signal. While not yet exceptional on every growth metric, the business is positioned for continued compounding.
Procept Biorobotics (PRCT) Q4 2025: Handpiece ASP Jumps 9% as Pricing Discipline Resets Growth Trajectory
Procept Biorobotics is at a key inflection, with a long runway in a large, underpenetrated market and a disruptive platform. The pricing reset and commercial overhaul create a more predictable, margin-accretive model. Growth is strong but not yet at a hyper-growth (40%+) rate for the coming year, and while unit economics and business model quality are improving, the transition period introduces execution risk. The business is clearly in growth mode, but not quite at the highest tier of signal due to near-term disruption and the need to prove sustained acceleration.
Lithium Argentina (LAC) Q4 2025: Cash Costs Fall 30% as Kachari-Olaraz Nears Nameplate, Unlocking Expansion Path
Lithium Argentina demonstrates a long reinvestment runway, material cost improvements, and a credible expansion path. While the business model is not highly disruptive, it is self-reinforcing with improving unit economics and cash flow. Growth is strong but not hypergrowth, and the outlook is positive but not exceptional. The article provides clear evidence of a transition from single-asset to scaled operator, with substantial valuation upside potential.
GlobalStar (GSAT) Q4 2025: Two-Way IoT Launch Expands Addressable Market by 50%
GSAT demonstrates a long reinvestment runway, significant recent developments, and improving unit economics. The business model is becoming more self-reinforcing and customer value is deepening. While the future is promising, some elements like government pipeline scale and IoT ramp are not yet exceptional, and cash flow acceleration is moderate. The business is transitioning toward growth but not all metrics are at the highest signal level.
Glaukos (GKOS) Q1 2026: iDoseTR Drives 58% U.S. Glaucoma Surge, Epioxa Launch Expands Access
Glaukos demonstrates strong growth, product adoption, and platform expansion, with clear signals of operating leverage and reinvestment opportunity. However, the business, while high-growth and innovative, is not completely unique or undiscovered, and some forward signals (e.g., Epioxa ramp, pipeline) are contingent on execution and payer access, capping the score below the maximum. Cash flow is improving but not yet accelerating, and some growth rates are in the 20-40% range rather than >40%.
Texas Pacific Land (TPL) Q4 2025: Water Sales Jump 36% as Data Center Opportunity Scales
TPL demonstrates a long reinvestment runway with high returns, record growth in water sales, improving margins, and a self-reinforcing business model. However, while the data center and desalination opportunities are promising, they are not yet fully commercialized, so future growth is not guaranteed and guidance is not exceptionally high. The business is transitioning toward secular growth but still carries legacy risk exposure.
Huya (HUYA) Q4 2025: Game-Related Revenue Surges 59% as Publishing and In-Game Items Drive Margin Upside
Huya demonstrates a long reinvestment runway, strong recent growth in new business lines, improving unit economics, and a business model that is increasingly self-reinforcing. However, some elements (AI, global expansion) are emerging rather than fully proven, and near-term growth, while robust, is not yet at the highest acceleration tier.
Local Bounti (LOCL) Q4 2025: Gross Margin Rises 400bps as Full Network Hits Capacity
Local Bounti demonstrates strong signals of a business transitioning into a growth phase with improving margins, network optimization, and expanding retail partnerships. The business model shows disruptive elements, but not all aspects (such as future growth rate or cash flow acceleration) are at the highest possible level. The business is actionable, but not quite exceptional in every signal dimension.
CYTK Q4 2025: MyCORSO Launch Activates 700+ REMS-Certified HCPs, Setting Up Commercial Inflection
CYTK is at a commercial inflection with a long runway, strong early launch signals, and a pipeline with expansion opportunities. However, while the growth potential is clear, the business is not yet showing exceptional (30%+) acceleration in guidance, and some elements (like cash flow and disruptive model) are not fully proven at this stage. The business is growth-oriented but not yet at the highest signal tier for explosive upside.
FLYX Q4 2025: 1,500bps Margin Expansion Signals Durable Operating Model Reset
FLYX demonstrates a strong reinvestment runway, structural margin improvement, and a shift to recurring revenue, with evidence of improving unit economics and compounding business model features. However, while growth is robust and the business is transitioning to a technology-enabled model, forward growth rates and disruption potential are not yet exceptional or category-defining, warranting a conservative deduction on several signal criteria.
Bentley Systems (BSY) Q4 2025: Asset Analytics Revenue Hits $50M Run Rate, AI Monetization Path Accelerates
Bentley Systems demonstrates a strong recurring revenue model, high retention, and emerging AI monetization. Asset analytics growth and capital allocation flexibility are positives, but the business is not at the level of hypergrowth or disruption seen in top-tier tech. The AI monetization path, while promising, is still early and subject to regulatory/adoption risks. Growth is robust but not explosive.
Oklo (OKLO) Q4 2025: CapEx Surges to $450M as Vertically Integrated Nuclear Platform Accelerates Deployment
Oklo demonstrates a long reinvestment runway, disruptive business model, and strong policy tailwinds. There is a major shift in CapEx and execution, but customer value deepening and cash flow acceleration are not yet fully proven at scale. Growth is strong but not yet at a 40%+ level. Overall, this is a high-signal, high-upside situation, but some elements (customer deepening, cash flow) are still in early innings.
ATAT Q4 2025: Retail Surges 67% as Hotel Pipeline Hits 779, Anchoring Brand-Led Growth
ATAT shows strong reinvestment runway and business evolution (retail up 67%, hotel pipeline robust). Unit economics and customer value are improving, and the business is transitioning toward a high-margin, brand-driven model. However, growth guidance (20-24%) and some risks around execution and margin pressure temper the signal slightly. The business is not entirely disruptive or at hypergrowth levels, but it is clearly in a strong growth phase with differentiated strategy.
Arcutis (ARQT) Q4 2025: Zareve Captures 45% Segment Share as Non-Steroidal Topicals Displace Steroids
The business shows strong reinvestment opportunities, operational leverage, and clear growth signals, but the model is not fully disruptive and some elements (e.g., future growth rate, exceptional backlog acceleration) are solid but not extraordinary. There is moderate but not extreme signal for a fund manager seeking outsized upside.
Tygo Energy (TYGO) Q4 2025: Revenue Jumps 92% as MLPE Volumes Outpace Competition
Tygo Energy demonstrates a strong reinvestment runway, disruptive potential, and improving unit economics. The business is growing rapidly with significant market share gains and margin improvement. While guidance is conservative and growth for 2026 is projected at 26–30% (not 40%+), the business is well-positioned for further upside if execution on new initiatives is successful. The signal is high, but not at the absolute maximum due to some conservatism in outlook and moderate, not explosive, forward growth.
AvePoint (AVPT) Q4 2025: Net New ARR Jumps 48% as AI Data Governance Drives Platform Expansion
AvePoint displays strong growth characteristics, with accelerating ARR, expanding enterprise wins, and a platform positioned for AI-driven expansion. However, while the business is clearly growth-oriented and disruptive within its niche, the runway and growth rates are not at the absolute highest tier (e.g., >40% across all metrics), and some areas (cash flow, guidance) are strong but not exceptional. The signal is high but not at the maximum possible level for a truly transformational or under-the-radar business.
SoFi (SOFI) Q1 2026: Cash Revenue Surpasses $1B for Second Straight Quarter, Underscoring Durable Growth
SoFi demonstrates a strong reinvestment runway, high growth, improving unit economics, and self-reinforcing business model. Customer value is deepening, and the business is on a strong growth trajectory, but the signal is slightly capped by the lack of truly exceptional future guidance (growth moderating to 30%), and the business model—while innovative—is not fully disruptive compared to some earlier-stage fintechs. Cash flow is improving but not yet at the 'machine' stage, and near-term growth is strong but not hyper-growth.
EVGO (EVGO) Q1 2026: AV and Ancillary Revenue Surges 300%, Highlighting New Growth Pathways
EVgo shows a long reinvestment runway, a major recent revenue inflection in AV/ancillary, improving unit economics, and self-reinforcing business model elements (contracted revenue, rideshare/AV partnerships). Customer value is deepening, but future growth is not yet exceptional/accelerating above 30%. The business model is semi-disruptive, and cash flow is improving but not yet accelerating. Revenue growth is strong but not over 40%. EVgo is a growth business, but not yet a category-defining breakout.
Element Solutions (ESI) Q1 2026: Electronics Organic Growth Hits 15% as AI Demand Drives Segment Outperformance
Element Solutions demonstrates a long reinvestment runway with high returns, double-digit organic growth in a key segment, improving unit economics, and a self-reinforcing business model. Customer value is increasing, guidance is raised, and the business is transitioning toward a higher growth, higher margin profile. However, the business is not exceptionally disruptive, and overall growth is strong but not at the highest acceleration tier. Risks in industrial segments and metals volatility temper the signal.
Axogen (AXGN) Q4 2025: Avance BLA Approval Unlocks 12-Year Exclusivity, Elevates Margin Pathway
Axogen has a long reinvestment runway (new indications, underpenetrated markets), a disruptive biologic business model, and recently achieved a large regulatory milestone (BLA approval with exclusivity). Unit economics and customer value are improving, and the business is transitioning to a growth phase with margin expansion ahead. However, growth guidance is under 20% and margin/FCF acceleration is not yet exceptional, so scores are conservative in those areas.
EXLS Q1 2026: Data and AI-Led Revenue Surges 28%, Now 60% of Portfolio
EXLS is demonstrating a strong pivot to AI-led services with double-digit growth and a high proportion of recurring revenue, indicating a solid reinvestment runway and improving unit economics. However, while the business model is evolving and disruptive, the pace of growth and guidance revision is strong but not yet exceptional, and some elements (such as cash flow acceleration and disruptive potential) are present but not at the highest level.
Amphenol (APH) Q1 2026: IT Datacom Orders Surge 78% as AI Demand Redefines Segment Mix
Amphenol is benefiting from a long reinvestment runway, double-digit growth, and clear operating leverage, with strong unit economics and self-reinforcing business model elements. However, some caution is warranted: while growth is robust, it is not yet at hypergrowth levels across the board, and the business model—though benefiting from secular trends—is not fully disruptive. Cash flow is strong but not accelerating at the highest rate, and while the business is clearly a growth story, some risks (concentration, integration, tax) temper the signal score.
Cytokinetics (CYTK) Q4 2025: MyCORSO Launch Engages 700+ HCPs, Setting Stage for Global Uptake
Cytokinetics is at a major inflection with its first commercial launch, strong early uptake, and multiple pipeline catalysts. The reinvestment runway is long, and the business model is disruptive with global expansion. However, customer value deepening and future growth rates are not yet fully proven, and cash flow is not yet accelerating, warranting a slightly lower score.
Root (ROOT) Q4 2025: Partnerships Drive Nearly 50% of New Writings, Unlocking Durable Growth Engine
Root displays a long reinvestment runway, strong growth in new channels, improving unit economics, and a self-reinforcing business model. Customers are becoming more valuable, and the business is transitioning to a platform with high growth characteristics. However, guidance for 2026 is for lower net income due to investment, and growth is strong but not at the most exceptional levels. The business is disruptive but not a hypergrowth outlier.
Day One Biopharmaceuticals (DAWN) Q4 2025: Ojemda Revenue Jumps 172% as Persistence and Pipeline Reshape Growth Trajectory
The business shows strong revenue growth, improving unit economics, a persistence-driven model, and a transition to a multi-asset platform. However, while the growth is impressive, the business is not yet at the level of exceptional/accelerating across all signal dimensions (e.g., pipeline is promising but unproven, and guidance is not for >40% growth). Still, the article surfaces several high-signal developments for investors.
Vertex (VRTX) Q1 2026: Non-CF Portfolio Drives 25% of Growth as Renal Franchise Accelerates
Vertex shows a strong reinvestment runway with new franchises, double-digit growth in non-CF products, improving economics, and a self-reinforcing business model. The renal franchise and gene-editing launches are disruptive, but not yet at exceptional growth rates, and some risk remains in pipeline execution and margin normalization. The business is clearly in a growth phase, but not all signals are at the highest possible level for disruption or acceleration.
Porch Group (PRCH) Q1 2026: Insurance Services Revenue Jumps 50%, Margin Engine Scales
Porch demonstrates a long reinvestment runway, major growth in insurance services, improving unit economics, a self-reinforcing model, and deepening customer value. However, while the growth is strong, it is not exceptional (not 40%+ overall), and the business, while disruptive in insurance, is not a pure high-growth technology platform with limitless optionality. There is still some cyclicality and execution risk, capping the signal score.
Notable Signals (12-15)
Articles with useful investment signals worth considering
TK Group (TK) Q4 2025: Spot Rates Jump 30% as Sanctions Shift Demand to Compliant Fleet
TK Group demonstrates a strong cash position, high spot rate leverage, and a disciplined, incremental fleet renewal strategy, supporting a long reinvestment runway and robust free cash flow. While the business is benefiting from exceptional macro tailwinds (sanctions, trade route shifts), some elements (network effects, customer value deepening) are less pronounced, and the business model—while strong—is not fully disruptive. Growth is solid but not hyperbolic. Overall, the signal is high but not at the absolute maximum.
BitDigital (BTBT) Q4 2025: Staking Revenue Surges 300% as Ethereum Strategy Drives Business Model Shift
BitDigital displays a clear business model pivot with a long reinvestment runway and disruptive potential in staking and AI infrastructure. There is significant growth in staking and cloud, strong margin expansion, and a managed wind-down of legacy mining. However, some signal is capped by the early stage of recurring revenue durability and the need for further proof of cash flow compounding and customer deepening.
LSB Industries (LXU) Q1 2026: EBITDA Jumps 44% as Supply Disruption Drives Market Tailwind
LSB Industries is showing strong growth, margin expansion, and capital deployment optionality, with a clear runway for reinvestment and industry tailwinds. However, the business model is not fundamentally disruptive, and while customer value and cash flow are improving, they are not yet at exceptional levels. The company is transitioning toward growth but is not yet a giant or uniquely self-reinforcing business. The article signals upside but not at the highest level of strategic transformation.
First Solar (FSLR) Q1 2026: Backlog Climbs to 47.9GW as CURE Rollout Unlocks $0.6B Revenue Potential
First Solar presents a long reinvestment runway, technology-driven margin expansion, and backlog strength, but some signal points are moderated by policy dependency and lack of evidence for >40% growth or truly exceptional customer value deepening. The business is clearly growth-oriented and disruptive, though some optionality is gated by external factors.
ZVRA Q4 2025: MyPlypha Drives 52 Annual Enrollments, Expanding Rare Disease Market Penetration
Zevra demonstrates a strong reinvestment runway and disruptive business model with clear growth signals, especially in rare disease market expansion and AI-driven patient identification. However, some elements such as unit economics, business model self-reinforcement, and cash flow acceleration are promising but not yet exceptional, keeping the overall signal score below the maximum.
Mobileye (MBLY) Q1 2026: ADAS Revenue Jumps 27% as China Export Volumes Accelerate
Mobileye demonstrates a long reinvestment runway, disruptive business model, and strong growth positioning, with clear evidence of strategic wins and expanding addressable markets. However, some metrics (unit economics, customer value, cash flow, top-line growth) are improving but not yet exceptional, and near-term results are tempered by mix and macro risks.
BTSG Q1 2026: Specialty Script Growth Surges 30% as Infusion and Operational Leverage Drive Margin Expansion
BTSG shows strong specialty and infusion growth, margin expansion, and operational leverage. While the business is growing quickly and cash flow is accelerating, it is not a disruptive model and the reinvestment runway, while solid, is not exceptional. There are clear improvements in unit economics and customer value, but the business, while high-quality, is not likely to deliver outlier upside beyond robust sector growth.
Castle Biosciences (CSTL) Q4 2025: TissueCypher Volume Soars 86%, Reinforcing GI Franchise Trajectory
Castle Biosciences has a long reinvestment runway, disruptive diagnostic models, and is showing very high growth in its GI franchise. Unit economics are improving but margin compression tempers signal. Customer value is increasing but not yet consistently deepening across all franchises. While the business is in growth mode, margin and pipeline investment trade-offs introduce some uncertainty for exceptional future earnings power.
CCC Intelligence Solutions (CCCS) Q4 2025: AI Revenue Reaches $100M as Emerging Solutions Scale 70%+
CCC exhibits a long reinvestment runway, strong network effects, and growing customer value. AI-driven solutions are scaling rapidly and the business model is disruptive within its vertical. However, growth rates, while strong, are not hyper-scale (under 40%), and cash flow is accelerating but not explosive. The business is not entirely unique or unknown, so signal is high but not at maximum.
Intuit (INTU) Q2 2026: AI-Driven Mid-Market Revenue Jumps 40% as Platform Model Deepens Competitive Moat
Intuit demonstrates strong growth in mid-market and platform adoption, with improving unit economics and a compounding business model. However, the business is relatively mature and Mailchimp’s lag tempers the overall runway. Growth is strong but not at hypergrowth levels, and while the model is robust, it’s not disruptive enough for a top score.
Tesla (TSLA) Q1 2026: CapEx Surges Toward $25B as AI, Robotaxi, and Optimus Ramp
Tesla demonstrates a long reinvestment runway, disruptive business model, and multiple avenues for platform leverage (AI, Robotaxi, Optimus). There is clear evidence of significant CapEx and strategic pivots. However, not all unit economics are improving rapidly (auto margins remain pressured), and customer value deepening is present but not exceptional. Growth is strong but not consistently over 40%, and near-term cash flow is negative, tempering the overall signal.
NXXT Q4 2025: Revenue Surges 195% as $750M Microgrid Pipeline Shifts Growth Narrative
NXXT shows a long reinvestment runway, transformative growth (195% revenue surge), clear improvement in unit economics, and a disruptive dual-engine model. However, compounding self-reinforcement and customer value deepening are emerging but not yet proven at scale. Backlog/guidance is strong but not yet exceptional, and cash flow is improving but not yet accelerating. The business is clearly in growth mode, but risks and execution hurdles temper the signal.
Alchemy (ALKT) Q1 2026: DSSP Clients Up 336%, Platform Expansion Drives ARPU and Margin Gains
Alchemy demonstrates a long runway with high returns on capital, significant backlog growth, and improving unit economics. The business is transitioning toward a disruptive, platform-centric model with strong ARR visibility and margin expansion. However, some levers such as AI monetization and customer value deepening are still nascent, and while growth is strong, it is not at the hypergrowth level (>40%). The business is clearly a growth story but not yet an outlier in all signal dimensions.
FIS (FIS) Q4 2025: Recurring ACV Sales Jump 20% as Data Moat Drives AI-Led Banking Growth
FIS demonstrates strong recurring revenue growth, margin expansion, and a data/AI moat, but the business is fairly well-known and mature, with moderate reinvestment optionality. There is a major business evolution (20%+ ACV sales growth, issuer integration), but not a truly exceptional acceleration (>40%). Unit economics, customer value, and business model self-reinforcement are all improving, but not at the level of a hypergrowth disruptor. The business is a growth business with moderate but not extraordinary signal.
COHU (COHU) Q1 2026: Orders Surge 57% as $750M AI Compute Pipeline Drives Platform Expansion
COHU shows a strong reinvestment runway, recent major business acceleration, and improving unit economics. The business model is becoming more self-reinforcing but software/customer value expansion is still early, so not all scores are maxed. Growth is robust but not yet at hypergrowth levels (>40%); recurring revenue is ramping but not dominant. The company is moving from cyclical to growth, with some execution and scaling risks limiting the signal score.
BMRN Q1 2026: Amicus Acquisition Adds $500M, Driving 20% Growth Trajectory Shift
BioMarin demonstrates a long reinvestment runway and has delivered a step-change in growth with the Amicus acquisition, immediately raising its growth baseline. Significant developments and strong backlog are evident, with clear improvement in unit economics and a business model that is partially self-reinforcing. Customer value is improving, but not consistently deepening yet. The future outlook is strong, with some elements of disruption and cash flow improvement, but not all metrics are at the highest threshold for a truly exceptional, disruptive growth story.
CDE Q4 2025: Free Cash Flow Surges to $313M as Silver Drives 42% of 2026 Outlook
CDE demonstrates strong reinvestment opportunities, recent significant growth, and improving unit economics. The business model is moderately self-reinforcing, with some signs of increasing customer value. While not fully disruptive, it is transitioning to a higher growth profile with accelerating cash flow. Revenue and EPS growth is projected in the 20-40% range, supporting a high but not perfect signal score.
NHI (NHI) Q4 2025: Shop NOI Soars 125% as Platform Expands to 12% of Portfolio
NHI is showing a clear business model transition with a long reinvestment runway, explosive Shop NOI growth, and improving unit economics. However, while the growth trajectory is strong, the business model is not fully disruptive, and some elements (e.g., cash flow acceleration, future growth guidance) are solid but not exceptional. The sector is interesting, but not at the bleeding edge of innovation.
Axsome Therapeutics (AXSM) Q4 2025: Avelity Scripts Jump 42% as Commercial Platform Scales
Axsome shows strong revenue growth, expanding commercial reach, and improving unit economics, with clear reinvestment opportunities and pipeline breadth. However, while the business is scaling and disruptive in CNS, the self-reinforcement and future growth are somewhat dependent on pipeline execution and payer dynamics, tempering the signal score.
McEwen Mining (MUX) Q4 2025: Los Azules NPV Doubles to $6.3B on Copper Price Surge
Los Azules presents a long reinvestment runway with high returns, and the copper NPV inflection is a major business evolution. Unit economics are good but not clearly improving to 'giant' status. Some self-reinforcing dynamics and customer value deepening are present but not dominant. The business model is disruptive in the copper context, and the IPO/financing could be exceptional catalysts, but execution and funding risks remain.
Vitacoco (COCO) Q1 2026: International Sales Surge 72% as Coconut Water Demand Accelerates
Vitacoco demonstrates a long reinvestment runway, accelerating category and international growth, and improving unit economics. However, while the business model is strong, it does not fully exhibit the deep self-reinforcement or disruptive qualities of a tech platform, and growth, though robust, is not at hyper-scaler levels. The business is a clear growth story but not an undiscovered or paradigm-shifting one, warranting a conservative approach to the signal score.
SentinelOne (S) Q4 2026: 65% of Enterprises Now Use 3+ Solutions as Platform Expansion Accelerates
SentinelOne demonstrates a long reinvestment runway, improving unit economics, strong platform effects, and increasing customer value. However, there is no evidence of a recent >40% growth inflection, and while the outlook is strong, it is not exceptional by the rubric's highest standard. The business is a clear growth story with disruptive elements and improving cash flow, but the growth rate is in the 20-30% range, not the highest tier.
Rapid Microbiosystems (RPID) Q4 2025: 78% Product Revenue Surge Anchors System Placement Momentum
Rapid Microbiosystems shows strong growth signals: a long reinvestment runway, disruptive business model, record placements, and a transition to recurring revenue. However, some metrics like customer value deepening and self-reinforcing advantages are emerging rather than fully proven. While the growth is robust, it is not yet at the highest acceleration tier, and margin expansion remains an execution risk.
UiPath (PATH) Q4 2026: AI Product ARR Tops $200M, Driving Platform Pull-Through
UiPath demonstrates a long reinvestment runway and clear disruptive potential with its AI and agentic automation platform. The $200M ARR milestone and high AI adoption among top customers are strong signals, as is the raised 30% margin target. However, unit economics and customer value are improving but not yet exceptional, and growth, while good, is not at the hypergrowth threshold. The business is positioned as a growth platform, but macro and execution risks temper the signal.
Vista (VIST) Q4 2025: Production Surges 59% as M&A and Cost Cuts Redefine Scale
Vista demonstrates strong growth, scale, and capital returns, with improving unit economics and a long reinvestment runway. The business model is evolving toward more export-led and capital efficient, but is not fully disruptive nor does it have the highest degree of self-reinforcement. Growth is strong but not at hyper-scale levels. Overall, signal is high for a Latin American E&P, but not at the very top end of the spectrum.
Clover Health (CLOV) Q4 2025: Membership Jumps 38% as Cohort Economics Drive First GAAP Profit Path
Clover Health demonstrates a strong reinvestment runway, significant recent growth, improving unit economics, and deepening customer value. The business is on a clear growth trajectory with accelerating profitability and revenue. However, while there are disruptive and self-reinforcing elements, the model is not fully defensible yet, and some forward-looking metrics are strong but not exceptional. Signal is high but not at the maximum as the business, while improving, is not yet a dominant, unassailable compounding machine.
Viking (VIK) Q4 2025: Advanced Bookings Jump 13%, Underscoring Demand Durability Into 2026
Viking demonstrates strong reinvestment runway, premium pricing power, and a defensible moat with direct bookings and repeat guests. However, the business is relatively mature in terms of occupancy, with future growth more reliant on pricing and capacity additions rather than explosive volume or disruptive business model shifts. Cash flow is strong but not rapidly accelerating, and while growth is robust, it is not at hyper-growth levels. The signal is high but not exceptional for a cruise operator of Viking's scale.
Rhythm Pharmaceuticals (RYTM) Q1 2026: HO Launch Drives 27% International Revenue Surge, Setting Up Global Expansion
Rhythm shows a long reinvestment runway, recent significant developments (notably the HO launch and international acceleration), and is positioned as a disruptive rare disease platform. However, while growth is strong, some metrics (unit economics, customer value, cash flow, and revenue/EPS growth) are improving but not yet exceptional or proven at scale, warranting a conservative approach to scoring.
NuScale (SMR) Q4 2025: Liquidity Surges to $1.3B as TVA Deal Advances, SMR Commercialization Momentum Builds
NuScale demonstrates a disruptive, asset-light business model with a long reinvestment runway and strong regulatory moat. However, while the company is at a commercialization inflection point, actual recurring revenue and cash flow acceleration remain to be proven, and the business is still transitioning from early-stage to growth. Unit economics and customer value are improving but not yet at full scale, and guidance is positive but not exceptional. The signal is strong but not at the highest possible level due to remaining execution and conversion risks.
MARA (MARA) Q4 2025: Starwood JV Unlocks 2.5 GW AI Compute Path, Pivoting Beyond Bitcoin Mining
MARA's pivot to AI/HPC infrastructure with a major JV and international expansion signals a long runway and disruptive potential. However, current unit economics and customer value are only modestly improving, and cash flow acceleration is not yet clear. The business is transitioning but not yet at high-growth inflection, so signal is strong but not maximal.
SPXC Q1 2026: Data Center Backlog Jumps 38%, Unlocking New Capacity Trajectory
SPXC demonstrates a strong reinvestment runway, a significant recent backlog jump (38% in data center), and clear unit economic improvement with scale. The business model shows some self-reinforcing elements (engineered-to-order/pricing power), but not network effects. Customer value is improving but not dramatically. Forward guidance is strong but not exceptional (>30%) for all segments. The business is semi-disruptive (software/engineered products), and cash flow is improving but not accelerating at a breakneck pace. Revenue/EPS growth is robust but not at a hypergrowth (>40%) level. This is a clear growth business, but the signal is not at the highest possible level due to some traditional industrial elements and lack of truly disruptive, compounding network effects.
Fathom Pharmaceuticals (PHAT) Q4 2025: Revenue Jumps 217% as GI Focus Drives Prescription Adoption
Fathom shows a strong reinvestment runway (GI focus, pipeline leverage) and a recent triple-digit revenue inflection. Unit economics are improving, but customer value and self-reinforcement are not yet compounding at the highest level. Growth is strong but not hyper-scaling, and the business is transitioning from launch to growth mode rather than being fully disruptive. Cash flow is improving, but not yet a machine. The business is a growth story but with some maturity risk as competition enters.
Archer Aviation (ACHR) Q4 2025: $2B Liquidity Fuels Certification and Commercialization Milestones
Archer has a long reinvestment runway, a disruptive business model, and a strong capital position. Recent certification and backlog growth are significant, but true scale and self-reinforcing economics are not yet proven. The business is transitioning to execution but has not yet demonstrated accelerating unit economics or cash flow; guidance and backlog suggest growth but not at extraordinary levels.
ANI Pharmaceuticals (ANIP) Q4 2025: Rare Disease Revenue to Reach 60% of $1B+ Sales in 2026
ANI Pharmaceuticals is executing a credible growth pivot into rare disease, with a long runway and high ROIC redeployment, but margin compression and royalty headwinds temper the upside. There is strong recent growth and backlog, but the business model—while evolving—is not fully disruptive or self-reinforcing yet. Revenue and EPS growth are solid but not at the highest acceleration tier, and risks around execution and margin remain.
Photronics (PLAB) Q1 2026: High-End IC Revenue Climbs 19% as Capacity Expansion Accelerates
Photronics demonstrates a long reinvestment runway with high returns, improving unit economics, self-reinforcing business model, and strong cash flow. However, while growth is robust, there is no evidence of a recent >40% inflection or guidance revision, and customer value deepening is only modest. The business is semi-disruptive but not a clear outsized growth outlier. Revenue/EPS growth is strong but not at hypergrowth levels.
Moody’s (MCO) Q4 2025: Private Credit Revenue Jumps 60% as AI-Driven Workflow Adoption Accelerates
Moody's demonstrates strong recurring revenue, margin expansion, and deepening customer value, with clear evidence of compounding advantages and cash flow growth. However, as a large, established player, its reinvestment runway is not exceptionally long, and while growth is robust, it is not at the hypergrowth threshold. The business model is defensible but not truly disruptive, and recent developments, though strong, do not signal a transformative inflection.
Harmonic (HLIT) Q4 2025: Backlog Soars 73%, Rest-of-World Diversification Drives Broadband Visibility
Harmonic demonstrates a significant business evolution with a 73% increase in backlog, strong global diversification, and a clear pivot to recurring software revenue. The reinvestment runway is long, and the business is transitioning into a growth phase with improving unit economics and customer value. However, while the model is semi-disruptive and recurring revenues are rising, the self-reinforcing nature and exceptional future growth are present but not at the highest level. The business is not yet on track to be a giant and guidance, while strong, is not at the highest acceleration tier.
Core Scientific (CORZ) Q4 2025: 350 Megawatts Energized, Co-Location Pivot Accelerates Data Center Scale
The business shows a substantial reinvestment runway and disruptive model shift, with a large pipeline and operational leadership. However, some signal elements are not fully at the highest level: unit economics and customer value are improving but not yet proven at scale; revenue and EPS growth are not yet above 40% and future growth, while promising, is not yet exceptional. The business is clearly in growth mode but with some execution risk.
EYPT Q4 2025: R&D Spend Climbs 45% as DuraView Nears Phase III Data Inflection
EYPT is at a pivotal late-stage inflection with a potentially disruptive sustained-release therapy in large addressable markets. The business model is not yet self-reinforcing, and customer value deepening is prospective, not proven. Growth potential is high but binary, and while the article demonstrates optionality and a clear path to value creation, the signal is capped by the all-or-nothing risk profile typical of late-stage biotech.
Randpac (PACK) Q4 2025: Automation Revenue Jumps 40% as Enterprise E-Commerce Drives Order Book Strength
Randpac shows strong automation growth and a large reinvestment runway, with clear inflection in automation profitability and a record backlog. However, while the growth is significant, the business is not fundamentally disruptive and faces macro/geographic risks. Some metrics (customer value, future guidance) are good but not exceptional, and network effects are emerging but not deeply entrenched.
Summit Therapeutics (SMMT) Q4 2025: Harmony 3 Interim PFS Analysis Accelerates Regulatory Path
Summit Therapeutics demonstrates a long reinvestment runway and disruptive platform potential, with regulatory acceleration and a broad pipeline. However, while the clinical and commercial opportunity is significant, there is not yet evidence of rapidly improving unit economics, consistently deepening customer value, or accelerating cash flow. The business is transitioning toward growth, but execution and regulatory risk remain, and the ultimate upside depends on successful data readouts and regulatory approvals.
Milestone Pharmaceuticals (MIST) Q4 2025: Cardamist Launch Drives $200M Cash Position, Sets Up Commercial Ramp
Milestone is moving from clinical to commercial stage with a first-in-class launch and a large addressable market. However, payer bottlenecks and early-stage commercialization limit immediate signal. There is runway and potential, but the business model's self-reinforcement, customer value, and cash flow are not yet proven at scale.
Regenxbio (RGNX) Q4 2025: $100M Milestone Unlock Signals Commercial Readiness Amid Pipeline Catalysts
Regenxbio is at a key transition with a late-stage pipeline and major commercial catalysts, and the milestone/royalty structure adds funding durability. The business model has disruptive elements (gene therapy, one-time treatments), but not all unit economics and network effects are proven at scale. Growth is strong but not yet at the highest tier, and while the outlook is positive, some risks (FDA, competition) temper the upside. The company is interesting, but not an under-the-radar compounder with clear 40%+ growth, so signal is solid but not maximal.
Savers Value Village (SVV) Q4 2025: U.S. Store Count Rises by 26 as Thrift Adoption Accelerates
SVV demonstrates a solid reinvestment runway, clear recent inflection in growth, and demographic tailwinds. However, while unit economics and business model advantages are present, they are not as deeply compounding or disruptive as the highest-signal businesses. The growth is strong but not explosive, and some elements (innovation, margin expansion) are incremental rather than transformative.
Fluent (FLNT) Q4 2025: Commerce Media Surges to 56% of Revenue, Marking Strategic Inflection
Fluent’s pivot to commerce media with rapid segment growth and clear reinvestment runway is well-supported by financials and management commentary. However, the business model’s self-reinforcing nature and customer value deepening, while present, are not yet at the highest level of compounding or stickiness. Adjacency growth is still emerging, and margin/cash flow acceleration is moderate, not exceptional. The business is now a clear growth story but not yet a category-defining compounder.
UEC (UEC) Q2 2026: Unhedged Sales Realize 25% Premium, Fueling $818M Liquidity for Expansion
UEC demonstrates a long reinvestment runway, disruptive vertical integration, and policy-driven demand optionality. However, unit economics, customer value, and cash flow are not yet accelerating at the highest levels; growth is contingent on regulatory approvals and conversion project execution. The business is transitioning to growth, but not yet showing the explosive metrics required for a top-tier signal score.
Sonita Senior Living (SNDA) Q4 2025: $1.8B CHP Merger Adds 93 Communities, Accelerates NOI Margin Expansion
Sonita demonstrates a long reinvestment runway, recent significant growth (NOI and EBITDA), and improving unit economics. The business model is becoming more self-reinforcing but is not yet a dominant platform. Customer value is improving modestly, and the future outlook is positive though not exceptional. The company is semi-disruptive within its sector, with cash flow and growth accelerating but not at the highest levels. It is a growth business but not one with outsized or unique upside relative to the broader REIT universe.
Ollie’s (OLLI) Q4 2025: 86 New Stores Drive 17% Sales Growth, Inflection Point in Scale and Productivity
Ollie's demonstrates strong growth, clear compounding customer value, and a solid capital return strategy. However, the reinvestment runway is not exceptionally long, and while the business is showing strong growth, it is not a hypergrowth or highly disruptive business. The business model has some self-reinforcing elements, but not to the extent of a true network effect. Signal is strong but not at the highest level due to the maturity and known nature of the off-price retail model.
Allogene (ALLO) Q4 2025: Cash Runway Extended Into 2028 as Alpha-3 and Allo329 Enter Proof Phase
Allogene has a long reinvestment runway and is targeting disruptive growth in both oncology and autoimmune disease. While clinical and commercial inflections are imminent, the business remains dependent on binary outcomes and does not yet show accelerating unit economics or cash flow. The signal is strong due to platform and market potential, but some elements (unit economics, cash generation, customer value) are not yet proven.
LIDR Q4 2025: Customer Base Jumps 33% as Pipeline Diversifies Beyond Automotive
LIDR demonstrates a long reinvestment runway, recent pipeline acceleration, and a disruptive, capital-light model. However, while customer and quoting growth is strong, unit economics, customer value, and cash flow are not yet exceptional or accelerating at the highest level. The business is transitioning to growth but hasn't fully proven out recurring scale, keeping some scores conservative.
EVEX Q4 2025: $13.5B Backlog Anchors 300-Flight Test Ramp as Certification Drives Spend
Eve has a long reinvestment runway, a disruptive business model, and a massive backlog, but much of it is non-binding and there is no current revenue. The business is pre-commercial, so unit economics and cash flow are not yet proven, though the trajectory is promising. Growth potential is high, but realization is gated by certification and execution risk, tempering the signal score.
CBUS Q4 2025: $10M Cost Cuts Extend Runway as Regulatory Tailwinds Unlock $200M Rice Royalties
CBUS has a long reinvestment runway and disruptive potential, with clear regulatory and commercial inflections. However, some elements (unit economics, customer value, cash flow, and growth rates) are promising but not yet fully proven or accelerating at the highest levels, warranting a conservative approach on those axes.
Coda Octopus (CODA) Q1 2026: Marine Tech Revenue Jumps 47%, Defense Adoption in Focus
The company shows strong growth in its core marine tech business (47% YoY), a long runway with AI-enabled products, and recurring rental revenue inflection, but defense contract timing and customer value deepening are still emerging. The business is not yet at giant scale, and while disruptive elements are present, the transition to program-based, high-margin recurring revenue is still in progress. Some optionality and growth are evident, but there are gating factors around defense adoption and contract cycles that limit the overall signal score.
Fold Holdings (FLD) Q4 2025: Credit Card Waitlist Tops 80,000, Unleashing Platform Scale
Fold shows a disruptive, high-growth trajectory with a long runway and clear new revenue engines. However, some areas like unit economics, customer value deepening, and cash flow acceleration are promising but not yet proven at scale. The business is transitioning to growth but still faces execution and market risks typical of early-stage fintechs.
Trevi Therapeutics (TRVI) Q4 2025: $188M Cash Runway Extends to 2028, Phase 3 Trials Set for Launch
Trevi Therapeutics demonstrates a strong reinvestment runway, recent inflection with pivotal trial launches, and clear growth potential. However, while the business is positioned for expansion and has operational leverage, elements such as network effects and customer value deepening are less evident at this stage. The business model is semi-disruptive within specialty pharma, and while cash flow and growth are improving, they are not yet exceptional or accelerating at the highest rates. The company is a growth business, but not at the level of a truly disruptive or hyper-scaling enterprise.
Ocean Power Technologies (OPTT) Q3 2026: Backlog Surges 165% as Defense Pipeline Hits $164M
OPT is transitioning to a platform model with a long reinvestment runway and disruptive potential, supported by a surging pipeline and defense contracts. However, margin and unit economics are still recovering and customer value expansion, while improving, is not yet proven at scale. The business is not yet a cash flow machine, and growth—while strong—is not at the highest tier. The signal is strong, but not exceptional given execution risks and the early stage of recurring revenue ramp.
Jabil (JBL) Q2 2026: AI Revenue Raised $1B as Intelligent Infrastructure Surges 46%
Jabil's AI and data center segment shows a long reinvestment runway and high growth, with a significant revenue guidance raise and improving unit economics. However, while the business is benefiting from secular AI trends and is a growth business, some elements (such as self-reinforcing model, customer value deepening, and disruptive model) are present but not at the highest possible level. The business is not a true disruptor and some growth is moderate, not exceptional, which tempers the overall signal score.
High Tide (HITI) Q1 2026: International Revenue Jumps 60% as German Expansion Accelerates
The business shows strong growth in international and core segments, with improving unit economics, cash flow, and market share. However, network effects and customer value deepening are present but not yet at the highest level. The growth is solid but not hyper-scaling, and some optionality remains unproven.
Expand Energy (EXE) Q4 2025: Hainesville Break-Even Drops 15% as Marketing Ambition Targets $0.20 Margin Uplift
Expand Energy demonstrates a strong operational foundation and a meaningful commercial pivot, with evidence of cost leadership and a potentially long reinvestment runway. However, some aspects of self-reinforcement, customer value deepening, and disruptive model are emerging rather than fully proven. The growth profile and margin expansion targets are ambitious but not yet exceptional or fully de-risked. Signal is solid but not at the highest level due to execution risks and the need for further proof of commercial transformation.
Alarm.com (ALRM) Q4 2025: Commercial & Energy Segments Grow 25%, Shifting SaaS Mix
Alarm.com demonstrates a strong reinvestment runway with device-driven SaaS, and recent segment growth is robust (25%+). The business model is self-reinforcing, and commercial/energy segments are growing faster than legacy. However, unit economics and customer value are improving but not yet exceptional, and growth rates, while strong, are not at the highest threshold. The business is transitioning to growth, but not yet at the disruptive or hypergrowth level.
Westwater Resources (WWR) Q4 2025: Kellyton CapEx Cut by $25M, Accelerating U.S. Graphite Supply Chain Buildout
The business has a long reinvestment runway, disruptive model, and strong policy/regulatory tailwinds. However, while growth potential is high, actual financial metrics (unit economics, revenue/eps growth) are not yet proven at scale, and there is still significant execution risk. Signal is strong but not at the level of an already scaling, high-growth business.
FENIC Pharmaceuticals (FENC) Q4 2025: PEDMARK Conversion Rate Jumps to 70% as AYA Expansion Accelerates
FENIC is at an inflection point with a long runway, strong recent growth, and operational leverage. However, while the AYA expansion is significant, the business is not yet a category-defining disruptor and faces execution and payer risks. Revenue and cash flow acceleration are likely, but the signal is not at the highest level due to the company's niche and the need for further proof of outsized growth.
Synopsys (SNPS) Q1 2026: ANSYS Lifts Backlog to $11.3B, Unlocking Silicon-to-System Expansion
The article demonstrates Synopsys is a growth business with a long reinvestment runway, significant backlog expansion, and disruptive elements (AI/ANSYS). However, IP economics and customer value expansion are still transitional, and growth is not yet exceptional (>30%). Cash flow is strong but not rapidly accelerating. The signal is solid, but not at the very highest level due to transitional headwinds and moderate growth rates.
Absci (ABSI) Q4 2025: ABS-201 Addresses $25B AGA Market as Phase 1-2A Safety Holds
Absci demonstrates a long runway with a disruptive AI-enabled drug discovery model and a large addressable market. There is a significant clinical inflection upcoming, but unit economics and customer value deepening are still emerging, not yet proven at scale. The business is transitioning from platform to asset-driven, with high growth potential but not yet at the acceleration or compounding stage. The signal is strong for a small/mid-cap biotech, but not at the highest level due to early-stage risk and pending proof-of-concept data.
Comstock (LODE) Q4 2025: $57.5M Equity Infusion Unlocks Metals Recycling Scale-Up
Comstock has a long reinvestment runway post-capital raise and is transitioning to a growth business with a disruptive recycling model. There is a major recent development (facility launch, equity raise) and potential for rapid growth, but the business is still pre-scale with revenue and customer ramp not yet proven, so some signals (unit economics, customer value, cash flow) are only moderately positive. The business is not yet a giant, and while the model is potentially self-reinforcing, this is not yet proven at scale. Revenue growth potential is high but not yet demonstrated, so scores are conservative.
Zhihu (ZH) Q4 2025: Marketing Services Jump 24% Sequentially as AI Monetization Accelerates
Zhihu is at a business model inflection with clear AI monetization optionality and a long runway, but many metrics (unit economics, cash flow, customer value) are improving only modestly or are at early stages. The business is transitioning to growth, but not yet at a breakout phase. The signal is strong but not exceptional.
MPTI Q4 2025: Backlog Surges 62% as Defense and Avionics Demand Redefine Growth Runway
MPTI demonstrates clear growth signals: a 62% backlog surge, defense sector tailwinds, and capital for expansion. However, while the growth runway is strong, some elements (unit economics, self-reinforcement, customer value deepening) are present but not yet at the highest tier. The business is transitioning toward a growth profile, but some legacy and integration risks temper the score.
WRAP (WRAP) Q4 2025: Subscription Revenue Jumps 85% as Platform Shift Drives Pipeline Surge
WRAP shows strong signals of a business model inflection with high revenue growth guidance, recurring revenue expansion, and a robust pipeline. However, the business is still transitioning, with some uncertainty around operational leverage, customer value deepening, and the durability of new initiatives. The company is not yet a proven compounding platform, but the signal is well above average for a small-cap transition story.
Capsovision (CV) Q4 2025: Hospital System Customers Surge 87% as AI Pipeline Accelerates
Capsovision demonstrates a disruptive, high-optional business model with clear growth signals (hospital channel inflection, pipeline progress, capital raise). However, while the runway and platform potential are strong, some areas (unit economics, customer value deepening, near-term cash flow) are not yet exceptional or fully proven, warranting a conservative signal score.
Huize (HUIZ) FY25: AI-Driven Self-Service Up 50%, Offsetting Margin Drag from International Mix
Huize shows strong growth signals—AI-driven efficiency, double-digit revenue growth, expanding customer base, and high retention. However, margin compression from international mix and regulatory headwinds temper the overall upside. The business model is semi-disruptive (AI and digital distribution), but international expansion introduces lower-margin revenue, limiting exceptional signal. While the company is transitioning to a higher-growth, tech-driven model, the risk/reward is more balanced than explosive.
Hyliion (HYLN) Q4 2025: Modular Platform Drives $40–50M Military Pipeline and Data Center Entry
Hyliion demonstrates a long reinvestment runway and disruptive potential via its modular Carno platform and entry into high-growth sectors (defense, data centers). Recent pipeline growth and defense contracts signal business evolution, but unit economics and business model self-reinforcement are still emerging, not yet fully proven. Customer value is improving but not consistently deepening. Future growth is promising but not yet exceptional or accelerating at the 30%+ level. The business model is disruptive with lateral opportunities. Cash flow is not yet accelerating, and revenue growth is forecast in the 20% range, not >40%. Hyliion is transitioning from R&D to growth, but execution and commercialization risks remain.
Joby Aviation (JOBY) Q4 2025: $1.8B Capital Infusion Fuels Production Ramp and Dubai Launch
Joby has a long runway and disruptive model, with clear capital and regulatory catalysts. However, the business is not yet demonstrating rapidly improving unit economics or customer value, and revenue/earnings growth is not yet at hypergrowth levels. Execution risk tempers the signal despite strong strategic positioning.
CBAT Q4 2025: Battery Revenue Jumps 36% as Next-Gen Ramp Drives Margin Reset
CBAT demonstrates a long reinvestment runway, recent explosive growth, and improving unit economics as scale increases. However, while there are signs of a self-reinforcing model and improving customer value, these are not yet fully proven or at the level of compounding giants. The business is transitioning with strong growth, but margin compression and dependency on commodity cycles temper the exceptionalism. Revenue and EPS growth are strong but not at the highest tier, and some risks remain around execution and customer concentration.
AIRO (AIRO) Q4 2025: $150M Drone Backlog Anchors 2026 Defense Growth Ambitions
AIRO demonstrates a long reinvestment runway with a large backlog and a disruptive business model pivoting to defense drones. There is a significant recent development (backlog and strategic realignment), but while the growth is solid (15%-25% guided), it is not exceptional or accelerating above 30%. Unit economics and customer value are improving but not yet at a giant scale. The business is transitioning to growth, but not all compounding advantages are fully evident yet.
Diomedica (DMAC) Q4 2025: R&D Spend Climbs 29% as Preeclampsia and Stroke Pipelines Advance
DMAC is a clinical-stage biotech with two late-stage, high-potential assets and a strong cash position. There is a long reinvestment runway and disruptive potential in preeclampsia, but the business is not yet showing compounding unit economics or accelerating cash flow. Backlog and guidance are promising but not exceptional, and growth is not yet at breakout levels. The business is positioned for growth, but much depends on execution and regulatory outcomes.
HCI (HCI) Q4 2025: Book Value Surges 3X in Two Years, Unlocking Buyback and M&A Firepower
HCI shows strong capital returns, a robust balance sheet, and high ROE, with clear growth levers via buybacks, M&A, and technology. However, while the business is well-positioned, the insurance sector's inherent cyclicality, competitive intensity, and weather risks temper the signal. Exio and tech optionality are promising but not yet proven to be compounding at platform scale. Growth rates, while strong, are not at hypergrowth levels.
AuthID (AUID) Q4 2025: Pipeline Surges to $30M as Enterprise Identity Demand Intensifies
AuthID demonstrates a long reinvestment runway and disruptive model, with a strong pipeline and enterprise traction. However, near-term financials and conversion rates remain muted, and unit economics are not yet clearly compounding. The business is transitioning, not yet a cash flow machine, and while the outlook is strong, it does not yet warrant the highest possible signal score.
nCino (NCNO) Q4 2026: AI Intelligence Units Adoption Drives 17% ACV Growth and Platform Stickiness
While nCino is showing strong growth, ACV retention, and AI-driven product momentum, it is not yet a clear outlier with a massive, uncapped reinvestment runway or 40%+ growth. The business is transitioning to AI-powered SaaS and platform pricing, which is disruptive, but the future trajectory is still subject to some adoption and execution risks. There are positive signals (international expansion, AI monetization, margin improvement), but the upside is not as extreme as true generational compounders.
VolitionRx (VNRX) Q4 2025: 133% Q4 Revenue Surge Signals Commercialization Pivot
VolitionRx is at a strategic inflection, with a validated platform and a licensing-driven model offering a long reinvestment runway if execution delivers. The 133% Q4 revenue surge and pipeline of licensing deals are material, but the recurring revenue base is not yet established. Unit economics are improving, but not yet at scale; business model has disruptive potential, but self-reinforcing dynamics are still emerging. Customer value is improving, but not yet consistently deepening. Backlog and guidance point to acceleration, but not yet exceptional. Cash flow is improving but not yet a 'machine.' Growth is strong but not at hypergrowth levels. The business is transitioning to growth, but execution risks remain.
SIFY Q4 2025: Data Center Backlog Jumps 81MW, CapEx Set to Rise Sharply
Strong signal from the 81MW backlog and capacity doubling plans, with clear growth runway and policy tailwinds. However, digital services underperformance, some uncertainty in margin improvement, and execution risks temper the overall signal. The business model is not fully self-reinforcing yet, and customer value deepening is only moderate.
TRX Gold (TRX) Q2 2026: EBITDA Annualized at $80M as Buckreef Expansion Targets 5,500 tpd Capacity
TRX Gold demonstrates a strong growth trajectory, with a clear reinvestment runway, major expansion plans, and improving unit economics. While margins and cash flow are robust, and the business is transitioning to a growth phase, some aspects (like network effects and customer value deepening) are less pronounced due to the nature of mining. Revenue and EPS growth are solid but not at the highest tier, and the business model, while self-funding and efficient, is not highly disruptive.
Interactive Brokers (IBKR) Q1 2026: Futures Volumes Up 20%, AI and Crypto Expansion Fuel Platform Leverage
IBKR demonstrates a long reinvestment runway, improving unit economics, and a self-reinforcing business model with growing customer value. However, there are no truly exceptional recent developments or 40%+ growth inflections, and the business is not disruptive in the strictest sense. Growth is strong but not explosive, and while the business is high-quality, it is already well-followed and mature, limiting signal for outsized valuation upside.
Salesforce (CRM) Q4 2026: AgentForce ARR Surges 169%, Redefining Enterprise AI Adoption
Salesforce is a well-known, mature business, so the reinvestment runway and disruptive optionality are somewhat capped relative to earlier-stage companies. However, AgentForce and Data360’s rapid growth, premium SKU uptake, and hybrid monetization model are significant business evolutions. Unit economics and customer value are improving, but the legacy drag and competitive threats temper the upside. The business is transitioning but not at the level of a hypergrowth disruptor.
Firmus Financial (FRST) Q1 2026: Core Revenue Jumps 34% as Operating Leverage Widens
Firmus Financial is showing strong operating leverage, accelerating core revenue, and a meaningful digital and AI-driven transformation. There is clear evidence of a reinvestment runway and improving unit economics. However, the business model—while evolving—is not truly disruptive or network-driven, and customer value metrics, while improving, are not yet exceptional. Growth is solid but not at hypergrowth levels, and while the outlook is positive, it is not extraordinary enough to warrant top marks for signal.
First Watch (FWRG) Q4 2025: 19% Margin Anchors Record 64 Openings, Digital and Menu Levers Drive 2026 Playbook
First Watch shows strong growth, margin resilience, and disciplined execution, with a long runway for expansion and improving unit economics. However, the business model is not highly disruptive, customer value deepening is present but not exceptional, and growth, while robust, is not at the highest acceleration tier. The signal is solid but not extraordinary.
WiseKey (WKEY) Q4 2025: Cash Surges 370% as Quantum Pipeline Tops $200M
WiseKey shows high potential with a long reinvestment runway, disruptive business model, and regulatory tailwinds, but some areas (unit economics, customer value, cash flow) remain in transition with risks around execution and commercialization. Growth is strong but not yet at hypergrowth levels, and some compounding advantages are still emerging rather than fully proven.
Welltower (WELL) Q1 2026: Senior Housing NOI Surges 22% as Portfolio Mix Shift Accelerates
Welltower demonstrates strong recent growth, margin expansion, and a clear pivot to higher-return assets, but as a large, well-followed REIT, its reinvestment runway and disruptive potential are somewhat capped. There are clear improvements in unit economics and cash flow, but the business, while transitioning and growing, is not highly disruptive or likely to deliver outsized upside relative to smaller, less-followed companies.
Fabrinet (FN) Q3 2026: Data Center Interconnect Revenue Jumps 90%, Fueling Multi-Vector Growth
Fabrinet shows strong growth vectors, capacity expansion, and customer diversification, with clear signals of long-term reinvestment opportunity and a disruptive business model. However, unit economics improvements and customer value deepening are present but not exceptional, and near-term risks (supply chain, margin) moderate the overall signal. Growth is strong but not at the highest tier, and the business, while transitioning to multi-vector growth, is not yet at the level of a runaway compounding platform.
Light & Wonder (LNW) Q4 2025: EBITDA Margin Jumps 500bps as Recurring Revenue Engine Accelerates
LNW is showing strong recurring revenue growth, margin expansion, and digital transformation, but is not an undiscovered or highly disruptive business with a massive reinvestment runway. Growth is solid and the business is transitioning toward digital/recurring models, but not at the scale or velocity to warrant top signal marks. The article highlights important recent developments (margin jump, digital scaling, strong FCF), but the company is still exposed to regulatory/tax headwinds and execution risks. There is clear value for investors, but the upside is more about steady quality improvement than explosive growth.
Indivior (INDV) Q1 2026: Sublocade Revenue Jumps 32% as EBITDA Margin Hits 51%
Sublocade's growth is impressive and the business is transitioning into a growth phase with strong unit economics and customer value improvement. However, the reinvestment runway, business model defensibility, and future exceptional growth are somewhat limited by dependence on one product and competitive risks. The company is not a classic high-ROIC compounder with a disruptive model, but it's executing well within its category.
PayPal (PYPL) Q1 2026: Fastlane Drives 80% Guest Checkout Conversion, Reinventing Merchant Holiday Strategies
Fastlane is a significant product innovation with clear evidence of improved conversion and early traction, but PayPal is a well-known, mature business and the article does not indicate a dramatic acceleration in overall company growth or profitability. The signal is strong for a major product lever, but not for a company-wide inflection or disruptive business model, warranting a conservative score.
Chimera Therapeutics (KYMR) Q1 2026: Gilead Triggers $45M Milestone as KT200 Advances, Extending Cash Runway to 2029
Chimera demonstrates a long reinvestment runway, major partnership milestones, and a disruptive platform, but unit economics, customer value, and cash flow acceleration are not yet fully proven given its pre-commercial stage. The business is a growth story but not yet showing exceptional acceleration in all metrics.
SHLS Q1 2026: Backlog Climbs 18% as Data Center and Solar Orders Fuel Visibility
Shoals demonstrates a strong reinvestment runway, record backlog growth, improving unit economics, and a growth business profile. However, while the business is expanding into new verticals, not all aspects are clearly disruptive or self-reinforcing at scale yet. Customer value is improving but not consistently deepening, and while guidance is raised, the future is good but not exceptional. Revenue growth is strong but not hypergrowth, and cash flow acceleration is moderate.
Wesco (WCC) Q1 2026: Data Center Sales Jump 70%, Backlog Surges 22% as Secular Tailwinds Accelerate
Wesco is showing strong secular tailwinds and multi-year visibility with data center sales and backlog growth, supporting a growth narrative. However, while the business is pivoting to secular growth, some elements (like self-reinforcing model and customer value deepening) are present but not yet dominant or proven at the highest level. Revenue and EPS growth are solid but not hyper-growth, and some risks around project timing and digital execution remain.
Crystal Biotech (KRYS) Q4 2025: Ex-US Launches Drive 18% Revenue Growth as Global Expansion Accelerates
Crystal Biotech demonstrates a strong reinvestment runway and recent significant growth driven by ex-US launches. There is evidence of a disruptive model and growth business status, but some aspects such as unit economics, customer value deepening, and cash flow acceleration are only moderately improving or have uncertainties due to international expansion and pricing. The signal is solid but not exceptional given the operational complexity and risk.
NeoVolta (NEOV) Q2 2026: Revenue Surges 334% as Georgia JV Targets 2 GWh Ramp
NeoVolta is at a pivotal inflection, showing a long reinvestment runway and disruptive business model with a major manufacturing ramp. Revenue is growing rapidly, but margin and unit economics are challenged, with only moderate improvement signaled. The business is transitioning toward growth, but execution risk remains high and cash flow is not yet accelerating. The signal is strong for a small-cap player, but not at the level of a proven, high-compounding business.
NeoGenomics (NEO) Q4 2025: NGS Revenue Jumps 23% as High-Value Test Shift Reshapes Growth Trajectory
NeoGenomics is showing strong growth in high-value segments and margin expansion, with a strategic pivot that suggests improving economics. However, the business is not exceptionally disruptive and faces execution and reimbursement risks, with some areas (like pharma segment and customer value deepening) less clearly compounding. The signal is strong but not at the highest level for exceptional business model or explosive near-term growth.
ITRON (ITRI) Q4 2025: ARR Jumps 20% as Grid Edge Backlog Tops $1B, Resiliency Segment Debuts
Itron demonstrates a clear shift to a recurring revenue model with strong ARR and backlog growth, and expanding TAM via acquisitions. However, unit economics improvement is limited by legacy drag, and customer value deepening is not yet consistent across the portfolio. Growth is solid but not hyper-scaling, and the business model is semi-disruptive rather than fully disruptive. The business is transitioning to growth, but not yet at the level of a high-multiple compounding platform.
First Solar (FSLR) Q4 2025: Gross Margin Climbs to 50% as Section 45X Credits Reshape Profitability
First Solar demonstrates a strong strategic position with a long reinvestment runway, significant recent developments (Section 45X credits), and a disruptive U.S.-centric model. However, some metrics such as unit economics, customer value, and future growth are solid but not exceptional, with ongoing margin and utilization headwinds. The business is growth-oriented but not compounding at the highest possible rates, and its upside is closely tied to policy support.
Cerebell (CBLL) Q4 2025: TAM Expands 75% as Platform Diversifies Into Delirium and Neonate Markets
Cerebell shows strong signal: a long reinvestment runway, disruptive platform expansion, and a multi-year growth thesis. However, while growth is robust, it is not yet at a hypergrowth (40%+) pace, and some improvements in unit economics and customer value are still emerging rather than fully proven. The business is transitioning towards a platform model with significant optionality, but commercial impact from new launches is back-end loaded, tempering near-term signal.
China Yuchai (CYD) 2H 2025: Heavy-Duty Engine Sales Surge 80%, Powering Margin Expansion
CYD is demonstrating strong growth in high-value segments and mix-driven margin expansion, with clear signals of a business model shift and innovation. However, export and recurring revenue streams are still emerging, and while the growth is robust, it is not yet at the most exceptional level across all dimensions.
AbCellera (ABCL) Q4 2025: Pipeline Expands to 4 Clinical Programs, $700M Liquidity Extends Runway
AbCellera has a long reinvestment runway and is pivoting to a proprietary pipeline with several clinical programs, indicating high potential. There is a binary, potentially high-impact clinical catalyst ahead. However, while the business model is becoming more self-reinforcing and disruptive, unit economics and customer value are not yet proven at scale. The company is transitioning from a legacy platform to a growth biotech, but execution risk and binary outcomes temper the signal.
CEROS (CERS) Q1 2026: IFC Revenue Surges 90% as Platelet Penetration Expands
CERS shows strong growth, a long runway, and some disruptive elements, but margin pressure, moderate customer value expansion, and only partial evidence of compounding self-reinforcement limit the signal. The business is transitioning toward greater scale with good but not exceptional near-term acceleration.
ChipMOS (IMOS) Q4 2025: Memory Revenue Surges 55%, Driving Margin Expansion and Strategic CapEx Shift
ChipMOS demonstrates a strong reinvestment runway, significant recent growth in memory, and improving margins. However, some business model elements (network effects, customer value deepening) are present but not dominant, and growth—while robust—is not yet at an exceptional, transformative level. The business is solidly in growth mode but not a category-defining disruptor.
BioCryst (BCRX) Q4 2025: Orladeyo Revenue Jumps 43% as HAE Franchise Deepens Portfolio
BioCryst demonstrates a strong reinvestment runway, recent significant growth, and improving unit economics. The business model has some self-reinforcing elements but is not fully compounding yet. Customer value is improving but not consistently deepening, and future guidance is good but not exceptional. The business is semi-disruptive, cash flow is moderately accelerating, and growth rates are solid but not explosive. The company is transitioning toward a growth business but is not yet a clear outlier.
Wave Life Sciences (WVE) Q4 2025: R&D Spend Rises 15% as Obesity and RNA Editing Pipeline Accelerates
Wave shows strong optionality, disruptive modality, and a long runway, with significant recent pipeline acceleration and capital to support growth. However, while growth potential is high, some metrics (unit economics, customer value, cash flow) are not yet proven at scale, and guidance is promising but not yet exceptional. The company is a growth story but still faces major clinical and regulatory risks.
Chimera Therapeutics (KYMR) Q4 2025: $1.6B Cash Extends Runway, KT621 Drives Paradigm Shift in Type 2 Disease
The company has a long reinvestment runway, significant market expansion potential, and disruptive pipeline assets. However, most growth is still prospective, with limited evidence of accelerating unit economics or cash flow at this stage. The business is high-potential but not yet proven as a compounding growth engine.
Crinetics (CRNX) Q4 2025: $1.4B Cash Position Extends Runway for Pipeline and Pelsonify Launch
Crinetics has a long reinvestment runway, recent commercial launch, and pipeline scale-up, but not all metrics are exceptional. There is strong growth potential and optionality (disruptive model, late-stage pipeline, cash runway), but unit economics, customer value, and cash flow are still in early phases. The business is a growth story, but not yet at the scale or acceleration of a top-decile biotech breakout.
SKYX Q4 2025: Plug-and-Play Smart Home Revenue Set to Surpass 10% Amid Builder and Retail Expansion
SKYX demonstrates a credible pivot to a higher-margin, recurring revenue model with early evidence of a long reinvestment runway and disruptive potential. However, the business is still in transition, with most revenue from legacy products and some uncertainty around the pace of smart product adoption and regulatory wins. Signal is strong but not yet exceptional due to execution and adoption risks.
Kopin (KOPN) Q4 2025: $37M Backlog Sets Stage for Defense-Driven Recovery
Kopin demonstrates a strong backlog, new partnerships, and a pivot to higher growth defense and automation markets, supporting a growth thesis. However, the business is not yet highly disruptive or showing 40%+ growth, and while optionality is present, compounding effects are still emerging. Unit economics, customer value, and model self-reinforcement are improving but not yet exceptional. Signal is solid but not extraordinary given the company's scale and market profile.
Huize (HUIZ) FY25: International Revenue Surges 84%, Margin Mix Shifts as AI Drives Platform Scale
Huize demonstrates strong topline and customer metrics, international expansion, and AI-driven efficiency, but margin dilution and the lower-margin nature of new business temper the signal. Growth is robust but not at the highest tier, and while the business is evolving, it's not yet a clear outsized winner or disruptor. The runway is good but not exceptional given margin and regulatory headwinds.
LNTH Q4 2025: NeuroSeq Triples Growth as Lantheus Refocuses on Diagnostics
Lantheus is transitioning to a focused, high-growth radiodiagnostics business with a long reinvestment runway, triple-digit growth in NeuroSeq, and a clear pivot from legacy assets. However, near-term growth is limited by transition and launch timing, and while the business model is improving, it is not yet highly self-reinforcing or disruptive at scale. Multiple avenues for future growth exist, but the next year is more setup than inflection.
IMDX Q4 2025: 28 Centers Join Registry as FDA Submission Drives Commercial Ramp
IMDX is at a major inflection with a long runway (registry pipeline, new indications), but some elements are not yet proven: unit economics are poised to improve but not yet demonstrated at scale, and self-reinforcing dynamics are emerging but not entrenched. The business is transitioning to growth, with commercial ramp and reimbursement visibility, but is not yet showing exceptional acceleration or disruptive dominance. Execution risk and cash burn remain, and the business is not yet a cash flow machine.
Endeavour Silver (EXK) Q4 2025: Silver Equivalent Output Jumps 146% on Terranera and Colpa Integration
Endeavour Silver is in a high-growth phase with major new assets and a multi-year runway (Terranera, Colpa, Pitarilla). There is substantial recent growth and optionality, but some elements (unit economics, self-reinforcement, customer value, cash flow) are still in transition or not fully proven at scale. The model is not highly disruptive, but growth is strong and the business is positioned for further upside if execution is strong.
Alpha Cognition (ACOG) Q4 2025: Zunvel Prescriber Base Expands 50% as Repeat Orders Anchor Growth Trajectory
Alpha Cognition is showing strong early signals: accelerating adoption, high repeat rates, and significant prescriber expansion. However, payer access is still a gating factor and the business, while on a growth trajectory, is not yet demonstrating the exceptional, compounding characteristics or disruptive business model that would merit a higher signal score. There is clear growth, but not at a scale or with a moat that would make it a top-tier signal case.
DARE (DARE) Q4 2025: $13.9M Grant Offset Powers Pipeline, Commercial Launches Set for 2026
DARE demonstrates a long reinvestment runway with high ROIC potential, significant grant-backed developments, and an emerging commercial profile. However, the business model's self-reinforcing elements and customer value deepening are present but not yet proven at scale. Growth is likely but not explosive, and while the outlook is strong, the company is still in transition rather than established high-growth mode.
Lucid Diagnostics (LUCD) Q4 2025: Test Volume Jumps 29% as VA and Medicare Access Catalysts Approach
The business is on the cusp of a major inflection, with strong evidence of growth potential and leverage to key policy catalysts (Medicare, VA). However, some elements (unit economics, self-reinforcing model, customer value, cash flow, growth rate) are not yet proven at scale and remain contingent on reimbursement milestones. Signal is solid but not at the highest level until inflection is realized.
Acumen (ABOS) Q4 2025: EBD Platform Spurs $36M Raise as Brain Penetration Hits 40X in Preclinical
Acumen is at a binary inflection with a potentially disruptive EBD platform and pivotal trial, but is still preclinical on key assets and remains a cash-burning clinical-stage biotech. The raise and preclinical data are notable, but the business is not yet demonstrating accelerating cash flow, proven improving unit economics, or exceptional near-term growth. The signal is solid for a high-risk pipeline biotech with optionality, but not at the highest tier for revenue/EPS growth or compounding economics.
Ormat Technologies (ORA) Q4 2025: Energy Storage Revenue Jumps 109%, Accelerating Diversification
Ormat is demonstrating strong segment growth, especially in energy storage, and has secured high-visibility contracts with major customers. However, the overall business is not a new disruptor and faces industry headwinds and risk around EGS commercialization. The reinvestment runway is solid but not exceptional, and while growth is strong, it is not at hypergrowth levels for the overall business.
Integra Resources (ITRG) Q4 2025: Florida Canyon Delivers $72M Cash Flow, Fuels Multi-Asset Growth
Integra has a long reinvestment runway and recent transformative developments (Florida Canyon cash flow, Delamar permitting). However, unit economics are improving but not yet at giant scale, and the business model—while gaining self-reinforcing elements—remains partly traditional. Customer value is improving but not dramatically so. Growth is strong but not at hypergrowth levels. The business is transitioning to growth, but risks and capital intensity temper the signal.
Vertical Aerospace (EVTL) Q4 2025: $200M Burn Fuels Battery and Defense Push as VALO Nears Transition
Vertical Aerospace demonstrates disruptive business model potential, strong defense/hybrid demand, and a differentiated battery-as-a-service platform. However, capital constraints, execution risk, and the absence of clear evidence for accelerating unit economics or cash flow limit the score. The business is transitioning with some growth optionality, but not all levers are at full strength yet.
LightInTheBox (LITB) Q4 2025: Branded Apparel Jumps 143%, Fueling Gross Margin to 65% High
While the business has shown a major inflection in branded apparel growth and margin expansion, the reinvestment runway and business model disruption are moderate rather than exceptional. There is clear improvement in unit economics, profitability, and growth, but the company is not yet a dominant, self-reinforcing platform with extraordinary optionality. The signal is strong for a turnaround, but not at the level of a truly exceptional growth compounder.
NRXP Q4 2025: R&D Spend Down $2.4M as Three Drug Approval Paths Converge
NRXP is at a critical inflection with three late-stage assets and an EBITDA-positive clinic network, but signal is tempered by heavy regulatory risk, limited evidence of compounding unit economics, and the early stage of commercial ramp. The business is not yet proven as a high-growth, compounding opportunity but has multiple potential catalysts and optionality.
Caledonia Mining (CMCL) Q4 2025: Free Cash Flow Jumps 483% as Bilbo’s Build Accelerates
Caledonia shows a long reinvestment runway with Bilbo’s, recent major growth developments, and potential for high returns on capital. However, unit economics, self-reinforcing model, and customer value are incrementally improving but not exceptional. The business is transitioning to growth, but execution and cost risks temper the signal. Revenue/EPS growth is likely above 20% but not 40%. The business model is semi-disruptive with moderate cash flow acceleration.
LifeZone Metals (LZM) Q4 2025: Kabanga Valuation Holds at $1.6B as FID Nears, Unlocking Strategic Optionality
Kabanga offers a long reinvestment runway and strategic optionality, with a significant valuation anchor and multiple suitors. There is strong evidence of business evolution and growth potential, but as a pre-revenue mining developer, some elements (unit economics, self-reinforcement, customer value) are less proven or only emerging. The business is transitioning to growth, but not yet demonstrating exceptional acceleration or disruptive model at scale.
Woodward (WWD) Q2 2026: Aerospace Sales Jump 25% as LEAP and GTF Aftermarket Near Legacy Crossover
Woodward is at an inflection with clear growth in the LEAP/GTF aftermarket, but the business is not highly disruptive or likely to compound at the highest rates. There is a strong growth signal (not exceptional), some improvement in unit economics and margin, and portfolio optimization, but the company is still transitioning and not a pure-play growth compounding story. The signal is solid but not outstanding for a well-followed industrial supplier.
Impinj (PI) Q1 2026: Endpoint IC Bookings Hit All-Time High as Market Share Jumps 1,700 Basis Points
Impinj demonstrates a long reinvestment runway, significant recent developments (record bookings, share gain), and a disruptive model, but evidence of compounding network effects or rapidly improving unit economics is moderate. Growth is good but not explosive, and the business is transitioning into a growth phase rather than already being a high-growth outlier. Some signals (e.g., backlog, cash flow) are positive but not exceptional.
Snail (SNAL) Q4 2025: Unit Sales Surge 33% as Multi-Studio Pipeline Targets 30% Revenue Growth
Snail is transitioning to an internal studio model with a long content pipeline, suggesting a reinvestment runway and growth phase. However, there is not yet evidence of exceptional (>40%) growth or rapidly improving unit economics. The business is not yet self-reinforcing at scale, and while model disruption and cash flow potential are present, they are not fully proven. The company is a growth business, but with execution and margin risks that temper the signal score.
Nyxoah (NYXH) Q4 2025: U.S. Genio Launch Drives 122% Revenue Growth, Sales Force Expands to 40
Nyxoah is in early hypergrowth with a large U.S. market opportunity and commercial inflection, but the business model is not yet self-reinforcing and unit economics, while improving, remain to be fully proven at scale. The business is transitioning toward growth, but not yet demonstrating the compounding characteristics or exceptional guidance that would warrant a higher signal score.
NeurAxis (NRXS) Q4 2025: Prior Auth Submissions Surge 10x as CPT Code Unlocks Pediatric Pipeline
NeurAxis is at a strategic inflection with a long growth runway, payer-driven adoption, and expanding addressable market. However, some metrics (unit economics, customer value, business model defensibility) are still emerging, not fully proven at scale, and adult/VA markets are contingent on future execution. The business is a growth story but not yet demonstrating exceptional acceleration across all vectors.
TGEN Q4 2025: Data Center Pipeline Expands as Chiller Capacity Scales to 100 Units
TGEN is at an inflection, with a potentially long runway and disruptive pivot to data center cooling. However, execution risk, margin pressure, and the need for order conversion temper the signal. The business is not yet a clear compounding machine, and some metrics (unit economics, customer value, cash flow) are promising but not definitively exceptional.
ASUR Q4 2025: Recurring Revenue Climbs to 91%, AI and Attach Rates Reshape Growth Trajectory
ASUR demonstrates strong growth momentum, a shift to recurring revenue, and some disruptive elements (AI automation, managed services), but the business is not a truly exceptional compounder or a widely underappreciated opportunity. The reinvestment runway is solid but not extraordinary, and while growth is robust, it is not at the level of a transformative inflection. The story is interesting but not unique or highly asymmetric.
Live Nation (LYV) Q4 2025: Venue Nation Costs Double to $50M as International Venue Expansion Accelerates
Live Nation has a long runway for reinvestment and is making a clear strategic pivot, with double-digit growth and international expansion. However, while there is strong growth and margin upside, the business is already well-followed and the pace of change, while robust, is not explosive or disruptive enough to merit a higher signal score. Unit economics and business model advantages are improving but not yet dominant, and regulatory/execution headwinds temper the overall upside.
VIAVI (VIAV) Q3 2026: Data Center Drives 54% NSC Surge, Margin Leverage Accelerates
VIAVI is showing strong growth and margin leverage, with a notable inflection in its data center and AI-related business. However, the company does not demonstrate an extremely long reinvestment runway or uniquely disruptive self-reinforcing model. While growth and operating leverage are solid, the business is not in the highest tier of signal for truly exceptional, underappreciated upside.
DocuSign (DOCU) Q4 2026: IAM Surges to 11% of ARR as AI Platform Drives $350M Expansion
DocuSign is transitioning to a higher-value platform model with improving unit economics and customer retention, but the overall growth profile (guidance of 8-9% ARR growth) is moderate for a SaaS business and does not represent a high-growth or disruptive business with a long reinvestment runway. While IAM is growing rapidly, the broader business is not accelerating at a rate that would indicate exceptional signal. The business model has some self-reinforcing and disruptive elements, but the upside is tempered by competitive risk and the company's scale/maturity.
Quanta Services (PWR) Q4 2025: $44B Backlog Signals Multi-Year Infrastructure Upside
Quanta Services has a long reinvestment runway and is showing strong backlog and growth, but the business model, while differentiated, is not highly disruptive. Unit economics and customer value are improving, but not at the level of a platform compounding giant. The signal is strong for infrastructure and industrials, but not in the exceptional or explosive category.
Abiona Therapeutics (ABEO) Q4 2025: ZivaSkin Patient Pool Doubles, Setting Stage for 7 QTC Ramp
Abiona has a long reinvestment runway with high returns potential, a disruptive business model, and strong growth signals (patient pool doubling, QTC ramp, margin expansion). However, some elements (unit economics, self-reinforcement, customer value) are still emerging and not fully proven at scale, so scores are conservative. The signal is strong but not at the highest level due to operational execution risks and early-stage commercial ramp.
Tuya (TUYA) Q4 2025: SaaS Recurring Revenue Up 37% as AI-Driven Services Scale
Tuya demonstrates a strong growth profile with a long runway for reinvestment and a clear shift to higher-margin recurring SaaS revenue. There is evidence of significant recent growth (SaaS up 37%), but the overall business is not yet at breakout hypergrowth levels. Unit economics are improving, but not yet at the scale of a giant. The business model is evolving toward self-reinforcing, but network effects are not yet dominant. While the business is transitioning to a growth model and expanding its developer ecosystem, it is not yet highly disruptive or exceptional in its future outlook. Revenue and EPS growth are strong (but not above 40%), and while the business is no longer legacy or stalling, it is best described as a transitioning/growth hybrid.
Contango Ore (CTGO) Q4 2025: $102M JV Distributions Set Stage for Debt-Free Growth Runway
Contango Ore is moving into a debt-free, cash-generative phase with a diversified project pipeline, which is positive. However, the business is not yet showing clear evidence of exceptional growth, massive backlog increases, or disruptive business model characteristics. Unit economics and customer value are improving but not at a transformative pace. The article presents a solid growth story, but the signal is not at the highest level due to execution and integration risks, and the company's relatively early stage in its multi-asset transition.
Vista (VIST) Q1 2026: Production Guidance Raised by 2%, Unlocking $700M Free Cash Flow Upside
Vista shows strong growth and inflection, but its reinvestment runway, business model defensibility, and customer value deepening are solid but not exceptional. The production and EBITDA growth is significant, but the business is not fundamentally disruptive or on track to be a giant. Backlog/guidance is improving, but not at a rate that warrants a top score. The business is growth-oriented and cash flow is set to accelerate, but the upside is more evolutionary than revolutionary.
Atlanticus (ATLC) Q4 2025: Mercury Acquisition Doubles Balance Sheet, Unlocks $2–$4 EPS Synergy Path
Atlanticus has a long reinvestment runway and is undergoing a transformational acquisition, but some signal questions (unit economics, self-reinforcement, customer value, cash flow, and growth rates) are only moderately positive or not fully proven. The business is interesting but not highly disruptive or accelerating at 40%+ rates.
NPK International (NPKI) Q1 2026: Rental Revenue Jumps 27% as Capacity Expansion Accelerates
NPKI demonstrates a long reinvestment runway, a significant capacity expansion, and strong top-line growth. However, margin compression, operational complexity, and the absence of truly disruptive business model elements or accelerating cash flow temper the signal score. Growth is strong but not at the highest tier, and risks around execution and integration are non-trivial.
Nektar Therapeutics (NKTR) Q4 2025: Cash Surges to $476M, Accelerating Phase III Immunology Push
Nektar has a long reinvestment runway and recent significant developments with the capital raise and pipeline advancement. However, unit economics and business model self-reinforcement are not yet proven at commercial scale. The business is transitioning to late-stage, but not yet a proven growth engine. Growth potential is high, but execution and commercial risk remain.
Turning Point Brands (TPB) Q4 2025: Modern Oral Revenue Jumps 266%, Shifting Portfolio Weight
TPB is undergoing a major portfolio shift with triple-digit growth in modern oral, but the business is not a clear-cut compounding disruptor with a long, uncapped runway. The reinvestment opportunity is solid but not exceptional, and while growth is significant, the business faces real headwinds (tax, margin, regulatory). The signal is strong for a niche consumer staples transition, but not for a truly exceptional, high-ROIC compounding story.
AMETEK (AME) Q1 2026: Orders Surge 23% as Backlog Hits $3.87B, Driving Guidance Lift
While AMETEK shows strong growth, backlog, and margin expansion, it is a well-established industrial with moderate reinvestment optionality and not an exceptional disruptor. The recent order surge is significant, but much of the business is mature with steady, not explosive, growth prospects. The business is not likely to deliver outsized upside versus other high-growth, high-ROIC opportunities.
Zymeworks (ZYME) Q4 2025: $250M Royalty Note Unlocks Capital for Share Buybacks and Asset Expansion
Zymeworks shows strong capital allocation moves and a promising royalty platform, but the business is still somewhat concentrated in a single asset and lacks the scale or disruptive moat of a top-tier compounding platform. Growth is solid but not explosive; while the future is promising, there are uncertainties around diversification and execution that limit the signal score.
Alliant Energy (LNT) Q1 2026: Data Center Load Drives 60% Peak Demand Surge, Reshaping Growth Trajectory
While the article highlights a major growth inflection and a long runway driven by hyperscale data center demand, the underlying business remains a regulated utility with moderate improvements in unit economics and customer value. The business model is evolving but not fully disruptive, and while growth is accelerating, it is not at the extreme end of the spectrum. The signal is strong for a utility, but not at the very highest level.
Coru (KRMD) Q4 2025: U.S. Market Share Jumps 18% as Pre-Fill Pipeline Expands
Coru demonstrates strong US and international growth with clear expansion levers and a multi-year pipeline. However, some elements (unit economics, customer value, self-reinforcement) are present but not exceptional or fully proven at scale. The business is growth-oriented, but the signal is slightly capped by the moderate scale and lack of disruptive, giant-scale characteristics.
DT Midstream (DTM) Q1 2026: Project Backlog Swells as Open Seasons Oversubscribe and Capacity Secured at Max Tariffs
DTM is positioned for multi-year growth with a large de-risked backlog and strong contract book, but as a midstream operator, its growth and optionality are solid but not exceptional. While the current environment is favorable, the business model is not highly disruptive, and cash flow acceleration is steady, not explosive. The signal is strong for a midstream, but not at the level of a platform or software disruptor.
ProPetro (PUMP) Q1 2026: ProPower Order Book Swells to 2.6 GW, Anchoring Multi-Year Growth
ProPower's 2.6 GW order book and pivot to digital infrastructure create a long reinvestment runway, but the business is not yet demonstrating giant-scale unit economics or exceptional (40%+) growth. The business model is evolving toward self-reinforcing, but network effects and outsized customer value are not yet proven. Growth is strong but not explosive, and the business is transitioning rather than fully in high-growth mode. The signal is solid but not at the highest possible level for disruptive, high-momentum businesses.
Standex (SXI) Q3 2026: Electronics Now 70% of Sales, Grid and Aerospace Drive $100M Growth Path
The article highlights a meaningful portfolio transformation and double-digit growth in key segments, but Standex is not a category-defining growth story and faces margin and execution headwinds. The business is transitioning to higher growth with some disruptive elements, but runway and compounding advantages are moderate. Signal is solid for an industrials name, but not exceptional.
Hudbay Minerals (HBM) Q4 2025: Net Debt Falls to Zero as Copper World JV Unlocks $420M in Growth Capital
Hudbay demonstrates a strong reinvestment runway, transformative JV, and robust growth agenda, but its business model and customer value trajectory are not deeply disruptive or compounding relative to the highest-signal businesses. Execution risk and commodity cyclicality temper the signal, and while growth is solid, it is not hyper-scaling or uniquely advantaged.
TSS (TSSI) Q4 2025: Systems Integration Revenue Jumps 80% as AI Rack Demand Accelerates
TSS demonstrates strong growth signals: a long reinvestment runway, recent contract extensions, and record revenue/EBITDA growth. However, some signal is tempered by reliance on a single customer, margin headwinds, and procurement segment volatility. While the business is transitioning into a growth story with disruptive AI infrastructure integration, some elements (unit economics, business model self-reinforcement, customer value deepening) are present but not yet exceptional.
AUNA (AUNA) Q4 2025: Peru Lifts EBITDA 14% as Mexico Recovery Drives 2026 Outlook
AUNA demonstrates a credible reinvestment runway and some disruptive elements in its B2G and risk-sharing models, but the business is still in transition with mixed signals on unit economics and customer value deepening. Growth is positive but not exceptional, and while the outlook is improving, it is not yet at the level of a breakout compounder.
Payoneer (PAYO) Q4 2025: B2B Revenue Jumps 28%, Upmarket Shift Accelerates Margin Expansion
Payoneer is showing a strong upmarket shift with double-digit B2B growth, margin expansion, and credible digital asset optionality. However, the business model, while improving, is not yet highly self-reinforcing, and customer value expansion is still emerging. Growth is solid but not at breakthrough levels, and while disruptive elements are present, the business is not yet at the highest tier of signal.
Newmark (NMRK) Q1 2026: Capital Markets Revenue Jumps 45%, Fueling Guidance Raise and Global Expansion
Newmark is showing strong growth, with a notable inflection in capital markets and international expansion, but the business is not highly disruptive or offering an unusually long reinvestment runway. Cash flow is accelerating and the business is transitioning toward higher recurring revenue, but most metrics are good rather than exceptional.
Wilden Group (WLDN) Q4 2025: Data Center Revenue Climbs to 11%, Powering Margin Above 20%
Wilden is showing clear growth and margin expansion, with a notable surge in data center/commercial demand and a significant increase in backlog. However, the business is not fully a high-ROIC, long-runway disruptor; there are some legacy/utility elements and tax-driven EPS volatility. The business is transitioning toward higher growth, but the overall upside signal is moderate rather than exceptional.
TPG (TPG) Q1 2026: Fee-Related Earnings Jump 36%, Credit Fundraising and AI Exposure Drive Platform Expansion
TPG is a large, well-followed asset manager. While the article demonstrates strong growth in FRE, AUM, and platform expansion, the business is not exceptionally disruptive or unknown. There is moderate optionality (credit, AI, energy), but not a truly long reinvestment runway at 20%+ ROIC. Recent growth is strong but not transformative, and while risk management and margin expansion are notable, the business model is not uniquely self-reinforcing versus peers. The signal is solid but not extraordinary for a fund manager seeking outlier opportunities.
Eldorado Gold (EGO) Q1 2026: Revenue Surges 50% as MacBay and Skouries Near Production
Eldorado is at an inflection with long reinvestment runway (major projects, multi-metal shift), significant recent developments (project ramp, revenue surge), and a growth profile. However, unit economics and self-reinforcing advantages are not yet clearly compounding, and while growth is substantial, it is not yet at the highest velocity or scale to warrant a top signal score. The business is transitioning, not yet a compounding giant.
Stagwell (STGW) Q4 2025: Marketing Cloud Soars 41%, AI Pivot Accelerates Margin Expansion
Stagwell shows strong organic growth in its marketing cloud (41%), doubling free cash flow, and margin expansion, but the reinvestment runway is moderate rather than exceptional, and the business model—while evolving—is not fully disruptive. There is strong growth in key segments and a political super cycle tailwind, but some growth is cyclical and client concentration risk is present. Unit economics and cash flow are improving, but the business is not yet on track to be a giant or to sustain 40%+ growth outside cyclical boosts.
UroGen Pharma (URGN) Q4 2025: Zesturi Launch Drives 21% Revenue Growth, Community Uptake Accelerates
UroGen is in a transition to growth with a high-potential commercial launch and a robust pipeline, but it is not yet a proven compounding machine. The business model is semi-disruptive, with some self-reinforcing elements but not a true platform. Revenue growth is strong but not yet at hypergrowth levels; some metrics (unit economics, cash flow) are improving but not exceptional. The signal is solid for a mid-cap biotech but not at the very highest level for strategic investor interest.
Esperion Therapeutics (ESPR) Q4 2025: Collaboration Revenue Jumps 232% on Japan Launch and Global Expansion
Esperion is undergoing a strategic transformation with a major acquisition and international expansion, supporting a longer reinvestment runway and new growth levers. However, while growth is accelerating and there are disruptive elements, the business is not yet a compounding juggernaut. Some metrics (unit economics, customer value) are improving but not at the highest possible level, and guidance is positive but not exceptional. The business is transitioning to growth, but remains exposed to execution and integration risk.
Vesta (VTMX) Q4 2025: Manufacturing Leases Hit 86%, Anchoring Route 2030 Momentum
Vesta shows a strong reinvestment runway, recent significant developments (pivot to manufacturing, land banking), and a business model that is transitioning to higher-value tenants. However, while growth is solid and strategic, it is not at the extreme acceleration or disruption level that would warrant top scores for all signal questions. Unit economics and customer value are improving, but not at a 'giant' or fully compounding level. The business is growth-oriented and well-positioned, but the signal is not extraordinary versus the rubric's highest bar.
FuelCell Energy (FCEL) Q1 2026: Data Center Pipeline Hits 1.5 GW as AI Demand Drives 80% of Backlog
FCEL demonstrates a long reinvestment runway and recent significant pipeline evolution, particularly with the AI/data center pivot. However, some elements such as unit economics, business model self-reinforcement, and customer value deepening are still emerging, not yet fully proven or exceptional. The business is transitioning with growth potential, but not yet at the level of a clear, high-momentum disruptive winner.
Embraer (ERJ) Q4 2025: Backlog Surges 20% to $31.6B, Elevating Multi-Year Growth Visibility
Embraer demonstrates a strong backlog, multi-year growth visibility, and some disruptive elements via partnerships and digitalization. However, the business is not a hypergrowth story and some business model advantages (network effects, customer value compounding) are present but not dominant. Cash flow is improving but not rapidly accelerating, and growth is solid but not explosive.
Central Puerto (CEPU) Q4 2025: $150M EBITDA Step-Up Anchored by Market Normalization and Asset Renewal
Central Puerto shows a long reinvestment runway and a step-up in EBITDA growth, with regulatory and asset renewal tailwinds. However, the business model is only partially self-reinforcing, customer value is improving but not consistently deepening, and growth is strong but not at hypergrowth levels. The story is investable but not exceptional or disruptive enough for a higher signal score.
HCC Q1 2026: Blue Creek Drives 55% Production Surge, Reshaping Cost and Volume Landscape
Blue Creek is a major growth catalyst, but HCC remains a cyclical, capital-intensive commodity producer with limited structural moats. The production ramp is significant, but the business does not exhibit the long-term compounding or disruptive characteristics of higher-signal businesses. The signal is above average due to the operational inflection, but not at the highest level.
ISG (III) Q4 2025: As-a-Service ACV Jumps 29%, Cloud and AI Redefine Market Leadership
ISG is benefiting from secular tailwinds in cloud and AI, with strong as-a-service growth and a clear pivot in industry economics. However, while growth is robust, the business is not an undiscovered or highly unique opportunity, and some metrics (unit economics, self-reinforcing model) are only moderately positive. The overall signal is solid but not exceptional for valuation upside.
Entrevision (EVC) Q4 2025: ATS Revenue Jumps 123% as Media Realigns for Election Year Surge
ATS shows high growth and improving unit economics, with a significant revenue surge and operating leverage, but the business is still transitioning and somewhat dependent on cyclical political advertising. The reinvestment runway is moderate given the need to prove digital and ad tech scale. The business model is semi-disruptive but not fully self-reinforcing yet, and while growth is strong, it is not yet at a level suggesting a giant or 40%+ sustained pace. Risks around the Media segment and political cycle limit the signal score.
TIGO Q4 2025: EBITDA Margin Climbs to 47% as Integration Drives Cash Flow Upside
TIGO is showing strong growth and margin expansion, with recent acquisitions driving a step-change in profitability and cash flow. There is evidence of improving unit economics and some self-reinforcing elements (integration playbook, pre-to-post migration), but the business is not a classic disruptive model and faces macro/regional risks. The growth rate is solid but not exceptional (>20% but not >40%), and while recent developments are material, the long-term reinvestment runway is moderate given the sector's maturity and regional volatility. The business is a growth story, but not at the highest end of the spectrum.
MediWound (MDWD) Q4 2025: Manufacturing Capacity Grows 6x, Setting Stage for Revenue Acceleration
MediWound has a meaningful reinvestment runway and is positioned for a potential inflection with manufacturing expansion and a broadening pipeline. However, actual revenue acceleration is contingent on regulatory and procurement milestones, with some uncertainty around execution. Unit economics and business model self-reinforcement are improving but not yet at giant scale. The business is transitioning to growth but not yet a clear high-growth disruptor, warranting a conservative signal score.
Lineage Cell Therapeutics (LCTX) Q4 2025: Oprogen Clinical Sites Up 100% as Pipeline Optionality Expands
Lineage demonstrates a long reinvestment runway, recent clinical and partnership momentum, and potential for high growth if pipeline milestones are met. However, the business is still in transition, with some uncertainty around unit economics, customer value, and model defensibility; growth is not yet at the level of a breakout compounding business.
Technova (TKNO) Q4 2025: Clinical Solutions Revenue Jumps 47% as Biotech Pipeline Builds
Technova shows a long reinvestment runway, with strong growth in clinical solutions and a clear path to margin expansion. There is a significant recent uptick in clinical revenue and backlog, and the company is positioned for growth as therapies commercialize. However, some elements (unit economics, self-reinforcing model, customer value, and cash flow acceleration) are improving but not yet exceptional or fully proven. The business is transitioning toward growth, but not yet at the highest level of signal for all disruptive/compounding factors.
Knife River (KNF) Q4 2025: Backlog Surges 38% to $1B, Driving Multi-Year Growth Visibility
Knife River is showing strong backlog growth, margin improvement, and clear acquisition-driven expansion, but the business is not exceptionally disruptive or high-growth (runway is good but not extraordinary, and growth is in the 15-20% range, not 40%+). Some business model self-reinforcement and cash flow improvement are present, but the business is not a category-defining compounder. Signal is solid but not exceptional.
Bridger Aerospace (BAER) Q4 2025: Core Revenue Up 23% as Fleet Expansion Drives 2026 Growth Outlook
Bridger Aerospace shows a solid growth runway with fleet expansion, legislative tailwinds, and technology-driven margin expansion. However, while there are clear growth drivers, some aspects like unit economics, customer value, and business model defensibility are still emerging rather than fully compounding. Revenue and EPS growth are strong but not at hypergrowth levels, and the model is transitioning rather than fully disruptive.
PMTS Q4 2025: Integrated Paytech Grows 20%, Unlocking High-Margin Digital Expansion
CPI Card Group is showing strong growth in its Integrated Paytech segment with high margins and a digital transformation underway. However, while the business is transitioning to higher quality recurring revenue, some areas (unit economics, business model self-reinforcement, and customer value expansion) show only moderate improvement or are still emerging. The business is not yet a clear compounding giant, and prepaid volatility and tariff risks temper the overall signal. The signal is solid but not exceptional, especially given the company's size and sector.
PAGS Q4 2024: Banking Gross Profit Jumps 80% as Deposits Cut Funding Costs
PAGS is transitioning toward a more resilient, higher-margin business model with strong banking profit growth and deposit leverage, but the business is not a clear-cut disruptor with a massive reinvestment runway or 40%+ top-line acceleration. There is evidence of improving unit economics and margin expansion, but the runway and compounding effects, while positive, are not extraordinary. The business model is still evolving, and while growth is solid, it is not at a hypergrowth/exceptional level.
Thought.ai (DAIC) Q4 2025: Recurring Revenue Base Emerges as Hardware Drives $4.5M Launch Quarter
The business shows a long runway and recent inflection, but it is still early in its SaaS transition. Unit economics and customer value are improving but not yet exceptional. The business model is semi-disruptive with some compounding features, and growth is strong but not at the highest tier. Execution risk and need for proof on recurring revenue temper the signal.
FIGS (FIGS) Q4 2025: International Revenue Soars 55% as Market Expansion Accelerates
FIGS shows a strong reinvestment runway (international growth, new channels), a recent step change in international revenue, and growth business characteristics. However, while the business is scaling and guidance is robust, unit economics improvements, self-reinforcement, and customer value deepening are present but not exceptional. The model is semi-disruptive, with moderate but not explosive future growth guidance.
Delcath Systems (DCTH) Q4 2025: R&D Spend to Rise 90% as Site Activations and Chopin Data Set Stage for 2026 Expansion
Delcath is showing strong growth, a long reinvestment runway, and a potentially disruptive model in ultra-orphan oncology. However, not all elements are exceptional: unit economics are solid but not dramatically improving, and while the business is transitioning to a higher growth phase, some levers (network effects, customer value deepening) are only modestly present. The signal is strong for a small-cap biotech, but not at the highest level given the operational risks, expense ramp, and still-limited pipeline data.
Niagen Bioscience (NAGE) Q4 2025: E-Commerce Grows 17% as NAD Leadership Drives Strategic Expansion
The business shows a long reinvestment runway with high returns on capital and recent strong growth, but some signal elements are capped by the business's moderate optionality and the fact that it is not a breakout, category-defining growth story. Unit economics are improving but not at a giant scale yet. The model has some self-reinforcing elements (IP, brand) but is not unassailable. Customer value is improving, but not dramatically. The future is positive but not exceptional, and the business is semi-disruptive with moderate cash flow acceleration.
APG (APG) Q4 2025: Data Center Revenue Climbs to 10% Share, Margin Expansion Accelerates
APG is transitioning to a higher-margin, recurring revenue model with secular tailwinds in data centers and specialty services, but the business, while solid and growing, is not highly disruptive or unique in its industry context. Growth is strong but not at hypergrowth levels, and while margins and cash flow are improving, the overall signal is moderate for a fund manager seeking asymmetric upside.
CAVA (CAVA) Q4 2025: New Restaurant Openings Drive 21% Revenue Growth, Margin Investment Signals Long-Term Play
CAVA demonstrates a long reinvestment runway, improving unit economics, and strong customer value growth. However, while the business is growing rapidly, there are no signs of a recent massive inflection or acceleration above 40%. The business model shows some self-reinforcing characteristics but is not yet fully compounding. It is disruptive for the category but not at the level of a platform business. Cash flow is improving but not yet accelerating dramatically. Revenue and EPS growth are strong but not above the highest threshold. Overall, the signal is solid for a scaled growth story, but not exceptional or explosive.
Sprout Social (SPT) Q4 2025: 22% Growth in 30K+ Customer Revenue Sets Foundation for Margin Expansion
Sprout Social shows a clear upmarket pivot, margin expansion, and a credible AI/product roadmap, suggesting a solid growth business with improving economics. However, the sub-30K segment is still a drag, and while enterprise momentum is strong, the business is not yet at the scale or disruption level to warrant the highest signal marks. Revenue growth is good but not hypergrowth, and while there are high-return opportunities, the business is not a breakout compounder yet.
MasTec (MTZ) Q1 2026: Backlog Surges $1.4B, Positioning for Multi-Year Infrastructure Upside
MasTec shows strong growth, backlog acceleration, and margin expansion, but the business is not a disruptive platform and does not have the same compounding advantages as tech leaders. The reinvestment runway is solid but not exceptional, and while growth is robust, it is not on track to be a giant or deliver 40%+ annualized growth. The signal is strong for an infrastructure player, but upside is capped by sector maturity.
Crescendo (CXDO) Q4 2025: ESI Acquisition Adds $26M Revenue, Accelerates Path to $100M Target
Crescendo is on a strong growth trajectory with the ESI acquisition, double-digit organic growth, and a clear reinvestment runway. However, while there are signs of improving unit economics and self-reinforcing business model, these are not yet at the level of a truly exceptional compounding business. AI and cloud initiatives are promising but not yet proven at large scale. Revenue and EPS growth are strong but not hyper-growth, and the business, while transitioning to higher quality, is not yet highly disruptive or dominant.
Cryoport (CYRX) Q4 2025: Commercial Cell & Gene Therapy Revenue Surges 29%, Anchoring Long-Term Growth
Cryoport demonstrates a strong growth profile, a clear inflection toward higher-value commercial revenue, and expanding partnerships. However, while the business shows a long runway and solid margin improvement, some elements (like self-reinforcement, customer value deepening, and disruptive potential) are present but not yet dominant or exceptional. The business is transitioning toward growth, but not all metrics signal a giant in the making.
ARES (ARES) Q1 2026: Institutional Fundraising Surges 46%, Fueling Record $30B Capital Raise
ARES is a scale leader in alternatives with strong fundraising, margin expansion, and a robust pipeline. However, as a well-known, mature platform, its reinvestment runway and self-reinforcing advantages are solid but not exceptional. Growth is strong but not hyper-scale, and while the business is not legacy, it is not a disruptive new entrant. The article signals solid, above-market growth and margin, but not outlier upside.
Rigel Pharmaceuticals (RIGL) Q4 2025: Net Product Sales Jump 60% as Portfolio Expansion Accelerates Cash Generation
Rigel shows strong recent growth and a shift to a multi-product platform, but the business is not yet a clear compounding machine with deep moats or a long, high-ROIC reinvestment runway. Some elements (pipeline, BD) have promise, but the signal is moderate given risks of sustaining growth and the specialty pharma context.
Marex (MRX) Q4 2025: Prime Services Now 25% of Profit, Diversifying Earnings Base
Marex shows strong signals of a business in transformation with a longer runway: Prime Services is driving diversification and profitability, there is evidence of upmarket client growth, and digital asset expansion could be a future lever. However, while the business is growing and margins are resilient, it is not yet a hypergrowth or disruptive platform with >40% growth or clear 20%+ ROIC redeployment. The business is transitioning to growth but not yet exceptional on all signal dimensions.
908 Devices (MASS) Q4 2025: Recurring Revenue Climbs to 35%, Solidifying Durable Growth Mix
The business is transitioning to a higher-quality, recurring-revenue model with strong unit economics and margin leverage. However, there is no evidence of a recent >40% growth inflection or a highly disruptive model; growth is solid but not explosive. The international opportunity and product pipeline offer optionality, but the overall signal is moderate rather than exceptional.
US Physical Therapy (USPH) Q4 2025: Hospital Alliances to Add $14M EBITDA as Margins Rebound
USPH is at an inflection point with new hospital alliances driving a step-change in EBITDA. While the business is showing improved economics and a clear growth lever, its reinvestment runway and disruptive potential are moderate relative to truly exceptional compounders. Growth is strong but not at hypergrowth levels, and the model, while improving, is not deeply self-reinforcing. Still, the developments are highly material for a mid-cap healthcare services business.
Limbach Holdings (LMB) Q4 2025: ODR Revenue Mix Hits 75%, Powering Margin-Focused Growth Path
While the article demonstrates a structural shift and strong growth, the business is not highly disruptive or likely to deliver exceptional (40%+) growth. The reinvestment runway is moderate, not long. Some elements (like margin expansion and vertical growth) are promising, but not yet at a scale or trajectory to warrant the highest signal scores. The business is transitioning to a growth model but remains in the mid-tier for signal.
KTB Q4 2025: Helly Hansen Integration Adds $100M Cash Flow, Unlocks Multi-Brand Margin Expansion
While Helly Hansen integration is a significant development, KTB is still a multi-brand apparel business with some legacy characteristics and moderate optionality. The business shows improving unit economics and margin expansion, but the overall runway is not exceptional. Growth is solid but not hyper-scaling, and while there are disruptive elements (Project Genius, digital expansion), the core model is not fundamentally disruptive. Risks remain around execution, tariffs, and Lee's turnaround.
Noble Corp (NE) Q1 2026: Contract Backlog Rises $565M as Deepwater Demand Tightens
Noble Corp is demonstrating strong backlog growth, high utilization, and a multi-year runway with improving fundamentals, but is not a truly disruptive business. Unit economics are improving, though not at an exceptional pace, and the business is transitioning toward growth with some legacy risk. The outlook is robust but not at a level of hyper-growth or exceptional disruption, so signal is solid but not top-tier.
Ventas (VTR) Q1 2026: $1.7B Senior Housing Acquisitions Expand SHOP to 60% of Portfolio
Ventas demonstrates a long runway in a secular growth segment (senior housing), with accelerating external investment and strong demographic tailwinds. However, while growth is robust, the business model is not highly disruptive, unit economics improvements are solid but not exceptional, and the company faces competition and operational complexity. The signal is strong but not at the highest level due to the sector's relatively mature dynamics and the business's lack of truly exceptional or disruptive characteristics.
KITT Q4 2025: ROV Revenue Jumps 190% as Defense and UAE Expansion Reshape Nauticus Playbook
KITT shows a major revenue inflection and strategic shift, but the business is not yet a proven compounding machine. There is evidence of a disruptive model and high growth potential (defense/UAE/software), but risks around customer concentration, execution, and long sales cycles temper the signal. The business is transitioning toward recurring revenue and growth, but not yet at the level of a clear, high-return compounding story.
CORT Q4 2025: 37% Tablet Volume Gain Reveals Cushing Franchise Demand Surge
CORT demonstrates a strong growth runway with clear demand signals and TAM expansion, but operational and regulatory risks temper the signal. While there are positive developments (notably in pipeline and demand), not all aspects reflect exceptional or compounding characteristics. The business is transitioning toward growth, but not all metrics are at the highest threshold for signal.
Visteon (VC) Q1 2026: $1B New Wins Signal AI Cockpit Acceleration Despite Memory Cost Drag
Visteon demonstrates a solid growth runway, recent major wins, and a pivot to higher-value AI products, but margin headwinds and some ongoing reliance on legacy cost structures constrain the signal. The business is not yet at the inflection of hyper-growth, and some metrics (unit economics, self-reinforcement, customer value) are improving but not exceptional. The business is clearly a growth business, but not a rare or disruptive outlier.
CBRE (CBRE) Q1 2026: Infrastructure Services Revenue Surges 60%, Anchoring Upgraded Full-Year Outlook
CBRE is showing strong growth in infrastructure services, with a 60% projected increase, and transactional businesses rebounding. However, the business is not fundamentally disruptive and is relatively well-known, with some maturity in its core operations. While some metrics are impressive, the company does not offer the kind of high-velocity, disruptive, or underappreciated growth that would merit a higher signal score. There is clear momentum, but the upside is somewhat capped by the company’s scale and established position.
Redwood Trust (RWT) Q1 2026: Sequoia JV Adds $8B Capacity, Unlocks 30% Volume Upside
Redwood is showing strong growth and business model evolution, but it is not a truly exceptional or disruptive business in the context of all public equities. The JV is a significant development with visible volume and EPS upside, but the runway is moderate compared to best-in-class compounders. Unit economics and margins are improving, but the model is not fundamentally disruptive. Growth is solid (not hypergrowth), and the company is transitioning to a more scalable, capital-light platform, but the sector remains cyclical and competitive.
NNOX Q4 2025: 360-System Agreements Signal Commercial Inflection, Restructuring Cuts $17.5M in Assets
NNOX is at a commercial inflection with a significant ramp in contracted systems and a reset cost structure, indicating a potential for high growth and margin improvement. However, actual revenue conversion is not yet proven, and some elements (unit economics, self-reinforcing model, customer value) are emerging but not fully established. The business is transitioning from validation to growth but is not yet a proven compounding engine.
Flexible Solutions International (FSI) Q4 2025: New Food Contracts Drive $50M Revenue Ambition Amid Margin Reset
The company is transitioning to higher-value, defensible markets with long-term contracts and a clear reinvestment runway. There is visible growth optionality (food contracts, Panama), but the business is not yet on a giant scale and unit economics are only moderately improving. The business model has some self-reinforcing elements (tariff/inflation protection, port proximity), but network effects and compounding advantages are not dominant. Revenue and EPS growth potential is strong but not at hypergrowth levels, and the business is transitioning rather than fully in growth mode.
V2X (VVX) Q1 2026: Backlog Surges 24% to $13.8B, Locking In Multi-Year Revenue Visibility
V2X demonstrates a strong backlog, high visibility, and a clear growth trajectory, but while the business is growing and innovating, it does not fully exhibit the disruptive, high-velocity characteristics required for a top signal score. Some elements, such as unit economics and business model self-reinforcement, are improving but not yet exceptional.
UCTT Q1 2026: $600M Convertible Debt Lowers Borrowing Cost, Unlocks Expansion for AI Cycle
UCTT has a long reinvestment runway and is positioned for growth in the AI cycle, but the business is not a clear disruptor and the growth, while strong, is not explosive. Unit economics and customer value are improving but not at outsized rates. The business is transitioning into a growth phase, but the overall signal is moderate given its scale and sector context.
Evotech (EVO) Q4 2025: Just Biologics Grows 40%, Reshapes Margin Profile for 2026
Evotech is transitioning to a higher-margin, technology-enabled model with a long reinvestment runway, strong revenue growth in biologics, and clear margin upside. However, some areas such as unit economics, business model self-reinforcement, and customer value deepening are improving but not yet exceptional or fully proven. The business is a growth story but not yet at the level of a disruptive, giant-scale compounding business, warranting a conservative signal score.
BlackBerry (BB) Q4 2026: QNX Backlog Surges 10%, Anchoring Durable Multi-Year Growth
BlackBerry demonstrates a long reinvestment runway in QNX, improving unit economics, a self-reinforcing model, and a strong competitive moat. However, growth rates, while positive, are not exceptional, and the business, though transitioning to growth, is not yet showing the explosive dynamics of a high-signal, high-upside compounder. The business is investable, but the signal is not at the highest level due to moderate rather than breakout growth.
IQSTEL (IQST) Q4 2025: SMS Volume Surges 25% as Platform Margin Expansion Accelerates
IQSTEL demonstrates a meaningful strategic pivot with margin expansion, new verticals, and disciplined M&A, but the business is not yet at the level of a clear breakout or dominant platform. While there is evidence of growth and optionality, the signal is somewhat dampened by execution risk, competitive landscape, and the company's relatively early stage in high-margin verticals.
Barfresh (BRFH) Q4 2025: Manufacturing Shift Lifts Revenue 94%, Unlocks $200M Capacity Path
Barfresh is transitioning from a constrained to a scalable platform, with a long reinvestment runway and a major facility-driven inflection. However, margin recovery and business model self-reinforcement are not fully proven yet, and while growth potential is high, near-term risks and execution hurdles remain. The business is not yet a clear compounding giant, and while the outlook is strong, it is not yet exceptional.
XBP (XBP) Q4 2025: New TCV Bookings Surge 53% as AI-Led Margin Expansion Emerges
XBP shows strong new bookings growth, a clear AI-led margin expansion story, and a transition toward higher-margin business. However, the business is still in transition, with lagged revenue realization and some uncertainty regarding the pace of margin and revenue ramp. The business is not yet a clear hypergrowth or dominant platform, but the signals are positive for a pivot to growth and margin improvement.
AirJewel Technologies (AIRJ) Q4 2025: $44M Cash Secured as Commercial Pipeline Set for 2026 Launch
The company has a long reinvestment runway, disruptive business model, and is entering a commercialization phase in a high-demand sector. However, revenue and EPS growth are not yet at breakout levels, and while the opportunity is large, there is still significant execution risk, limited proof of unit economics at scale, and only moderate evidence of improving customer value or accelerating cash flow. Signal is strong for an early-stage company, but not at the level of a proven hyper-growth story.
Omeros (OMER) Q4 2025: $240M Novo Nordisk Deal and Yartemlia Launch Reset Growth Trajectory
Omeros demonstrates a solid growth trajectory with a long reinvestment runway, a transformational deal, and a high-value orphan launch. However, while the business is pivoting toward growth and has disruptive elements, some aspects (unit economics, compounding model, customer value) are still emerging or not yet proven to be exceptional. The signal is strong but not at the highest possible level due to execution and pipeline risk.
MongoDB (MDB) Q4 2026: RPO Doubles to $1.47B as Atlas and EA Deals Reshape Growth Mix
MongoDB shows a strong reinvestment runway (hybrid, AI-native, upmarket), significant backlog growth, and is a growth business with accelerating cash flow. However, while disruptive and with some self-reinforcing model attributes, the business model is not fully exceptional (AI-native still nascent, some volatility in deal timing, and not all metrics are compounding at the highest level). Revenue growth is strong but not hypergrowth, and some metrics (unit economics, customer value) are improving but not exceptional.
Inventiva (IVA) Q4 2025: Native 3 Enrollment Tops 1,000, Setting Stage for Pivotal MASH Data
Inventiva is at a pivotal point with a clear binary catalyst (Native 3), a focused late-stage asset, and significant potential upside if successful. However, as a single-asset biotech, the business is not currently demonstrating broad-based compounding or disruptive network effects, and its signal is capped by the binary nature of the outcome and lack of current commercial momentum. There is moderate evidence of improving economics and a potentially large market, but the risk profile and stage of development temper the signal score.
RenovoRx (RNXT) Q4 2025: Active Site Pipeline Triples, Anchoring $3-4M Revenue Target
RenovoRx presents an early-stage, high-margin business with a clear path to revenue growth via site expansion and a pivotal clinical catalyst. However, the underlying business is still proving out its unit economics at scale, and while the model is promising, it is not yet self-reinforcing or showing network effects. Growth is strong but not yet exceptional, and execution risk remains high.
Virgin Galactic (SPCE) Q4 2025: $750K Ticket Pricing and 26% Cost Cut Set Stage for Commercial Launch
Virgin Galactic is at a major inflection, with disruptive potential and a large addressable market, but remains pre-revenue with high execution risk. There are positive signals in pricing, backlog, and process innovation, but unit economics and customer value are not yet proven at scale. The business model is disruptive, but the transition to commercial operations is unproven, capping the signal score.